[
  {
    "letter_name": "ultra-chem-labs-corporation-641742-12202022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "drug product is adulterated",
      "unapproved new drug",
      "misbranded",
      "failure to ensure drug products are in compliance with CGMP",
      "failure to conduct evaluation for active ingredient suitability",
      "failure to determine methanol content",
      "failure to establish adequate procedures for investigations and nonconformances",
      "failure to provide adequate training for employees",
      "failure to establish a stability program",
      "failure to retain reserve samples",
      "failure to prepare adequate batch control and production records",
      "failure to conduct appropriate laboratory testing",
      "failure to test samples of each component for identity and conformity",
      "failure to validate and establish reliability of component supplier’s test analyses",
      "misbranding under section 502(j)",
      "misbranding under section 502(a)",
      "misbranding under section 502(e)(1)(A)",
      "misbranding under section 502(ee)"
    ],
    "recommendations": [
      "test retain samples of distributed batches for methanol",
      "consider removing all adulterated batches from the U.S. market",
      "provide a comprehensive assessment and remediation plan for quality unit",
      "conduct adequate release testing including strength and identity testing",
      "provide a list of chemical and microbial test methods and specifications",
      "conduct a comprehensive, independent review of material system",
      "provide chemical and microbiological quality control specifications for components",
      "commit to conducting specific identity tests for each incoming component batch",
      "engage a qualified consultant to assist in meeting CGMP requirements",
      "clarify intentions regarding future drug manufacturing"
    ]
  },
  {
    "letter_name": "profounda-inc-642595-02012023",
    "violated_terms": [
      "Failure to establish written procedures for production and process control (21 CFR 211.100(a))",
      "Inadequate written testing program for stability characteristics (21 CFR 211.166(a))",
      "Inadequate design and maintenance of the purified water system (21 CFR 211.63)",
      "Inadequate laboratory controls (21 CFR 211.160(b))",
      "Failure to withhold components until tested and released (21 CFR 211.84(a))"
    ],
    "recommendations": [
      "Provide a comprehensive validation program for manufacturing processes.",
      "Develop a robust stability program with ongoing assessments.",
      "Remediate the design and maintenance of the water system.",
      "Conduct a thorough review of laboratory practices and microbiological hazards.",
      "Implement a rigorous testing protocol for incoming components."
    ]
  },
  {
    "letter_name": "safecor-health-llc-657886-09052023",
    "violated_terms": [
      "Inadequate inspection of packaging and labeling facilities (21 CFR 211.130(e))",
      "Failure to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "Failure to test samples of each component for conformity with specifications (21 CFR 211.84(d)(2))",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)"
    ],
    "recommendations": [
      "Conduct a comprehensive evaluation of packaging and labeling operations to identify failure modes and human error points.",
      "Improve cleaning validation program to include worst-case scenarios and appropriate testing.",
      "Implement a robust testing protocol for incoming components to ensure compliance with quality specifications.",
      "Develop a comprehensive assessment and remediation plan for the quality control unit to enhance documentation practices and data integrity."
    ]
  },
  {
    "letter_name": "nortec-quimica-sa-639894-12082022",
    "violated_terms": [
      "current good manufacturing practice (CGMP)",
      "adulterated API",
      "failure to exercise sufficient controls over computerized systems",
      "failure of quality unit to review batch production records",
      "inadequate evaluation of batch related documentation",
      "lack of traceability of previous drug analyses",
      "failure to ensure accuracy and integrity of data"
    ],
    "recommendations": [
      "Provide a comprehensive, third-party assessment and CAPA plan for computer system security and integrity.",
      "Implement a process to ensure the traceability of analytical worksheet forms.",
      "Review all raw data generated during each test and completed laboratory control records when making batch release decisions.",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Submit a detailed corrective action plan to ensure the reliability and completeness of all data generated."
    ]
  },
  {
    "letter_name": "yusef-manufacturing-laboratories-llc-621026-02082022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.84(d)(1) and (2)",
      "21 CFR 211.192",
      "21 CFR 211.160(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Provide a risk assessment for using non-pharmaceutical grade ethanol.",
      "Provide chemical and microbiological quality control specifications for incoming components.",
      "Describe how each component lot will be tested for conformity with specifications.",
      "Summarize results from testing all components to evaluate reliability of COA.",
      "Summarize the program for qualifying and overseeing contract facilities.",
      "Conduct a comprehensive review of the material system for supplier qualification.",
      "Conduct a retrospective review of all invalidated OOS results.",
      "Provide a comprehensive assessment of the overall system for investigating deviations.",
      "Provide a comprehensive assessment of the change management system.",
      "Provide methanol and other test results for all hand sanitizer batches.",
      "Provide a detailed summary of the validation program for ensuring control throughout the product lifecycle.",
      "Provide a comprehensive assessment and CAPA plan for the stability program."
    ]
  },
  {
    "letter_name": "vi-jon-llc-622087-03312022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.160(b)",
      "21 CFR 211.67(b)",
      "21 CFR 211.192",
      "21 CFR 211.68(b)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "section 601(c) of the Act"
    ],
    "recommendations": [
      "Provide chemical and microbiological quality control specifications for incoming components.",
      "Establish a procedure for water system monitoring with routine microbial testing.",
      "Define current action/alert limits for total counts and objectionable organisms in the water system.",
      "Implement a procedure for ongoing control, maintenance, and monitoring of the water system.",
      "Conduct a comprehensive, independent assessment of manufacturing operations.",
      "Perform a detailed risk assessment addressing contamination hazards.",
      "Complete investigations into all batches with potential objectionable microbial contamination.",
      "Establish appropriate microbiological batch release specifications for drug products.",
      "Provide a comprehensive, independent review and remediation plan for the water system.",
      "Conduct a detailed risk assessment for observed water system failures.",
      "Implement a comprehensive, independent assessment of the investigation system for deviations and complaints.",
      "Review and improve change management systems.",
      "Ensure QU has authority and resources for effective oversight.",
      "Conduct a comprehensive assessment and CAPA plan for computer system security and integrity.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "matthew-725-inc-dba-thrive-pharmacy-610679-07222021",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products due to significant CGMP violations",
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "Failure to establish an adequate written testing program for stability characteristics",
      "Failure to establish adequate written procedures for production and process control",
      "Misbranding of drug products due to inadequate directions for use",
      "False or misleading labeling of drug products"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems",
      "Engage a third-party consultant with relevant drug manufacturing expertise to assist in the evaluation",
      "Implement corrective actions to address CGMP violations and prevent recurrence of sub-potent products",
      "Ensure compliance with section 503A and the requirements of section 505 and 502(f)(1)"
    ]
  },
  {
    "letter_name": "laboratoires-clarins-568157-04232019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, and purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a))."
    ],
    "recommendations": [
      "A retrospective, independent review of all invalidated OOS results obtained for products currently on the U.S. market and within expiry, including a CAPA plan.",
      "A validation plan for ensuring a state of control throughout the product lifecycle, including a timeline for performing appropriate process performance qualification (PPQ).",
      "A comprehensive plan to evaluate cleaning and disinfection procedures and practices, including scientific rationale for cleaning and disinfection validation strategy."
    ]
  },
  {
    "letter_name": "tismor-health-and-wellness-pty-limited-588104-12052019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to exercise appropriate controls over computer systems",
      "failure to establish written procedures for production and process control",
      "failure to establish laboratory controls",
      "failure to validate Excel spreadsheet used for assay calculation",
      "failure to ensure data integrity",
      "failure to ensure quality of drugs produced as a contract facility"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Provide a detailed plan to remediate and evaluate the effectiveness of the laboratory system.",
      "Provide a comprehensive assessment and remediation plan for the quality unit.",
      "Provide a comprehensive, independent assessment of computer system performance and security.",
      "Provide a data-driven qualification program for production and packaging processes.",
      "Provide a complete assessment of documentation systems used throughout manufacturing and laboratory operations.",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting.",
      "Provide results of tests for diethylene glycol in glycerin batches used to manufacture drug products.",
      "Provide a full risk assessment for drug products that contain glycerin.",
      "Respond with corrective actions and preventive actions to ensure compliance with CGMP."
    ]
  },
  {
    "letter_name": "master-paints-chemicals-corp-672462-03132024",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a list of chemical and microbiological specifications, including test methods, used to analyze each batch of drug products before batch disposition decisions.",
      "Commit to providing DEG and EG test results for all lots of high-risk drug components used in the manufacture of drug products.",
      "Provide a comprehensive assessment and remediation plan to ensure the quality control unit is given the authority and resources to function effectively."
    ]
  },
  {
    "letter_name": "polimeros-y-servicios-sa-586323-08222019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to assure that the drug product bore an expiration date supported by appropriate stability testing",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "misbranding under section 502(c) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a list of all analytical test methods and specifications used to analyze each batch of drug products",
      "Provide a summary of test results obtained from retrospective testing of retain samples",
      "Conduct a comprehensive and independent review of laboratory practices and provide a CAPA plan",
      "Establish a chemical and microbiological quality control specification for incoming components",
      "Provide a comprehensive plan to evaluate cleaning procedures and validation studies for manufacturing equipment",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Conduct a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "swabplus-lp-584803-10312019",
    "violated_terms": [
      "Inadequate Component Testing",
      "Inadequate Water System Monitoring",
      "Unsuitable Microbial Test Methods",
      "Inadequate Method Validation",
      "Inadequate Quality Control Unit",
      "Inadequate Computer System Controls"
    ],
    "recommendations": [
      "Provide detailed chemical and microbiological quality control specifications for incoming components.",
      "Establish a procedure for routine microbial testing of the water system.",
      "Implement growth promotion testing for prepared media and neutralization of preservatives.",
      "Validate analytical test methods prior to use.",
      "Develop a comprehensive assessment and remediation plan for the quality control unit.",
      "Conduct a thorough assessment of computer system security and integrity."
    ]
  },
  {
    "letter_name": "proquimes-s-productos-quimicos-especializados-sa-610069-04052021",
    "violated_terms": [
      "Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.",
      "Failure to adequately perform qualification of critical equipment and ancillary systems.",
      "Failure to adequately validate written procedures for the cleaning and maintenance of equipment.",
      "Failure to test the identity of each batch of incoming production material."
    ],
    "recommendations": [
      "Provide a remediation plan that assures ongoing management oversight throughout the manufacturing lifecycle of all API.",
      "Conduct a comprehensive evaluation of the equipment used at your facility throughout API manufacturing and provide a CAPA plan.",
      "Provide appropriate improvements to your cleaning validation program, with emphasis on worst-case conditions.",
      "Conduct a comprehensive review of your material system to ensure all suppliers are qualified and materials are appropriately dated."
    ]
  },
  {
    "letter_name": "vilvet-pharmaceutical-566336-02252019",
    "violated_terms": [
      "Your firm failed to establish an adequate quality control unit and procedures applicable to the quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products.",
      "Your firm lacked written procedures regarding critical quality control unit functions.",
      "Quality unit procedures were inadequate.",
      "Drugs must be manufactured in conformance with CGMP.",
      "Failure to properly list a drug product is prohibited and will render the drug misbranded."
    ],
    "recommendations": [
      "Develop and enhance written procedures for the review and assessment of executed batch records for release.",
      "Provide a summary of your consultant’s assessment of your quality system and the timeline to implement these procedures.",
      "Provide your plans to establish a quality unit, including its structure, authority, responsibilities, and timeline.",
      "Ensure that drugs are made in accordance with CGMP.",
      "Correct the drug listing violation by ensuring all drugs are listed with the FDA."
    ]
  },
  {
    "letter_name": "woorilife-health-672936-12282023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in manufacturing.",
      "Conduct a full risk assessment for drug products containing any ingredient at risk for DEG or EG contamination.",
      "Establish a comprehensive assessment and remediation plan for the quality control unit.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "urban-electric-power-635791-12272022",
    "violated_terms": [
      "Adulteration of drug products due to contamination with acetaldehyde and acetal at unacceptable levels.",
      "Failure to conform to Current Good Manufacturing Practice (CGMP) requirements.",
      "Lack of retain samples for distributed drug products as required by 21 CFR 211.170(b).",
      "Unacceptable levels of acetaldehyde and acetal impurities exceeding USP limits."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements as per 21 CFR 211.34.",
      "Perform a comprehensive audit of the entire operation for CGMP compliance.",
      "Address all deficiencies and systemic flaws to ensure ongoing CGMP compliance."
    ]
  },
  {
    "letter_name": "sovereign-pharmaceuticals-llc-634233-10052022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failure to list drugs with FDA as required by section 510 of the FD&C Act",
      "failure to properly list a drug with the FDA will render it misbranded under section 502(o) of the FD&C Act",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure to adequately validate the manufacturing processes",
      "failure to thoroughly investigate any unexplained discrepancy or failure of a batch (21 CFR 211.192)",
      "failure to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d))"
    ],
    "recommendations": [
      "Provide a data-driven and scientifically sound analysis that identifies all sources of variability.",
      "Provide a detailed summary of your validation program for ensuring a state of control.",
      "Provide a timeline for performing appropriate PPQ for each of your drug products.",
      "Conduct a comprehensive, independent assessment of the design and control of your firm’s manufacturing operations.",
      "Perform a retrospective, independent review of all invalidated OOS results.",
      "Provide a comprehensive review and remediation plan for your OOS result investigation systems.",
      "Conduct a comprehensive assessment of adequacy of your stability samples.",
      "Provide a detailed risk assessment on the impact to product quality.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a consultant to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "spartan-chemical-company-inc-614450-12152021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "insanitary conditions under section 501(a)(2)(A) of the FDCA",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded drugs under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction into interstate commerce prohibited under sections 301(a) and (d) of the FD&C Act",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure to thoroughly investigate unexplained discrepancies (21 CFR 211.192)",
      "failure of quality control unit to ensure compliance with CGMP (21 CFR 211.22)"
    ],
    "recommendations": [
      "Provide a remediation plan for ongoing management oversight throughout the manufacturing lifecycle.",
      "Conduct a comprehensive, independent assessment of the water system design, control, and maintenance.",
      "Implement a thorough remediation plan to install and operate a suitable water system.",
      "Discuss efforts toward systematic, comprehensive corrective action and preventive action (CAPA).",
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations and discrepancies.",
      "Provide a detailed action plan to remediate the investigation system.",
      "Provide an independent assessment and remediation plan for the CAPA program.",
      "Ensure appropriate improvements to the cleaning validation program.",
      "Provide a comprehensive assessment and remediation plan to ensure the quality unit is given authority and resources to function effectively.",
      "Commit to perform Antimicrobial Effectiveness Testing (AET) on drug products."
    ]
  },
  {
    "letter_name": "snugz-usa-inc-570361-06122019",
    "violated_terms": [
      "Your firm failed to perform appropriate laboratory determination of satisfactory conformance to final specifications for each batch of drug product (21 CFR 211.165(a) and (b)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and (2)).",
      "Your firm failed to establish an adequate quality control unit (21 CFR 211.22(a) and (d)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)).",
      "Your firm failed to clean, maintain, and sanitize equipment and utensils (21 CFR 211.67(a))."
    ],
    "recommendations": [
      "Provide procedures for testing all finished drug dosage products according to your firm’s specifications.",
      "Update procedures for incoming component testing, including a CAPA plan.",
      "Establish an adequate quality control unit with appropriate authority and resources.",
      "Provide protocols for validation and qualification activities.",
      "Develop a comprehensive plan to evaluate cleaning procedures and practices."
    ]
  },
  {
    "letter_name": "patcos-cosmetics-pvt-ltd-669465-12152023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide a commitment to provide DEG and EG test results from testing retains for all lots of high-risk drug components used in the manufacture of drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Provide a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "randol-mill-pharmacy-610545-09172020",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products under section 501(a)(2)(A) of the FDCA",
      "Insanitary conditions during drug production",
      "Failure to establish an adequate system for cleaning and disinfecting",
      "Failure to ensure appropriate clothing for manufacturing personnel",
      "Failure to establish written procedures to prevent microbiological contamination",
      "Failure to have separate areas to prevent contamination",
      "Failure to establish a written testing program for drug stability",
      "Failure to clean and maintain equipment and utensils properly",
      "Misbranded drug products under section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations including facility design and procedures",
      "Perform media fill tests under challenging conditions",
      "Conduct smoke studies under dynamic working conditions",
      "Revise cleaning procedures to include the use of deactivators for hazardous drug products",
      "Provide sufficient information and documentation for corrective actions taken"
    ]
  },
  {
    "letter_name": "simex-logistics-sa-de-cv-610529-01282021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "failure to perform finished product testing as required by 21 CFR 211.165",
      "failure to adequately test prior to release",
      "misleading representation of the concentration of the active ingredient",
      "not GRASE for use under the conditions prescribed",
      "does not comply with section 505G of the FD&C Act"
    ],
    "recommendations": [
      "provide plans to reformulate the drug product",
      "develop a remediation plan for ongoing management oversight",
      "design a detailed program for validating and monitoring manufacturing processes",
      "provide a list of appropriate chemical and microbial test methods",
      "engage a qualified consultant to evaluate operations for CGMP compliance",
      "perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "vitae-enim-vitae-scientific-inc-620576-03172022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.22",
      "21 CFR 211.192",
      "21 CFR 211.110(a)"
    ],
    "recommendations": [
      "Establish and follow appropriate written procedures to prevent microbiological contamination of drug products.",
      "Perform thorough smoke studies in ISO 5 classified areas under dynamic conditions.",
      "Conduct a comprehensive, independent risk assessment of all contamination hazards.",
      "Provide a detailed remediation plan with timelines to address findings.",
      "Conduct smoke studies after remediating design flaws in aseptic operations.",
      "Perform a comprehensive independent review of the media fill program.",
      "Evaluate the impact of unqualified personnel on microbiological examinations.",
      "Establish an adequate system for monitoring environmental conditions.",
      "Provide a comprehensive independent review of the personnel and environmental monitoring program.",
      "Ensure drug products manufactured are in compliance with CGMP.",
      "Conduct an independent assessment of all contract laboratory methods.",
      "Perform a retrospective assessment of the change in supplier for sterile components.",
      "Thoroughly investigate any unexplained discrepancies or failures of batches.",
      "Establish control procedures to monitor and validate manufacturing processes.",
      "Create a formalized 100% visual inspection program for drug products."
    ]
  },
  {
    "letter_name": "ls-promotions-inc-685889-08052024",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a) and 211.165(b))",
      "Failure to establish and follow an adequate written testing program for stability characteristics of drug products (21 CFR 211.166(a))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Quality control unit's failure to ensure compliance with CGMP and established specifications (21 CFR 211.22)"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each batch of drug products before disposition.",
      "Conduct full chemical and microbiological testing of retain samples for all batches distributed to the U.S.",
      "Establish a comprehensive assessment and CAPA plan for the stability program.",
      "Develop a detailed summary of the validation program for ensuring a state of control throughout the product lifecycle.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "laboratorios-jaloma-sa-de-cv-609287-01252021",
    "violated_terms": [
      "adulterated under section 501(d)(2)",
      "adulterated under section 501(a)(2)(B)",
      "unapproved new drug under section 505(a)",
      "misbranded under sections 502(j), (a), (e) and (ee)",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a)",
      "misbranded under section 502(j)",
      "misbranded under section 502(a)",
      "misbranded under section 502(e)(1)(A)",
      "misbranded under section 502(ee)"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements.",
      "Perform a comprehensive audit of the entire operation for CGMP compliance.",
      "Evaluate the completion and efficacy of corrective actions and preventive actions.",
      "Provide a detailed investigation into the substitution of ethanol with methanol.",
      "List all raw materials used to manufacture hand sanitizer products.",
      "Provide a list of all batches of hand sanitizer shipped to the U.S.",
      "Submit copies of complete batch records for all distributed batches.",
      "Provide analytical test results for hand sanitizer products."
    ]
  },
  {
    "letter_name": "precision-analitica-integral-sa-de-cv-609784-02052021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Provide an updated, detailed investigation into your failure to perform raw material or finished product testing",
      "Provide a list of all raw materials used to manufacture all of your hand sanitizer drug products",
      "Provide a list of all batches of any hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Provide details regarding your supplier qualification program",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of your entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "wild-child-wa-pty-ltd-589463-12062019",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed CAPA for full remediation.",
      "Provide an assessment of each drug product process and a detailed summary of the validation program.",
      "Conduct a comprehensive review of the material system and provide documentation of test results for all lots of active ingredients."
    ]
  },
  {
    "letter_name": "ningbo-pulisi-daily-chemical-products-co-ltd-577795-08132019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "failure to perform appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to follow an adequate written testing program designed to assess the stability characteristics of drug products",
      "failure to establish written procedures for production and process control",
      "failure to validate the manufacturing processes"
    ],
    "recommendations": [
      "Provide a revised finished drug product release procedure",
      "Provide a summary of test results obtained from testing retain samples of all OTC drug products",
      "Provide a procedure for incoming component testing",
      "Describe in detail how you plan to test each incoming component lot",
      "Specify how you plan to establish the reliability of your suppliers’ test results",
      "Provide a comprehensive assessment and CAPA plan to ensure the adequacy of your stability program",
      "Provide a validation plan for ensuring a state of control throughout the product lifecycle",
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Provide the quality unit with appropriate authority and sufficient resources"
    ]
  },
  {
    "letter_name": "ningbo-bst-clean-and-care-products-co-ltd-587788-11272019",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a))",
      "Quality control unit failed to ensure compliance with CGMP and established specifications (21 CFR 211.22)",
      "Failure to maintain buildings in a good state of repair (21 CFR 211.58)",
      "Failure to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications for each batch of drug products before disposition.",
      "Develop an action plan for full chemical and microbiological testing of retain samples.",
      "Implement a comprehensive independent assessment and CAPA plan for the stability program.",
      "Ensure the quality unit has authority and resources to function effectively.",
      "Conduct a retrospective assessment of cleaning effectiveness to evaluate cross-contamination hazards.",
      "Establish a cleaning validation program incorporating worst-case conditions."
    ]
  },
  {
    "letter_name": "medlife-pharmacy-and-compounding-inc-607417-04242020",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "mmc-healthcare-ltd-684644-09242024",
    "violated_terms": [
      "Failure to establish an adequate quality control unit (21 CFR 211.22(a))",
      "Inadequate controls over computer systems (21 CFR 211.68(b))",
      "Failure to establish accuracy, sensitivity, specificity, and reproducibility of test methods (21 CFR 211.165(e))"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality control unit",
      "Independent assessment and CAPA plan for computer system security and integrity",
      "Independent assessment of laboratory practices and detailed remediation plan for test methods"
    ]
  },
  {
    "letter_name": "noticias-mexico-hoy-grupo-multimedia-sa-de-cv-609658-06272022",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "sure-biochem-laboratories-llc-646619-03242023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drugs",
      "laboratory control mechanisms",
      "scientifically sound specifications",
      "growth promotion testing procedures",
      "validation of alternative microbial methods",
      "inadequate quality unit",
      "incomplete laboratory records",
      "failure to retain CGMP-related data"
    ],
    "recommendations": [
      "Comprehensive independent assessment of laboratory practices and procedures",
      "Retrospective assessment of prior testing for method suitability",
      "Comprehensive investigation into data integrity lapses",
      "Establish quantitative acceptance criteria for growth promotion testing",
      "Engage a qualified CGMP consultant",
      "Retrospective review of records for testing using received materials",
      "Comprehensive assessment and remediation plan for quality unit",
      "Independent assessment of documentation practices",
      "Prompt, complete, and transparent analytical information to customers"
    ]
  },
  {
    "letter_name": "laboratorio-pharma-international-srl-614766-09152021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranding",
      "failure to establish laboratory controls",
      "failure to establish adequate written testing program",
      "failure to test samples of each component for conformity",
      "failure to establish stability testing program",
      "failure to ensure appropriate component testing",
      "failure to provide adequate stability data",
      "failure to disclose complete domestic address or telephone number",
      "failure to comply with section 505G of the FD&C Act"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment and CAPA plan for finished product testing",
      "List chemical and microbial specifications for drug products",
      "Conduct full chemical and microbiological testing of retain samples",
      "Provide a comprehensive assessment of laboratory practices and procedures",
      "Establish an adequate stability testing program",
      "Provide stability data to support hand sanitizer shelf life",
      "Test samples of each component for conformity with specifications",
      "Provide a summary of results from testing all components",
      "Conduct a comprehensive review of material system for supplier qualifications",
      "Address any product quality or patient safety risks"
    ]
  },
  {
    "letter_name": "vintage-chemical-inc-673930-03272024",
    "violated_terms": [
      "Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a) and 211.165(b)).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2))."
    ],
    "recommendations": [
      "Confirm whether you will discontinue manufacturing drugs on shared equipment and provide a plan for separation of manufacturing areas.",
      "Provide a list of chemical and microbiological specifications, including test methods, for each batch of drug products.",
      "Conduct a comprehensive review of your material system to ensure all suppliers are qualified and materials are assigned appropriate expiration or retest dates.",
      "Provide a risk assessment for all drugs produced on shared equipment and address product quality and patient safety risks.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "yangzhou-suxiang-medical-instrument-co-ltd-686655-07082024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a))."
    ],
    "recommendations": [
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements before resuming drug manufacturing operations.",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Evaluate the completion and efficacy of all Corrective and Preventive Actions (CAPAs) before pursuing resolution of compliance status."
    ]
  },
  {
    "letter_name": "shilpa-medicare-limited-607877-10092020",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your firm failed to follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product including the review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications (21 CFR 211.198(a)).",
      "Your firm is in violation of the Field Alert reporting requirements set forth in 21 CFR 314.81(b)(1)(ii)."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide an independent assessment and remediation plan for your complaint handling program.",
      "Engage a consultant qualified to evaluate your operations as set forth in 21 CFR 211.34."
    ]
  },
  {
    "letter_name": "zermat-international-sa-de-cv-647232-04062023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failed to establish and follow an adequate written testing program for stability",
      "failed to establish adequate written procedures for production and process control",
      "failed to exercise responsibility to ensure drug products are in compliance with CGMP",
      "failed to ensure adequate oversight for the manufacture of OTC drug products",
      "failed to determine levels of 'arsenic' and a 'limit of (b)(4)' as required by USP",
      "failed to correct repeat violations"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a remediation plan",
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Establish a comprehensive review and remediation plan for OOS result investigation systems",
      "Provide a detailed summary of the validation program for ensuring a state of control",
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records",
      "Provide a current risk assessment of the potential effects of observed failures on drug quality",
      "Develop a management strategy that includes a global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "zhuhai-aofute-medical-technology-co-ltd-590945-01092020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(c) and (x) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to perform critical quality control tests before batch release",
      "failure to evaluate the suitability of incoming component lots",
      "failure to establish an adequate quality control unit",
      "failure to establish adequate written procedures for production and process control",
      "failure to validate manufacturing process for 'Magic Spray'",
      "failure to ensure accuracy and integrity of data"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed remediation plan",
      "Provide a list of chemical and microbial specifications used to analyze each batch",
      "Provide a complete assessment of documentation systems and a detailed CAPA plan",
      "Conduct a comprehensive independent review of the material system",
      "Provide a remediation plan to ensure the quality control unit is effective",
      "Provide a remediation plan for production and process control procedures",
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the cleaning system",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Provide a detailed corrective action plan to ensure reliability and completeness of all data"
    ]
  },
  {
    "letter_name": "xiamen-wally-bath-manufacture-co-ltd-669407-11152023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide chemical and microbiological quality control specifications for testing incoming components.",
      "List chemical and microbial specifications used to analyze each batch of drug products before release.",
      "Provide a comprehensive assessment and CAPA plan for the stability program, including stability studies and ongoing testing."
    ]
  },
  {
    "letter_name": "southern-tier-home-infusion-inc-dba-pharmacy-innovations-667414-09202023",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "sections 505(a) and 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in conducting the comprehensive evaluation.",
      "Notify the FDA in writing of the specific steps taken to address any violations within fifteen (15) working days.",
      "Provide documentation related to steps taken to prevent recurrence of violations before resuming production."
    ]
  },
  {
    "letter_name": "united-pharmacy-553916-02112019",
    "violated_terms": [
      "section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)",
      "current good manufacturing practices (CGMP) (section 501(a)(2)(B))",
      "labeling with adequate directions for use (section 502(f)(1))",
      "FDA approval prior to marketing (section 505)",
      "section 501(a)(2)(A) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "sections 505(a) and 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in conducting the comprehensive evaluation.",
      "Provide documentation to demonstrate that the (b)(4) is validated for its intended use.",
      "Provide sufficient documentation, such as a photograph or a purchase order, to evaluate the stated corrective action regarding gowning apparel.",
      "Provide documentation of completion of media fills performed according to the updated SOP."
    ]
  },
  {
    "letter_name": "mcconnell-labs-inc-638958-10182022",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "sircle-laboratories-llc-615098-09212021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.22",
      "21 CFR 211.198(a)",
      "21 CFR 211.130",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Provide a comprehensive assessment plan to ensure that suppliers are suitably qualified and appropriate oversight is maintained.",
      "Provide a comprehensive, independent assessment of your change management system.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Provide a retrospective assessment of complaints received by Sircle that were or should have been shared with your CMOs.",
      "Provide a corrective action and preventive action (CAPA) plan to improve labeling operations.",
      "Describe how top management supports quality assurance and reliable operations.",
      "Provide an independent assessment and remediation plan for your CAPA program."
    ]
  },
  {
    "letter_name": "mayons-pharmaceuticals-pvt-ltd-607388-09042020",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance.",
      "Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.",
      "Failure to establish adequate written procedures for cleaning equipment and its release for use in manufacture of API."
    ],
    "recommendations": [
      "Provide chemical and microbiological quality control specifications for testing and releasing each incoming lot of components.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.",
      "Conduct a comprehensive, independent retrospective assessment of your cleaning effectiveness.",
      "Improve your cleaning validation program with emphasis on worst-case conditions."
    ]
  },
  {
    "letter_name": "tec-laboratories-inc-568666-03202019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to conduct appropriate laboratory testing",
      "failure to thoroughly investigate any unexplained discrepancy",
      "failure to evaluate the impact of out-of-limit results on drug products",
      "not labeled or formulated in accordance with the Skin Protectant Drug Products for Over-the-Counter Use final rule",
      "not the subject of an approved new drug application"
    ],
    "recommendations": [
      "Provide an action plan for promptly testing retained samples of all batches released to the U.S. market that are still within expiry.",
      "Provide the results of these tests to the FDA within 60 days of receipt of this letter.",
      "Provide verification studies for each microbiological testing method used for drug products.",
      "Provide a list of batches made while the purified water system was not operating within limits, along with a risk assessment for each batch.",
      "Investigate the violations, determine the causes, and prevent their recurrence."
    ]
  },
  {
    "letter_name": "skin-atelier-inc-dba-skinprint-582512-10012019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranded drugs",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "inadequate finished drug product release testing",
      "failure to ensure drug products are in compliance with CGMP",
      "inadequate quality control unit oversight",
      "failure to establish and follow an adequate written testing program for stability",
      "inadequate cleaning procedures",
      "failure to provide access to information during inspection"
    ],
    "recommendations": [
      "Provide a summary of all chemical and microbial test methods and specifications used to analyze each batch of drug products.",
      "Provide a summary of results obtained from testing reserve samples of all drug product batches within expiry.",
      "Provide a comprehensive, independent review of laboratory practices and a detailed corrective and preventive action (CAPA) plan.",
      "Provide a comprehensive assessment with CAPA to ensure the quality control unit is effective.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of the stability program.",
      "Provide a comprehensive plan to evaluate cleaning procedures and practices.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "smart-surgical-inc-dba-burst-biologics-614361-02022022",
    "violated_terms": [
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(4)",
      "21 CFR 1271.15",
      "21 CFR 1271.75(a)(1)",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.84(a)",
      "21 CFR 211.192",
      "21 CFR 211.165(e)"
    ],
    "recommendations": [
      "Review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice.",
      "Conduct routine media fill simulations semi-annually to evaluate the state of control of the aseptic process."
    ]
  },
  {
    "letter_name": "zydus-lifesciences-limited-685224-08292024",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications (21 CFR 211.192)",
      "Inadequate investigation of contamination identified in drug products",
      "Multiple cross-contamination events due to inadequate cleaning",
      "Failure to adequately investigate glass particulate contamination in drug products",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination of sterile drug products (21 CFR 211.113(b))",
      "Poor aseptic behavior observed during drug product filling",
      "Inadequate airflow simulations during aseptic processing",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a) and 211.100(b))"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a detailed action plan to remediate the investigation system, including improvements in investigation competencies and CAPA effectiveness.",
      "Perform a comprehensive risk assessment of contamination hazards in aseptic processes, including human interactions and facility layout.",
      "Develop a detailed remediation plan with timelines to address findings from the contamination hazards risk assessment.",
      "Ensure appropriate aseptic practices and cleanroom behavior during production with routine supervisory oversight.",
      "Conduct a thorough retrospective review and risk assessment regarding the impact of poor aseptic technique on drug quality.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "verde-cosmetic-labs-llc-622534-03302022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.22",
      "21 CFR 211.165(b)",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)",
      "21 CFR 211.180(e)",
      "21 CFR 211.67(b)",
      "21 CFR 211.160(a)"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a comprehensive, independent assessment of your change management system.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program.",
      "Provide an assessment of each drug product process to ensure a data-driven and scientifically sound program.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide a timeline for performing process performance qualification for each of your marketed drug products.",
      "Provide a CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment.",
      "Provide a comprehensive, independent retrospective assessment of your cleaning effectiveness.",
      "Provide a CAPA plan based on the retrospective assessment of your cleaning program.",
      "Provide a summary of updated standard operating procedures (SOPs) for verification and validation of cleaning procedures.",
      "Provide a comprehensive, independent assessment of your water system design, control, and maintenance.",
      "Provide a PW system validation report.",
      "Provide a procedure for your water system monitoring that specifies routine microbial testing.",
      "Provide a detailed risk assessment addressing the potential effects of the observed water system failures."
    ]
  },
  {
    "letter_name": "rocky-mountain-pharmacy-inc-574231-05092019",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "21 CFR 211.67(b)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.84(d)(6)",
      "21 CFR 211.165(a)",
      "21 CFR 211.165(b)",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Notify the FDA in writing of the specific steps taken to correct violations within fifteen (15) working days.",
      "Include an explanation of each step being taken to prevent the recurrence of violations.",
      "Provide copies of related documentation.",
      "If unable to complete corrective action within 15 working days, state the reason for the delay and the time within which the correction will be completed."
    ]
  },
  {
    "letter_name": "rlc-labs-inc-607596-10092020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded under section 502(o) of the FD&C Act",
      "failure to conform to compendial standards for strength, quality, or purity",
      "failure to review and approve written procedures for production and process control",
      "failure to provide data to demonstrate that manufacturing processes have been validated",
      "sub-potent drug products",
      "failure to follow a written testing program for stability characteristics",
      "failure to test samples of each component for conformity with specifications",
      "failure to establish an adequate quality control unit",
      "failure to fulfill registration and listing obligations under section 510(j) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle",
      "Provide a timeline for performing appropriate process performance qualification (PPQ) for each marketed drug product",
      "Provide a comprehensive, independent assessment and corrective action and preventive action (CAPA) plan for the stability program",
      "Establish specifications for testing each component lot for conformity with specifications",
      "Provide a comprehensive assessment and remediation plan to ensure the quality unit is given the authority and resources to effectively function",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "national-chemical-laboratories-662110-11082023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "failure to validate and establish the reliability of component supplier’s test analyses",
      "failure to ensure drug products comply with CGMP",
      "failure to establish an adequate ongoing stability program",
      "failure to establish adequate procedures for out-of-specifications",
      "failure to provide adequate oversight for the manufacture of drug products",
      "failure to conduct appropriate cleaning validation"
    ],
    "recommendations": [
      "Provide a description of how you will test each component lot for conformity with specifications",
      "Submit your standard operating procedure for COA validation",
      "Provide a summary of your program for qualifying and overseeing contract facilities",
      "Provide a comprehensive assessment and remediation plan for the quality control unit",
      "Submit a comprehensive, independent assessment and CAPA plan for the stability program",
      "Provide a timeline for process performance qualification for marketed drug products",
      "Improve the cleaning validation program with emphasis on worst-case conditions",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive six-system audit for CGMP compliance",
      "Respond in writing within 15 working days addressing violations and corrective actions"
    ]
  },
  {
    "letter_name": "takeda-pharmaceutical-company-limited-603596-06092020",
    "violated_terms": [
      "Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).",
      "Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether the batch has already been distributed (21 CFR 211.192)."
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Conduct a risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities.",
      "Perform a comprehensive, retrospective, independent review of all batches that remain within expiry in the U.S. market, incorporating the knowledge of hazards gained from your risk assessment."
    ]
  },
  {
    "letter_name": "lxr-biotech-llc-652756-07172023",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm failed to establish adequate written procedures for production and process control.",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Provide specific corrective actions and preventive actions (CAPA) for the violations.",
      "Conduct adequate testing on components used to manufacture drug products.",
      "Perform full release testing, including strength and identity testing of active ingredients, prior to batch release.",
      "Establish an adequate quality unit with responsibilities and authority to oversee manufacturing operations."
    ]
  },
  {
    "letter_name": "professional-disposables-international-inc-617201-01072022",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies or failures of batches to meet specifications (21 CFR 211.192)",
      "Inadequate investigations into out-of-specification (OOS) test results",
      "Failure to submit NDA Field Alert reports (FARs) in compliance with 21 CFR § 314.81(b)(1)(i) and (ii)",
      "Drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations and OOS results.",
      "Provide a revised procedure for when an OOS laboratory investigation triggers a broader investigation.",
      "Perform a retrospective review of all invalidated OOS results for U.S. products.",
      "Develop and implement an SOP for handling FARs and training for relevant employees.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "renas-organic-613036-02112022",
    "violated_terms": [
      "unapproved new drugs",
      "misbranded drugs",
      "unapproved new animal drug",
      "adulterated under section 501(a)(5)",
      "unsafe food additive",
      "prohibited act under section 301(ll)"
    ],
    "recommendations": [
      "Take prompt action to address the violations cited in this letter.",
      "Notify the FDA in writing within fifteen working days of receipt of this letter about the specific steps taken to address any violations.",
      "Include an explanation of each step being taken to prevent the recurrence of any violations."
    ]
  },
  {
    "letter_name": "nartex-laboratorios-homeopaticos-sa-de-cv-608540-11042020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "21 CFR 211.100(a)",
      "21 CFR 211.84(d)(2)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "21 U.S.C. 351(a)(2)(B)"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Describe your program for process performance qualification and ongoing monitoring of both intra-batch and inter-batch variation.",
      "Provide a timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.",
      "Provide your process performance protocols and written procedures for qualification of equipment and facilities.",
      "Conduct a risk assessment for products that remain on the market within expiry.",
      "Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.",
      "Provide the chemical and microbiological quality control specifications used to test and release each incoming lot of component.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Include a commitment to always conduct at least one specific identity test for each incoming component lot.",
      "Summarize results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.",
      "Include your standard operating procedure (SOP) that describes the COA validation program."
    ]
  },
  {
    "letter_name": "nephron-pharmaceuticals-corporation-dba-nephron-sterile-compounding-center-llc-644180-10212022",
    "violated_terms": [
      "section 503B of the FDCA",
      "section 505 of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 582 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.165(b)",
      "21 CFR 211.192",
      "21 CFR 211.113(b)",
      "CFR 211.180(a)",
      "21 CFR 211.194(a)(8)",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 201(g) of the FDCA",
      "section 201(p) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations.",
      "Implement quality oversight and controls over the manufacture of drugs.",
      "Select a qualified contractor and maintain sufficient oversight of the contractor’s operations to ensure CGMP compliance."
    ]
  },
  {
    "letter_name": "skyless-llc-636200-01232023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to conduct tests to verify the identity of each component",
      "failure to establish an adequate Quality Unit",
      "failure to establish necessary procedures for raw materials evaluation",
      "failure to properly list drug products with FDA"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices",
      "Provide a list of chemical and microbial specifications for drug products",
      "Conduct a comprehensive review of material system and supplier qualifications",
      "Establish a detailed summary of the validation program for quality control",
      "Implement a CAPA plan to address deficiencies in quality systems",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Provide a timeline for performing appropriate process performance qualification"
    ]
  },
  {
    "letter_name": "windlas-healthcare-private-limited-595494-03102020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "21 CFR 211.194(a)",
      "21 CFR 211.192",
      "21 CFR 211.22(a)",
      "section 501 (a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "A retrospective, independent assessment of your OOS investigation into the 18-month related substances testing.",
      "A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Your corrective action and preventive action (CAPA) plan to implement routine, vigilant quality management oversight of laboratory equipment.",
      "A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "An independent assessment and remediation plan for your CAPA program.",
      "A retrospective, independent review of all invalidated laboratory incidents and OOS results.",
      "A comprehensive review and remediation plan for your OOS result investigation systems.",
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "A complete assessment of documentation systems used throughout your manufacturing and laboratory operations.",
      "A comprehensive investigation into the extent of the inaccuracies in data records and reporting.",
      "A current risk assessment of the potential effects of the observed failures on the quality of your drugs.",
      "A management strategy for your firm that includes the details of your global corrective action and preventive action plan.",
      "Engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "results-rna-llc-578997-07292019",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "stemell-inc-579013-08282019",
    "violated_terms": [
      "FD&C Act",
      "PHS Act",
      "21 CFR 1271.3(d)",
      "21 CFR 1271.10(a)",
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(4)",
      "21 CFR 1271.10(a)(1)",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)",
      "21 CFR 211.100(a)",
      "21 CFR 211.80(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.166(a)",
      "21 CFR 211.68(a)",
      "21 CFR 211.198(a)",
      "21 CFR 1271.45-1271.90"
    ],
    "recommendations": [
      "Take prompt action to correct the deviations set forth in the warning letter.",
      "Respond in writing within fifteen (15) working days of receipt of the letter outlining specific steps taken or planned to correct the noted violations.",
      "Include documentation necessary to show that correction has been achieved.",
      "If unable to complete all corrective actions within fifteen (15) working days, explain the reason for the delay and the time frame for completion.",
      "Ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations."
    ]
  },
  {
    "letter_name": "sun-pharmaceutical-industries-ltd-636199-10162023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)",
      "21 CFR 211.63",
      "21 CFR 211.192",
      "21 CFR 211.67(a)"
    ],
    "recommendations": [
      "Provide a plan to ensure appropriate aseptic practices and cleanroom behavior during production.",
      "Conduct a thorough retrospective review and risk assessment evaluating how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of drug products.",
      "Review the media fill program and CAPA to ensure accurate simulation.",
      "Provide a comprehensive, independent risk assessment of all contamination hazards.",
      "Develop a detailed remediation plan with timelines to address contamination hazards.",
      "Conduct a thorough evaluation and risk assessment of equipment suitability for its intended use.",
      "Implement a CAPA plan for routine operations management oversight of facilities and equipment.",
      "Perform an independent retrospective review of manufacturing batch records.",
      "Conduct a comprehensive, independent assessment of the investigation system for deviations and discrepancies.",
      "Provide a CAPA plan to improve cleaning processes and practices.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "taka-usa-inc-dba-cosmetic-innovations-587521-07292020",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for each batch of drug product (21 CFR 211.165(a)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and (2)).",
      "Your firm failed to establish a written testing program to assess the stability characteristics of drug products (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, documentation, and analyst competencies.",
      "Establish a detailed corrective action and preventive action plan (CAPA) for each violation.",
      "Implement a written testing program for stability characteristics of drug products.",
      "Engage a qualified CGMP consultant to assist in compliance."
    ]
  },
  {
    "letter_name": "lighteyez-limited-665450-02152024",
    "violated_terms": [
      "adulterated under section 501(a)(1) of the FD&C Act",
      "violates section 301(a) of the FD&C Act",
      "do not conform to Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "violates sections 301(d) and 505(a) of the FD&C Act",
      "failed to have adequate quality oversight responsibility over your manufacturer’s activities",
      "not generally recognized as safe and effective (GRASE)",
      "introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act",
      "container closure system will provide inadequate protection against foreseeable external factors"
    ],
    "recommendations": [
      "provide the updated address for the headquarters of LightEyez",
      "provide the name and address of all LightEyez facilities that manufacture drug products distributed to the U.S. market",
      "provide a complete list of all drug products owned by LightEyez and offered for sale or distributed to the U.S. market",
      "issue a voluntary recall of all batches of MSM Eye Repair Drops and all other LightEyez sterile drug products remaining within expiry",
      "conduct complete investigations into the failure and extend to all sterile batches with potential microbial contamination",
      "respond to this office in writing within 15 working days"
    ]
  },
  {
    "letter_name": "surgenex-llc-615254-11152021",
    "violated_terms": [
      "manufacture of cellular products for allogeneic use",
      "products intended for injection and purported to be sterile",
      "products are drugs as defined in section 201(g) of the FD&C Act",
      "products are biological products as defined in section 351(i) of the PHS Act",
      "HCT/Ps that do not meet all the criteria in 21 CFR 1271.10(a)",
      "failure to meet the criterion in 21 CFR 1271.10(a)(2)",
      "failure to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1)",
      "failure to establish and follow appropriate written procedures designed to prevent microbiological contamination",
      "failure to have an adequate system for monitoring environmental conditions",
      "failure to establish written procedures for production and process control",
      "failure to thoroughly investigate any unexplained discrepancy",
      "failure to establish and follow a written testing program designed to assess the stability characteristics of drug products",
      "distribution of CGMP-deficient products without valid biologics licenses"
    ],
    "recommendations": [
      "respond in writing within fifteen (15) working days outlining specific steps taken or planned to correct the noted violations",
      "include documentation necessary to show that correction has been achieved",
      "explain the reason for any delay in completing corrections and the time frame for completion"
    ]
  },
  {
    "letter_name": "purechempros-llc-649677-09012023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products",
      "Unapproved new drugs",
      "Misbranding",
      "Failure to establish a quality unit",
      "Failure to test samples of each component",
      "Failure to assure expiration date supported by stability testing"
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance",
      "Provide a report verifying implementation and adequacy of corrective and preventive actions"
    ]
  },
  {
    "letter_name": "ndal-mfg-inc-621656-03282022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of section 505(a) of the FD&C Act",
      "failure to ensure drug products manufactured are in compliance with CGMP",
      "failure to establish procedures for the approval of components",
      "failure to investigate out of specification (OOS) results",
      "failure to evaluate customer complaints",
      "failure to thoroughly investigate any unexplained discrepancy",
      "failure to assure that the drug product bore an expiration date supported by appropriate stability testing",
      "lack of adequate stability program"
    ],
    "recommendations": [
      "Establish a quality unit (QU) with authority and resources to effectively function",
      "Provide a comprehensive assessment and remediation plan for the QU",
      "List chemical and microbial test methods and specifications used for lot analysis",
      "Conduct audits of CMOs to ensure compliance with CGMP",
      "Perform a thorough retrospective and comprehensive risk assessment of all CGMP documentation",
      "Establish stability specifications and initiate full shelf life studies",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "signature-biologics-llc-631039-09182023",
    "violated_terms": [
      "FD&C Act",
      "PHS Act",
      "21 CFR 1271.10(a)",
      "21 CFR 1271.15",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.160(b)",
      "21 CFR 211.167(a)",
      "21 CFR 211.100(a)",
      "21 CFR 211.42(c)(10)(v)",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Establish and follow appropriate written procedures to prevent microbiological contamination of drug products.",
      "Implement an adequate system for monitoring environmental conditions in aseptic processing areas.",
      "Establish scientifically sound and appropriate specifications for laboratory controls.",
      "Conduct laboratory testing to determine conformance to pyrogen-free requirements.",
      "Establish written procedures for production and process controls.",
      "Implement an adequate system for cleaning and disinfecting to produce aseptic conditions.",
      "Establish a written testing program to assess stability characteristics of drug products."
    ]
  },
  {
    "letter_name": "omeza-llc-665762-12122023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to maintain buildings in a clean and sanitary condition (21 CFR 211.56(a))",
      "failure to conduct identity testing of components (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "failure to follow a written stability testing program (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Provide a summary of results from testing reserve samples of all drug product batches within expiry.",
      "Provide a summary of all environmental monitoring data associated with the production of all drug product batches.",
      "Provide detailed procedures to maintain buildings free from pests and in a clean and sanitary state.",
      "Provide a risk assessment for all drug products distributed to the U.S. market.",
      "Conduct a comprehensive review of the material system for supplier qualification.",
      "Provide a summary of results from identity testing reserve samples of all API used in previously released drug products.",
      "Provide an updated supplier management procedure with detailed testing requirements.",
      "Provide a comprehensive assessment and CAPA plan for the stability program."
    ]
  },
  {
    "letter_name": "pharmcore-inc-dba-hallandale-pharmacy-605569-03112020",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "21 CFR 211.42(c)",
      "21 CFR 211.113(b)",
      "section 301(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Notify the FDA in writing of the specific steps taken to correct violations within fifteen working days.",
      "Include an explanation of each step being taken to prevent the recurrence of violations."
    ]
  },
  {
    "letter_name": "torrent-pharma-inc-584701-10282019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to use equipment of appropriate design",
      "inadequate design of water system",
      "failure to investigate discrepancies",
      "inadequate investigation into microbiological results",
      "inadequate quality systems",
      "failure to provide adequate directions for use"
    ],
    "recommendations": [
      "engage a consultant qualified to assist in meeting CGMP requirements",
      "provide a comprehensive assessment of the design of water systems",
      "develop a thorough corrective action and preventive action (CAPA) plan",
      "include blueprints for the water systems",
      "implement an effective program for ongoing control and maintenance",
      "provide validation reports for new water systems",
      "develop a detailed CAPA plan to remediate the investigation system",
      "ensure timely, thorough, and effective investigations",
      "implement routine operations management oversight"
    ]
  },
  {
    "letter_name": "nationwide-laboratories-llc-571774-04052019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranded drug",
      "inadequate quality control unit",
      "inadequate oversight of contract manufacturing organizations (CMOs)",
      "inadequate batch review and release",
      "failure to establish and follow adequate written procedures for handling complaints"
    ],
    "recommendations": [
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Establish qualification procedures for CMOs",
      "Conduct a comprehensive assessment of the quality unit's authority and resources",
      "Perform a retrospective review of all batches released in commercial distribution",
      "Implement corrective action and preventive action (CAPA) plans",
      "Address potentially unreported complaints due to lack of a working toll-free number"
    ]
  },
  {
    "letter_name": "seatex-llc-672951-04012024-0",
    "violated_terms": [
      "Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Inadequate investigation of unexplained discrepancies or failures of batches (21 CFR 211.192).",
      "Failure to conduct identity testing for each component of a drug product (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Comprehensive assessment of cleaning effectiveness and CAPA plan for cleaning procedures.",
      "Complete assessment of documentation systems and CAPA plan for documentation practices.",
      "Description of testing for conformity of each lot and commitment to conduct identity tests.",
      "Assessment and remediation plan for quality control unit responsibilities and oversight."
    ]
  },
  {
    "letter_name": "teligent-pharma-inc-587592-11262019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to thoroughly investigate unexplained discrepancies",
      "inadequate investigations into out-of-specification (OOS) test results",
      "failure to follow an adequate written testing program for stability testing",
      "failure to follow adequate written procedures for handling complaints",
      "failure to establish adequate written procedures for production and process control",
      "failure to submit NDA Field Alert Reports (FARs) in a timely manner",
      "repeated CGMP violations"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of the system for investigating deviations and OOS results",
      "Implement a CAPA plan to improve investigations and root cause analysis",
      "Provide a comprehensive evaluation of the stability program and ensure compliance with SOPs",
      "Ensure the quality unit has the authority and resources to perform its duties effectively",
      "Conduct a retrospective review of all invalidated OOS results",
      "Establish a detailed summary of the validation program for ensuring product quality",
      "Provide a timeline for performing appropriate process performance qualification (PPQ)",
      "Submit corrective actions regarding distributed products affected by the violations"
    ]
  },
  {
    "letter_name": "quimica-magna-de-mexico-sa-de-cv-608751-10152020",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "provide a detailed investigation into how the hand sanitizer drug products were misrepresented",
      "provide a list of all raw materials used to manufacture hand sanitizer drug products",
      "provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "provide copies of the complete batch records for all batches distributed to the U.S.",
      "provide a complete, comprehensive, independent assessment of the quality unit"
    ]
  },
  {
    "letter_name": "stokes-healthcare-inc-dba-epicur-pharma-677624-04022024",
    "violated_terms": [
      "Failure to meet the conditions of section 503B of the FDCA",
      "Drug products produced under insanitary conditions",
      "Adulterated drug products under section 501(a)(2)(A) of the FDCA",
      "Misbranded drug products under section 502(f)(1) of the FDCA",
      "Failure to conduct adequate testing and validation procedures",
      "Failure to establish written procedures for quality control and production processes",
      "Failure to adequately investigate discrepancies in drug product specifications"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design and procedures",
      "Engage a third-party consultant with sterile drug manufacturing expertise",
      "Implement corrective actions to address insanitary conditions and CGMP violations",
      "Improve training and oversight for the Quality Unit",
      "Submit updated Standard Operating Procedures (SOPs) for adverse event reporting",
      "Ensure compliance with labeling requirements for compounded drug products"
    ]
  },
  {
    "letter_name": "wintac-limited-606700-08132020",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products (21 CFR 211.113(b))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures.",
      "Conduct smoke studies under dynamic conditions, with thorough evaluations of aseptic interventions and operator positioning.",
      "Perform a detailed remediation plan based on a third-party review of contamination hazards."
    ]
  },
  {
    "letter_name": "seatex-llc-672951-04012024",
    "violated_terms": [
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a comprehensive, independent retrospective assessment of your cleaning effectiveness.",
      "Provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations.",
      "Provide a description of how you will test each lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "re-gen-active-lab-inc-620763-05272022",
    "violated_terms": [
      "manufacture of cellular products for allogeneic use",
      "products intended for injection and purported to be sterile",
      "HCT/Ps not regulated solely under section 361 of the PHS Act",
      "failure to meet the criterion in 21 CFR 1271.10(a)(2)",
      "failure to meet the minimal manipulation criterion in 21 CFR 1271.10(a)(1)",
      "failure to establish and follow appropriate written procedures for aseptic process validation",
      "failure to routinely calibrate, inspect or check equipment",
      "failure to establish written procedures for cleaning and maintenance of equipment",
      "failure to establish written procedures for production and process controls",
      "failure to satisfy general biological products standards for sterility testing",
      "failure to establish written procedures for receipt, identification, storage, handling, sampling, testing, approval or rejection of components",
      "failure to establish written testing program for stability characteristics",
      "failure to prepare batch production and control records"
    ],
    "recommendations": [
      "respond in writing within fifteen (15) working days",
      "outline specific steps taken or planned to correct noted violations",
      "include documentation necessary to show that correction has been achieved",
      "explain how to prevent these violations from occurring again",
      "provide reasoning and supporting information if products are believed to not be in violation"
    ]
  },
  {
    "letter_name": "yahon-enterprise-co-ltd-675592-06052024",
    "violated_terms": [
      "Failure to conduct appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a)).",
      "Failure to test samples of each component for conformity with specifications (21 CFR 211.84(d)(2)).",
      "Failure to assure drug products bore an expiration date supported by stability testing (21 CFR 211.137(a)).",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each batch of drug products before release.",
      "Detail plans for testing each lot of incoming components for identity, strength, quality, and purity.",
      "Submit a comprehensive assessment and CAPA plan for the stability program, including stability studies and ongoing monitoring.",
      "Provide a remediation plan for the quality control unit to ensure effective oversight and compliance with CGMP."
    ]
  },
  {
    "letter_name": "neilmed-pharmaceuticals-inc-650263-05262023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product, including glycerin and propylene glycol.",
      "Your firm failed to clean, maintain, and sanitize equipment and utensils at appropriate intervals.",
      "Deficiencies in the investigation of out-of-specification (OOS) bioburden test results involving Burkholderia cepacia complex (BCC) and yeast and mold."
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of your material system to ensure all suppliers are qualified and materials have appropriate expiration or retest dates.",
      "Implement a CAPA plan based on a comprehensive assessment of your cleaning program, including timelines for completion and improvements to cleaning effectiveness.",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "one-way-drug-llc-dba-partell-specialty-pharmacy-573455-03132019",
    "violated_terms": [
      "section 503A of the FDCA",
      "current good manufacturing practice (CGMP)",
      "labeling with adequate directions for use",
      "FDA approval prior to marketing",
      "section 501(a)(2)(A) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Cease to use for compounded prescription products the following items until a USP monograph is available for each one: indole-3-carbinol, L-carnosine, pimobendan, and saw palmetto.",
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third party consultant with relevant sterile drug manufacturing expertise to assist in conducting the comprehensive evaluation.",
      "Notify the FDA 15 days prior to resuming production of any sterile drugs in the future."
    ]
  },
  {
    "letter_name": "laboratorios-quantium-llc-569146-02252019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug product",
      "unapproved new drug",
      "failure to establish an adequate quality control unit",
      "failure to withhold from use each lot of components",
      "failure to clean and maintain equipment",
      "failure to establish written procedures for production and process control",
      "failure to assure that the drug product bore an expiration date supported by appropriate stability testing",
      "use of unqualified suppliers",
      "use of expired raw material",
      "failure to validate manufacturing process",
      "failure to provide stability data",
      "use of unsuitable inactive ingredients",
      "use of the term 'rheumatism'"
    ],
    "recommendations": [
      "Provide test results to demonstrate that retain samples conform to final specifications",
      "Develop an action plan to address risks posed by marketed products",
      "Conduct a comprehensive assessment with corrective actions for the quality control unit",
      "Perform a comprehensive, independent review of the material system",
      "Establish cleaning procedures and validate cleaning protocols",
      "Detail a validation plan for ensuring a state of control throughout the product lifecycle",
      "Provide a comprehensive assessment and CAPA for the stability program",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "tan-alize-kozmetik-ve-temizlik-urunleri-659854-08032023",
    "violated_terms": [
      "Failure to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))",
      "Drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))",
      "Failure to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))"
    ],
    "recommendations": [
      "Provide DEG and EG test results from testing retains for all lots of high-risk drug components used in the manufacture of drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Provide chemical quality control specifications used to test each incoming lot of high-risk drug components.",
      "Conduct a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Summarize your program for qualifying and overseeing contract facilities that test the drug products you manufacture.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "superior-glove-works-ltd-641100-12162022",
    "violated_terms": [
      "Adulteration of drug products due to unacceptable levels of impurities in ethanol API.",
      "Failure to conduct adequate testing of incoming components and finished drug products.",
      "Lack of appropriate written procedures for production and process control."
    ],
    "recommendations": [
      "Conduct a comprehensive review of material systems and supplier qualifications.",
      "Implement full chemical and microbiological testing for all batches prior to release.",
      "Establish detailed documentation practices and corrective action plans to ensure compliance with CGMP."
    ]
  },
  {
    "letter_name": "optikem-international-inc-680264-06202024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.42(c)(10)",
      "21 CFR 211.113(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.165(b)",
      "21 CFR 211.22(a)",
      "21 CFR 211.194",
      "21 CFR 211.166",
      "21 CFR 211.25(a)"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent risk assessment of all contamination hazards.",
      "Provide a detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment.",
      "Implement routine, vigilant operations management oversight of facilities and equipment.",
      "Establish and follow appropriate written procedures to prevent microbiological contamination.",
      "Perform adequate process simulations (e.g., media fills) before producing sterile products.",
      "Ensure appropriate aseptic practices and cleanroom behavior during production.",
      "Establish adequate laboratory controls and conduct appropriate laboratory testing.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "nugeneration-technologies-llc-645821-03132023",
    "violated_terms": [
      "Failure to conduct adequate release testing for drug products, including identity and strength testing (21 CFR 211.165(a)).",
      "Inadequate testing of incoming components for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Lack of an adequate written testing program for stability characteristics of drug products (21 CFR 211.166(a)).",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial test methods and specifications for each drug product lot.",
      "Conduct a comprehensive independent assessment of laboratory practices and provide a remediation plan.",
      "Review and validate incoming material controls and establish a robust water system monitoring program.",
      "Develop a comprehensive stability program with stability-indicating methods and ongoing stability studies.",
      "Create a detailed validation program for manufacturing processes, including timelines for completion."
    ]
  },
  {
    "letter_name": "nanomateriales-quimicos-avanzados-sa-de-cv-609969-09152021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "current good manufacturing practice (CGMP) violations",
      "unapproved new drug in violation of section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "misbranded under sections 502(f)(1), (a), (e)(1)(A), (c), and (x) of the FD&C Act",
      "failed to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failed to conduct at least one test to verify the identity of each component",
      "failed to establish an adequate quality control unit",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "provide a list of all raw materials used to manufacture all your hand sanitizer drug products",
      "provide a list of all batches of any hand sanitizer drug products shipped to the United States",
      "provide copies of the complete batch records for all batches distributed to the United States",
      "provide a summary of corrective actions taken to ensure your hand sanitizer products can be manufactured at the label claim concentration",
      "provide details regarding your raw material identity testing",
      "provide a comprehensive assessment and remediation plan to ensure your quality unit is given the authority and resources to effectively function",
      "engage a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "mariposa-labs-llc-558110-03142019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drug products",
      "failure to approve or reject procedures or specifications",
      "failure to establish adequate specifications",
      "failure to follow written procedures for handling complaints",
      "failure to establish adequate written procedures for production and process control",
      "failure to validate manufacturing processes",
      "failure to document complaints consistently",
      "failure to bear adequate directions for use"
    ],
    "recommendations": [
      "Provide complete and appropriate specifications for each drug product",
      "Conduct a risk assessment of batches manufactured without complete testing",
      "Provide a comprehensive assessment with corrective and preventive actions (CAPA)",
      "Conduct a retrospective, independent review of all complaints",
      "Conduct a comprehensive, independent review of your material system",
      "Conduct a comprehensive, independent assessment of your overall system for investigating deviations",
      "Conduct a prompt risk assessment for batches manufactured with unvalidated processes",
      "Specify actions to take as a result of the risk assessment",
      "If resuming production, ensure full compliance with all CGMP requirements",
      "Cancel your firm’s registration if no longer manufacturing drugs"
    ]
  },
  {
    "letter_name": "stason-pharmaceuticals-inc-604889-07082020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to assure dissolution attributes throughout shelf life",
      "inadequate investigation into dissolution failures",
      "failure to exercise appropriate controls over computer systems",
      "failure to ensure integrity of electronic test data"
    ],
    "recommendations": [
      "Comprehensive assessment of overall system for investigating deviations and discrepancies",
      "Completed root cause investigation and CAPA for dissolution failures",
      "Comprehensive table of all dissolution testing performed on temozolomide capsules",
      "Dissolution testing of retain samples for all lots of temozolomide capsules",
      "Comprehensive assessment of manufacturing process for temozolomide capsules",
      "Summary of current standard operating procedures for cleaning verification and validation",
      "Comprehensive independent assessment and CAPA plan for computer system security and integrity",
      "Complete assessment of documentation systems used throughout manufacturing and laboratory operations",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "us-pharmaceuticals-inc-573233-06062019",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Use of appropriately designed equipment (21 CFR 211.63)",
      "Establishment of laboratory controls (21 CFR 211.160(b))"
    ],
    "recommendations": [
      "Comprehensive assessment of investigation systems and detailed CAPA plan",
      "Independent assessment of water system design and maintenance with a thorough CAPA plan",
      "Revised water system sampling plan and validation outcomes"
    ]
  },
  {
    "letter_name": "sun-pharmaceutical-industries-limited-677337-06182024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.67(a)",
      "21 CFR 211.192",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "inadequate cleaning and maintenance of manufacturing equipment",
      "inadequate investigations of laboratory events",
      "failure to thoroughly investigate unexplained discrepancies"
    ],
    "recommendations": [
      "Provide a comprehensive, independent retrospective assessment of cleaning effectiveness",
      "Develop a corrective action and preventive action (CAPA) plan based on the retrospective assessment",
      "Implement routine, vigilant operations management oversight of facilities and equipment",
      "Address gaps identified by a third-party consultant in the equipment maintenance program",
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Create a comprehensive review and remediation plan for OOS result investigation systems",
      "Assess and remediate the overall system for investigating deviations, discrepancies, complaints, and failures",
      "Evaluate and improve the CAPA program",
      "Conduct a comprehensive assessment of laboratory practices and procedures",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "pinnacle-transplant-technologies-llc-646783-10012024",
    "violated_terms": [
      "sections 301(d) of the FD&C Act",
      "section 505(a) of the FD&C Act",
      "section 351(a)(1) of the PHS Act",
      "section 501(a)(2)(B) of the FD&C Act",
      "21 CFR Parts 210 and 211",
      "21 CFR 211.113(b)",
      "21 CFR 211.160(b)",
      "21 CFR 211.192",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.42(c)(10)(v)",
      "21 CFR 211.67(a)",
      "21 CFR 1271.3(d)",
      "21 CFR 1271.10(a)"
    ],
    "recommendations": [
      "Establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile.",
      "Establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity.",
      "Thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications.",
      "Have an adequate system for monitoring environmental conditions in an aseptic processing area.",
      "Establish an adequate system for cleaning and disinfecting the room to produce aseptic conditions.",
      "Maintain equipment and utensils at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
    ]
  },
  {
    "letter_name": "mirfeel-korea-co-ltd-627401-06222022",
    "violated_terms": [
      "Adulteration of MOISTURIZING HAND SANITIZER Peppermint Scented due to benzene contamination",
      "Failure to conduct adequate finished drug product testing",
      "Failure to verify identity of raw materials",
      "Inadequate stability testing program",
      "Misbranding of hand sanitizers packaged in food-like containers"
    ],
    "recommendations": [
      "Conduct a detailed investigation into benzene contamination and provide impurity testing results",
      "Establish a comprehensive testing program for raw materials and drug products",
      "Implement a robust stability testing program with defined attributes and timelines",
      "Engage a qualified CGMP consultant to evaluate operations and compliance"
    ]
  },
  {
    "letter_name": "landy-international-679066-06122024",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a))",
      "Inadequate testing of batches of hand sanitizer drug products for identity and strength of active ingredient (ethanol)",
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Inadequate testing of incoming ethanol for methanol contamination",
      "Inadequate testing of glycerin for identity and contamination with diethylene glycol (DEG) or ethylene glycol (EG)",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Inadequate design and maintenance of water system used in drug manufacturing",
      "Lack of appropriate controls over computer systems to ensure data integrity (21 CFR 211.68(b))"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of laboratory practices and provide a detailed remediation plan.",
      "List chemical and microbial specifications used to analyze each lot of drug products before disposition.",
      "Perform full chemical and microbiological testing of retain samples for all batches distributed to the U.S.",
      "Establish adequate written procedures for production and process control.",
      "Implement a robust ongoing control, maintenance, and monitoring program for the water system.",
      "Retain an independent third-party consultant to assist in remediation and ensure compliance with CGMP.",
      "Conduct training for employees on relevant regulations and procedures."
    ]
  },
  {
    "letter_name": "scientific-solutions-global-llc-574921-06282019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish adequate written procedures for production and process control",
      "failure to establish a quality control unit"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before a lot disposition decision",
      "Provide a summary of results obtained from testing retain samples of all drug products within expiry",
      "Provide your updated SOP describing how you plan to test each component lot for conformity",
      "Commit to test each lot of components received for identity",
      "Provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations",
      "Conduct a comprehensive review of your manufacturing processes to determine your current state of control",
      "Develop a data-driven and scientifically sound validation program",
      "Include a timeline for performing process performance qualification for each of your drug products",
      "Conduct a comprehensive assessment with CAPA to ensure your QU is given the authority and resources to effectively function",
      "Engage a consultant qualified to assist your firm in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "mxl-comercial-sa-de-cv-609335-11102020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of your entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "outin-futures-corp-684688-09252024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded under section 502(c), (f)(2), and (x) of the FD&C Act",
      "failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a))",
      "failed to exercise appropriate controls over computer or related systems (21 CFR 211.68(b))",
      "failed to establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a) and (d))",
      "failed to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failed to provide adequate warnings as required under M020",
      "failed to include a domestic address or domestic telephone number as required under section 502(x) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations.",
      "Provide a comprehensive, independent assessment of computer system performance and security.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide an assessment of each drug product process to ensure that there is a data-driven and scientifically sound program.",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.",
      "Conduct a comprehensive investigation into the extent of the inaccuracies in data records and reporting.",
      "Provide a current risk assessment of the potential effects of the observed failures on the quality of your drugs.",
      "Provide a management strategy for your firm that includes the details of your global CAPA plan."
    ]
  },
  {
    "letter_name": "pfizer-healthcare-india-private-limited-594972-03252020",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Adequate investigations and timely implementation of CAPA plans",
      "Root cause analysis for sterility testing failures",
      "Investigation of environmental monitoring deficiencies",
      "Data integrity practices and documentation systems"
    ],
    "recommendations": [
      "Comprehensive assessment of investigation systems for deviations and discrepancies",
      "Remediation plan for CAPA program effectiveness",
      "Assessment of documentation practices and CAPA plan for improvements",
      "Independent assessment of laboratory practices and resources",
      "Revised investigations regarding sterility failures and environmental controls"
    ]
  },
  {
    "letter_name": "panacea-biotec-limited-607837-09242020",
    "violated_terms": [
      "Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).",
      "Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Implement a thorough, independent assessment, and CAPA for your pressure differential system, including a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention, and overall system control."
    ]
  },
  {
    "letter_name": "tailor-made-compounding-llc-594743-04012020",
    "violated_terms": [
      "section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)",
      "current good manufacturing practices (CGMP) (section 501(a)(2)(B))",
      "labeling with adequate directions for use (section 502(f)(1))",
      "FDA approval prior to marketing (section 505)",
      "section 501(a)(2)(A) of the FDCA",
      "section 211.113(b)",
      "section 211.42(c)(10)(v)",
      "section 211.84(d)(1) and (2)",
      "section 211.42(c)(10)(iv)",
      "section 211.68(a)",
      "section 211.192",
      "section 501(c) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Implement appropriate written procedures to prevent microbiological contamination of drug products.",
      "Establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions.",
      "Conduct tests to verify the identity of each component of a drug product.",
      "Establish an adequate system for monitoring environmental conditions in aseptic processing areas.",
      "Routine calibration, inspection, or checking of equipment used in drug manufacturing.",
      "Thoroughly investigate any unexplained discrepancies or failures of a batch or its components."
    ]
  },
  {
    "letter_name": "little-moon-essentials-llc-677260-09172024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded products",
      "failure to conduct identity testing for components",
      "failure to validate supplier's test analyses",
      "failure to test incoming raw materials",
      "failure to demonstrate suitability of water used in manufacturing",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to establish written procedures for production and process control",
      "failure to assure drug product expiration dates supported by stability testing",
      "failure to establish adequate written responsibilities and procedures for quality control unit"
    ],
    "recommendations": [
      "Implement a supplier qualification program",
      "Engage a third-party laboratory for supplier testing",
      "Conduct a comprehensive independent review of material systems",
      "Provide chemical and microbiological quality control specifications",
      "Perform testing on all components for identity and purity",
      "Establish a stability program for drug products",
      "Create a quality control department with defined responsibilities",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "natuzen-co-ltd-677942-05032024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements before resuming drug manufacturing operations.",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Evaluate the completion and efficacy of all corrective action and preventive action (CAPA) before pursuing resolution of compliance status."
    ]
  },
  {
    "letter_name": "max-chemical-inc-682037-06202024",
    "violated_terms": [
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Lack of written procedures for production and process control (21 CFR 211.100(a)).",
      "Inadequate quality control unit oversight (21 CFR 211.22)."
    ],
    "recommendations": [
      "Implement testing protocols for all components to ensure identity and conformity with specifications.",
      "Establish written procedures for production and process control to ensure drug products meet identity, strength, quality, and purity.",
      "Strengthen the quality control unit to ensure compliance with CGMP, including adequate finished product testing, stability programs, investigations of testing failures, and employee training."
    ]
  },
  {
    "letter_name": "rij-pharmaceutical-llc-558815-03282019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to establish adequate written procedures for production and process control",
      "failure to ensure water system produces suitable water for drug manufacturing",
      "failure to conduct process validation studies",
      "failure to establish laboratory controls",
      "failure to thoroughly investigate discrepancies or failures",
      "failure to establish adequate written responsibilities and procedures for the quality control unit",
      "failure to ensure laboratory records include complete data"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your water system design, control, and maintenance",
      "Provide a comprehensive corrective action and preventive action (CAPA) plan for your water system",
      "Provide a validation plan for ensuring a state of control throughout the product lifecycle",
      "Provide a review of all drug products covered by a USP monograph",
      "Provide data to show stability of packaged products over intended shelf-life",
      "Provide a comprehensive, independent evaluation of your change management system",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "wittman-pharma-inc-683081-08062024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP)",
      "21 CFR 211.22",
      "21 CFR 211.192",
      "21 CFR 211.165(b)",
      "21 CFR 211.160(b)",
      "21 CFR 211.67(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.84(d)(1)"
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Investigate and determine the causes of any violations and prevent their recurrence.",
      "Correct any violations promptly."
    ]
  },
  {
    "letter_name": "strides-pharma-science-limited-576722-07012019",
    "violated_terms": [
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture."
    ],
    "recommendations": [
      "Provide a thorough review of production for any OOS results with inconclusive or no root cause identified, including a CAPA plan that identifies root causes and specifies meaningful improvements.",
      "Provide all reserve sample testing results and include all analytical data for the API and drug product batches.",
      "Conduct an assessment of the extent of data integrity deficiencies at your facility and provide a current risk assessment of the potential effects of the observed failures on the quality of your drugs.",
      "Develop a management strategy that includes a detailed corrective action plan to ensure the reliability and completeness of all data generated by your firm."
    ]
  },
  {
    "letter_name": "shangrao-chunyu-technology-co-ltd-610194-02032021",
    "violated_terms": [
      "Adulteration of Instant – Hand Sanitizer – Moisturizing due to ethanol content being only 58% instead of the labeled 75%.",
      "Failure to comply with CGMP requirements as evidenced by the use of unsuitable testing methods."
    ],
    "recommendations": [
      "Conduct a detailed investigation into the discrepancy in ethanol content.",
      "Provide a comprehensive list of raw materials and suppliers for all hand sanitizer products.",
      "Submit a full reconciliation of all batches shipped to the U.S. and third-party analysis for ethanol content.",
      "Include complete batch records for all distributed products.",
      "Engage a qualified CGMP consultant for a comprehensive audit and remediation plan."
    ]
  },
  {
    "letter_name": "omni-lens-pvt-ltd-688151-10022024",
    "violated_terms": [
      "Quality control unit failures to ensure compliance with CGMP (21 CFR 211.22)",
      "Lack of adequate quality unit oversight",
      "Delegation of quality unit responsibilities to contract manufacturing organizations (CMOs)",
      "Failure to conduct necessary aseptic processing studies and testing"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality unit authority and resources",
      "Evaluation of procedures for robustness and appropriateness",
      "Provisions for quality unit oversight throughout operations",
      "Final review of each batch before disposition decision",
      "Management support for quality assurance and resource provision"
    ]
  },
  {
    "letter_name": "rebom-co-ltd-682811-06262024",
    "violated_terms": [
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))."
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Conduct a comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Perform adequate stability studies and testing for all components used in manufacturing."
    ]
  },
  {
    "letter_name": "mym-hidrominerales-sa-de-cv-610066-04092021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e)(1)(A), (f)(2), (x) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "List all batches of hand sanitizer drug products shipped to the U.S.",
      "Submit complete batch records for all batches distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "premier-nutra-pharma-inc-640210-12092022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components",
      "failed to establish and follow appropriate written procedures to prevent objectionable microorganisms",
      "failed to prepare batch production and control records with complete information",
      "failed to establish an adequate quality unit",
      "failed to establish written procedures defining quality unit responsibilities"
    ],
    "recommendations": [
      "Provide a thorough and independent evaluation of your operations",
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations",
      "Provide a comprehensive, independent assessment of the design and control of your firm’s manufacturing operations",
      "Conduct a detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination",
      "Complete investigations into all batches with potential objectionable microbial contamination",
      "Establish appropriate microbiological batch release specifications",
      "Provide all chemical and microbial test methods used to analyze each of your drug products",
      "Summarize results from testing retain samples of all drug product batches within expiry",
      "Develop a CAPA plan based on the retrospective assessment of your cleaning and disinfection program",
      "Assess documentation systems used throughout your manufacturing and laboratory operations",
      "Conduct a risk assessment of products released to the U.S. market without adequate and approved production and control documentation",
      "Provide an independent, comprehensive assessment and remediation plan to ensure your quality unit is established"
    ]
  },
  {
    "letter_name": "omega-tech-labs-llc-679700-07232024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.113(a)",
      "21 CFR 211.100(a)",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.166(a)",
      "21 CFR 211.22",
      "section 501(a)(2)(B) of the FD&C Act",
      "section 505(a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of the design and control of your firm’s manufacturing operations.",
      "Conduct a detailed risk assessment addressing the hazards posed by distributing combination products potentially contaminated with objectionable organisms.",
      "Complete investigations into all batches with potential objectionable microbial contamination.",
      "Establish appropriate microbiological batch release specifications for each of your drug products.",
      "Provide a comprehensive independent assessment of your water system design, control, and maintenance.",
      "Implement a thorough remediation plan to install and operate a suitable water system.",
      "Establish a written testing program designed to assess the stability characteristics of drug products.",
      "Provide a comprehensive assessment and remediation plan to ensure your quality control unit is effective.",
      "Engage a consultant qualified to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "ningbo-huize-commodity-co-ltd-581345-08022019",
    "violated_terms": [
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22 (a)).",
      "Falsified documents include cleaning validation reports, batch records for multiple drug products, and annual product reviews.",
      "SPF 30 SUNSCREEN LOTION 30mL is misbranded under sections 502(f)(1) and (f)(2) of the FD&C Act, 21 U.S.C. 352(f)(1) and (f)(2).",
      "SPF 30 SUNSCREEN LOTION 60mL is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1)."
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function.",
      "Conduct a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.",
      "Engage a qualified consultant to assist your firm in meeting CGMP requirements and perform a comprehensive audit of your entire operation for CGMP compliance.",
      "Provide a comprehensive investigation into the extent of the inaccuracies in data records and reporting, including a detailed investigation protocol and methodology."
    ]
  },
  {
    "letter_name": "natural-beauty-care-pty-ltd-611974-06092021",
    "violated_terms": [
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to conduct at least one test to verify the identity of each component of a drug product",
      "failure to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products",
      "inadequate quality systems",
      "failure to identify critical process parameters and monitor process controls"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each lot of drug products before disposition.",
      "Develop an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Conduct a comprehensive, independent assessment of laboratory practices and provide a remediation plan.",
      "Perform identity tests on incoming lots of active pharmaceutical ingredients.",
      "Establish a written testing program for stability characteristics and appropriate storage conditions.",
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive audit."
    ]
  },
  {
    "letter_name": "shuzy-rock-inc-630110-09012022",
    "violated_terms": [
      "Adulterated drug products under section 501(a)(2)(A) of the FD&C Act.",
      "Adulterated drug products under section 501(c) of the FD&C Act due to subpotency.",
      "Failure to register with FDA as required by section 510 of the FD&C Act.",
      "Failure to properly list drug products as required by section 510(j) of the FD&C Act.",
      "Insanitary conditions observed during the inspection.",
      "Inadequate quality control unit responsibilities.",
      "Inadequate documentation practices."
    ],
    "recommendations": [
      "Conduct a detailed investigation into the subpotency of hand sanitizer products.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit.",
      "Implement remediation plans for production and process controls.",
      "Establish adequate cleaning controls and validate cleaning procedures.",
      "Design and control a suitable water system for drug manufacturing.",
      "Provide timelines for completed process performance qualification for marketed drug products."
    ]
  },
  {
    "letter_name": "medgel-private-limited-654085-07202023",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Inadequate investigation of humidity excursions",
      "Quality control unit responsibilities (21 CFR 211.22)",
      "Testing of components for identity and conformity (21 CFR 211.84(d)(1) and 211.84(d)(2))"
    ],
    "recommendations": [
      "Provide microbiological and (b)(4) test results for drug products currently in the U.S. market",
      "Conduct a retrospective review of all invalidated OOS results",
      "Develop a comprehensive review and remediation plan for OOS result investigation systems",
      "Implement a risk assessment for finished products on the market",
      "Establish a program for qualifying and overseeing contract testing facilities"
    ]
  },
  {
    "letter_name": "tropicosmeticos-sa-de-cv-609041-08102021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drugs prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of methanol for ethanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "Submit copies of complete batch records for all batches distributed to the U.S.",
      "Conduct a comprehensive independent assessment of laboratory practices and provide a remediation plan",
      "Test each component lot for conformity with specifications and commit to testing every lot of ethanol for methanol content",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "mimedx-group-inc-662942-12202023",
    "violated_terms": [
      "FD&C Act",
      "PHS Act",
      "21 CFR 1271.10(a)",
      "21 CFR 211.100(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.110(a)(6)",
      "21 CFR 211.160(b)(3)",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(a)",
      "21 CFR 211.84(b)"
    ],
    "recommendations": [
      "Establish adequate written procedures for production and process control.",
      "Establish laboratory controls that include scientifically sound and appropriate specifications.",
      "Implement in-process control procedures that include bioburden testing.",
      "Ensure drug product samples are representative of the entire batch.",
      "Conduct tests to verify the identity of each component of a drug product.",
      "Withhold each lot of components from use until tested and released by the quality control unit.",
      "Include specifications for elemental impurities and endotoxin in final specifications.",
      "Provide a disinfectant efficacy study for processing facility and production equipment."
    ]
  },
  {
    "letter_name": "virgin-scent-inc-dba-artnaturals-631780-09012022",
    "violated_terms": [
      "Adulteration of drug products under section 501(a)(2)(B) of the FD&C Act",
      "Failure to comply with Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211)",
      "Misbranding of drugs under section 502(o) of the FD&C Act",
      "Failure to properly list drug products with the FDA as required by section 510(j) of the FD&C Act",
      "Inadequate quality control unit oversight (21 CFR 211.22)",
      "Failure to prepare complete batch production and control records (21 CFR 211.188)"
    ],
    "recommendations": [
      "Establish a Quality Unit (QU) with defined responsibilities and authority to oversee manufacturing processes.",
      "Implement written procedures for investigations, recalls, and complaint handling.",
      "Conduct a comprehensive assessment of documentation systems and develop a corrective action plan.",
      "Ensure ongoing management oversight throughout the manufacturing lifecycle of all drug products.",
      "Engage a qualified consultant to assist in meeting CGMP requirements if resuming drug manufacturing.",
      "Provide a final reconciliation of OTC drug product inventory following fire clean-up operations."
    ]
  },
  {
    "letter_name": "mb-solutions-llcbiospectrum-cbd-610649-07222021",
    "violated_terms": [
      "unapproved new drugs",
      "misbranded drugs",
      "unsafe food additive",
      "adulterated food",
      "unapproved new animal drugs",
      "adulterated animal food"
    ],
    "recommendations": [
      "Take prompt action to address the violations cited in this letter.",
      "Notify FDA in writing within fifteen working days of receipt of this letter of the specific steps taken to address the violations.",
      "Include an explanation of each step being taken to prevent the recurrence of any violations.",
      "Provide copies of related documentation."
    ]
  },
  {
    "letter_name": "nantong-furuida-packaging-products-co-ltd-667984-11172023",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "You have not demonstrated that you are testing incoming lots of the active pharmaceutical ingredients (APIs) used to manufacture your OTC drug products to determine their identity.",
      "You released an API for use in drug manufacturing based on a component supplier’s certificate of analysis (COA) without proper qualification or verification.",
      "You provided a supplier’s COA for isopropyl alcohol that does not include methanol testing specifications.",
      "You failed to provide evidence of long-term stability studies to corroborate product stability projections."
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of your material system to ensure all suppliers are qualified and materials have appropriate expiration or retest dates.",
      "Provide chemical and microbiological quality control specifications for testing and releasing each incoming lot of components.",
      "Describe how you will test each component lot for conformity with specifications and establish the reliability of supplier results.",
      "Summarize results from testing all components to evaluate the reliability of COAs from manufacturers.",
      "Outline your program for qualifying and overseeing contract facilities that test drug products.",
      "Provide methanol test results for all batches of hand sanitizer shipped to the U.S. within expiry."
    ]
  },
  {
    "letter_name": "msm-nutraceuticals-llc-dba-msm-health-solutions-584018-10242019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of section 505(a) of the FD&C Act",
      "released finished OTC drug products without adequate testing",
      "failed to perform appropriate laboratory determination of satisfactory conformance",
      "failed to establish adequate written procedures for production and process control",
      "failed to assure that the drug product bore an expiration date supported by appropriate stability testing",
      "failed to conduct at least one test to verify the identity of each component of a drug product"
    ],
    "recommendations": [
      "Provide a summary of your test requirements and specifications that align with USP <5>",
      "Conduct a comprehensive, independent assessment of your laboratory practices and provide a detailed CAPA plan",
      "List chemical and microbial specifications used to analyze each lot of drug products",
      "Provide a remediation plan for ongoing management oversight throughout the manufacturing lifecycle",
      "Provide a comprehensive, independent assessment of your change management system",
      "Provide a comprehensive, independent assessment and CAPA to ensure the adequacy of your stability program",
      "Provide a comprehensive, independent review of your material system to determine supplier qualifications",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "westwood-laboratories-llc-674728-04172024",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192)",
      "Inadequate investigation of complaints for OTC drug products",
      "Failure to test samples of each component for identity and conformity (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Failure to establish laboratory controls (21 CFR 211.160(b))",
      "Inadequate qualification and control of water system used in drug manufacturing (21 CFR 211.100(a))",
      "Inadequate cleaning validation for shared equipment"
    ],
    "recommendations": [
      "Conduct an independent, comprehensive review of the complaint handling program",
      "Perform a risk assessment for drug products containing ingredients at risk for contamination",
      "Establish a detailed summary of the validation program for product lifecycle control",
      "Implement a comprehensive remediation plan for the water system",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "pharmedica-usa-llc-648269-04282023",
    "violated_terms": [
      "Drug products manufactured under insanitary conditions",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "Inadequate facility design and controls for sterile drug product manufacturing",
      "Failure to establish adequate written procedures for production and process control",
      "Inadequate qualification of equipment and validation of processes",
      "Failure to conduct appropriate laboratory testing for drug products",
      "Failure to test samples of each component for identity and conformity",
      "Quality control unit failed to ensure compliance with CGMP"
    ],
    "recommendations": [
      "Cease manufacturing and distribution of all drug products",
      "Conduct a voluntary recall of drug products manufactured with active ingredient MSM",
      "Notify FDA prior to resuming drug manufacturing operations",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive six-system audit for CGMP compliance"
    ]
  },
  {
    "letter_name": "us-continental-marketing-inc-570748-05022019",
    "violated_terms": [
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).",
      "Failure to ensure the sterility of ophthalmic drug products manufactured under contract.",
      "Inadequate facilities and controls to manufacture sterile drugs.",
      "Contamination of ophthalmic drug products with Bacillus spp. and high levels of particulate matter."
    ],
    "recommendations": [
      "Establish an adequate quality control unit with the authority to approve or reject all relevant components and products.",
      "Implement measures to ensure the sterility of drug products, including proper sterilization of containers and closures.",
      "Ensure that contract manufacturers have adequate facilities and controls for sterile drug manufacturing.",
      "Develop and propose specific corrective and preventative actions for the CGMP violations observed."
    ]
  },
  {
    "letter_name": "tja-health-llc-678539-07172024",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your firm failed to adequately test incoming raw materials used for the manufacture of your drug products.",
      "Your firm produced (b)(4) water that was used as a component in the production of your drug products without demonstrating its suitability.",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates.",
      "Provide the chemical and microbiological quality control specifications you use to test and release each incoming lot of components.",
      "Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Provide a commitment to provide DEG and EG test results for all lots of high-risk drug components used in the manufacture of your drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination.",
      "Provide your total microbial count limits to monitor whether the water system is producing water suitable for the intended uses for each of your drug products.",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "omega-delta-co-inc-636606-11022022",
    "violated_terms": [
      "adulterated under section 501(a)(2)(A) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "Current Good Manufacturing Practice (CGMP) violations",
      "failed to exercise its responsibility to ensure drug products are in compliance with CGMP",
      "failed to test samples of each component for identity and conformity",
      "failed to establish adequate written procedures for production and process control"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit (QU)",
      "Conduct identity testing for each component lot",
      "Establish reliability of suppliers’ certificates of analysis (COAs)",
      "Develop a comprehensive remediation plan for the design, control, and maintenance of the water system",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Address the impact of observed water system failures on drug product quality"
    ]
  },
  {
    "letter_name": "triad-rx-inc-569659-02052019",
    "violated_terms": [
      "section 503A of the FDCA",
      "current good manufacturing practices (CGMP)",
      "labeling with adequate directions for use",
      "FDA approval prior to marketing",
      "section 501(a)(2)(A) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Notify the FDA in writing of the specific steps taken to correct violations within fifteen working days."
    ]
  },
  {
    "letter_name": "laboratorio-magnachem-international-673796-06182024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to thoroughly investigate unexplained discrepancies (21 CFR 211.192)",
      "failure to establish adequate laboratory controls (21 CFR 211.160(b))",
      "failure to exercise appropriate controls over computer systems (21 CFR 211.68(b))"
    ],
    "recommendations": [
      "Conduct a thorough investigation to evaluate all potentially affected batches and implement a timely and effective CAPA.",
      "Provide a retrospective, independent review of all invalidated OOS results.",
      "Establish adequate laboratory controls and validate test methods.",
      "Implement a comprehensive assessment and CAPA plan for computer system security and integrity.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "ningbo-poplar-daily-use-669486-02052024",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a))",
      "Failure to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))",
      "Failure to establish and follow an adequate written testing program for stability characteristics of drug products (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each batch of drug products before disposition.",
      "Develop an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Provide a summary of results obtained from testing retain samples from each batch.",
      "Establish a written testing program to assess stability characteristics and determine appropriate storage conditions and expiration dates.",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements and perform a comprehensive audit."
    ]
  },
  {
    "letter_name": "sanit-technologies-llc-dba-durisan-614278-07272021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "quality control unit failed to ensure compliance with CGMP",
      "lack of quality control over batch release",
      "failed finished product specifications for total aerobic microbial count",
      "release of contaminated drug products",
      "failure to investigate out-of-specification results",
      "failure to ensure water system suitability",
      "failure to establish finished product drug specifications",
      "failure to establish a stability program"
    ],
    "recommendations": [
      "Acknowledge responsibility for all products that remain in the market and are within expiry",
      "Indicate how to maintain quality assessments, including ongoing review of adverse events and customer complaints",
      "Provide a full reconciliation for all drug products that have not been recalled",
      "Provide documentation for any disposed drug products",
      "Provide a detailed plan for the dissolution of the business",
      "Contact the agency before resuming drug manufacturing operations"
    ]
  },
  {
    "letter_name": "s-j-international-enterprises-public-company-limited-668482-01262024",
    "violated_terms": [
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)",
      "Inadequate batch production and control records (21 CFR 211.188)",
      "Data integrity issues",
      "Delaying or limiting access to records during inspection"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for the quality control unit",
      "Detailed corrective action and preventive action (CAPA) plan for documentation practices",
      "Investigation into data integrity lapses and management strategy for global CAPA plan",
      "Engagement of a qualified CGMP consultant for compliance evaluation"
    ]
  },
  {
    "letter_name": "salon-technologies-international-inc-630566-12212022",
    "violated_terms": [
      "Adulteration of drug products due to unacceptable levels of impurities (acetaldehyde, acetal, benzene).",
      "Failure to conduct impurity testing of active pharmaceutical ingredients and finished products prior to distribution.",
      "Non-compliance with Current Good Manufacturing Practice (CGMP) requirements under section 501(a)(2)(B) of the FD&C Act."
    ],
    "recommendations": [
      "Conduct a detailed investigation into the presence of unacceptable levels of impurities in hand sanitizer products.",
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive audit of operations.",
      "Remove adulterated batches from distribution and implement finished product testing for each batch."
    ]
  },
  {
    "letter_name": "liq-e-sa-de-cv-609128-11192020",
    "violated_terms": [
      "adulterated within the meaning of section 501(d)(2) of the FD&C Act",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (i), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions before pursuing resolution of your firm’s compliance status with FDA"
    ]
  },
  {
    "letter_name": "lohxa-llc-581785-09102019",
    "violated_terms": [
      "Failure to establish and follow an adequate written testing program for stability characteristics (21 CFR 211.166(a))",
      "Inadequate cleaning and maintenance of equipment (21 CFR 211.67(a))",
      "Insufficient investigation of discrepancies (21 CFR 211.192)"
    ],
    "recommendations": [
      "Provide stability protocol(s) and summary data supporting the 6-month expiration dates for repackaged unit dose products.",
      "Submit a comprehensive plan to evaluate cleaning procedures and practices for each piece of manufacturing equipment, including cleaning validation protocols and summary reports.",
      "Conduct a comprehensive assessment of the system for investigating deviations, complaints, and out-of-specification results, including a CAPA plan."
    ]
  },
  {
    "letter_name": "mohawk-laboratories-division-nch-corporation-635780-01182023",
    "violated_terms": [
      "Adulteration of drug products due to contamination with acetaldehyde and acetal at unacceptable levels.",
      "Failure to comply with Current Good Manufacturing Practice (CGMP) requirements.",
      "Drug products manufactured do not conform to specifications for acetaldehyde and acetal per 21 CFR 211.160(b).",
      "Finished product testing not conducted as required under 21 CFR 211.165."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Perform a comprehensive audit of the entire operation for CGMP compliance.",
      "Investigate and determine the causes of violations and prevent their recurrence.",
      "Notify the FDA before resuming manufacturing operations."
    ]
  },
  {
    "letter_name": "new-era-naturals-llc-566658-01302019",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.",
      "Your firm failed to establish and follow written procedures for the preparation of master production and control records designed to assure uniformity from batch to batch.",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products.",
      "Your firm manufactures human over-the-counter drugs for U.S. commercial distribution but has failed to fulfill its drug listing obligations under section 510 of the Act."
    ],
    "recommendations": [
      "Provide finished drug product testing procedures and specification documents.",
      "Establish testing protocols for incoming raw materials and validate supplier analyses.",
      "Prepare updated master production records with complete information.",
      "Define roles and responsibilities of a quality control unit.",
      "Fulfill drug listing obligations with FDA."
    ]
  },
  {
    "letter_name": "utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021",
    "violated_terms": [
      "Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile",
      "Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing",
      "Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures",
      "Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards",
      "Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess",
      "Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures",
      "Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product",
      "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications",
      "Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products",
      "Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product",
      "Failure to prepare batch production and control records for each batch of drug product produced",
      "Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product",
      "Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment",
      "Failure to assign and label each HCT/P that you manufacture with a distinct identification code"
    ],
    "recommendations": [
      "Cease the manufacture and processing of new HCT/Ps until processes and procedures have been reviewed and audited",
      "Do not distribute HCT/Ps that remain in inventory until they have been resampled and retested for contamination",
      "Obtain a valid biologics license to lawfully market a drug that is a biological product",
      "Ensure compliance with IND requirements for biological products"
    ]
  },
  {
    "letter_name": "pharmaplast-sae-648883-04132023",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.",
      "Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals.",
      "You failed to perform adequate identity testing for each component lot used in the production of your drug products.",
      "Your API, ethanol, is not tested for methanol content.",
      "Your procedures did not ensure that you test glycerin for presence of diethylene glycol (DEG) or ethylene glycol (EG).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment."
    ],
    "recommendations": [
      "Provide a comprehensive review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Results of tests for DEG and EG in retain samples of all glycerin lots used to manufacture your drug products.",
      "A full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market.",
      "Limit test of methanol and test results for all batches released and distributed.",
      "Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning.",
      "Appropriate improvements to your cleaning validation program.",
      "A summary of updated standard operating procedures (SOPs) for verification and validation of cleaning procedures."
    ]
  },
  {
    "letter_name": "prime-lab-llc-667057-01022024",
    "violated_terms": [
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Inadequate assurance of the quality of raw materials used in drug products",
      "Failure to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "Inadequate oversight by the quality unit (21 CFR 211.22(a) and 211.22(d))"
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components within 30 days",
      "Conduct a full risk assessment for drug products within expiry that contain ingredients at risk for DEG or EG contamination",
      "Establish adequate written procedures for cleaning and maintenance of equipment",
      "Create a comprehensive assessment and remediation plan for the quality unit to ensure effective oversight"
    ]
  },
  {
    "letter_name": "winder-laboratories-llc-567869-03262019",
    "violated_terms": [
      "Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a comprehensive plan to evaluate the adequacy of cleaning procedures, practices, and validation studies for each piece of non-dedicated manufacturing equipment.",
      "Conduct an independent and retrospective review of all audit trails since January 1, 2016, including all samples aborted, any deletions, and each sample set aborted or deleted.",
      "Include a product impact analysis for drug products manufactured on equipment that was moved to production areas from your warehouse."
    ]
  },
  {
    "letter_name": "sani-care-salon-products-inc-673747-04242024",
    "violated_terms": [
      "Quality control unit responsibilities and failures",
      "Inadequate monitoring and validation of manufacturing processes",
      "Lack of stability studies and expiration dating for products",
      "Failure to conduct appropriate laboratory testing for drug products",
      "Inadequate supplier qualification and testing of incoming materials"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality unit",
      "Timeline for process performance qualification for marketed products",
      "Detailed program for monitoring manufacturing processes",
      "Independent assessment of water system design and maintenance",
      "Risk assessment for water system failures and their impact on drug quality",
      "Plans for separation of pharmaceutical and nonpharmaceutical manufacturing areas",
      "Improvements to cleaning validation program",
      "Updated standard operating procedures for cleaning verification and validation",
      "Corrective action and preventive action plan for stability program",
      "Independent assessment of laboratory practices and procedures"
    ]
  },
  {
    "letter_name": "soliteint-kozmetikai-kft-685146-10102024",
    "violated_terms": [
      "Failure to conduct appropriate laboratory testing for drug products prior to release (21 CFR 211.165(a) and 211.165(b)).",
      "Inadequate testing of active pharmaceutical ingredients (APIs) and failure to validate supplier analyses (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Lack of adequate written procedures for production and process control (21 CFR 211.100(a)).",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a comprehensive assessment of laboratory practices and a detailed remediation plan.",
      "Conduct a thorough review of the material system and establish robust testing protocols for incoming components.",
      "Develop a detailed validation program for manufacturing processes and ensure ongoing monitoring.",
      "Implement a comprehensive assessment and remediation plan for the quality control unit and stability testing procedures."
    ]
  },
  {
    "letter_name": "limpo-quimicos-sa-de-cv-608859-09302021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug product(s) currently in distribution from the U.S. market",
      "Provide a detailed investigation into how the hand sanitizer drug product was substituted with methanol",
      "Provide a detailed investigation into how the NeoNatural gel Hand Sanitizer contained lower ethanol levels than labeled",
      "Provide a list of all raw materials used to manufacture hand sanitizer drug products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "midlab-incorporated-642374-02152023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranding",
      "failure to conduct appropriate laboratory testing",
      "failure to investigate unexplained discrepancies",
      "failure to ensure compliance with CGMP",
      "failure to establish adequate written procedures for production and process control"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each batch of drug products.",
      "Provide an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Conduct a retrospective, independent review of all out-of-specification results.",
      "Provide a comprehensive review and remediation plan for OOS result investigation systems.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit."
    ]
  },
  {
    "letter_name": "renatilabs-inc-646353-06012023",
    "violated_terms": [
      "21 U.S.C. 321(g)",
      "42 U.S.C. 262(i)",
      "21 CFR 1271.3(d)",
      "21 CFR Part 1271",
      "21 CFR 1271.10(a)",
      "21 CFR 1271.15",
      "21 CFR 1271.3(c)",
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(1)",
      "21 CFR 211.165(f)",
      "21 CFR 211.113(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.188(b)",
      "21 CFR 211.166(a)",
      "21 U.S.C. 355(i)",
      "42 U.S.C. 262(a)(3)"
    ],
    "recommendations": [
      "Obtain a valid biologics license for the product.",
      "Ensure compliance with current good manufacturing practice (CGMP) requirements.",
      "Establish and follow appropriate written procedures to prevent microbiological contamination.",
      "Establish written procedures for production and process control.",
      "Establish laboratory controls that include appropriate specifications and standards.",
      "Prepare batch production and control records for each batch of drug product.",
      "Establish and follow a written testing program to assess stability characteristics."
    ]
  },
  {
    "letter_name": "mcdaniel-life-line-llc-571303-05162019",
    "violated_terms": [
      "unapproved new drug",
      "misbranded drug",
      "adulterated drug",
      "insanitary conditions",
      "failure to establish a quality control unit",
      "failure to follow adequate written procedures for complaints",
      "failure to perform laboratory testing for drug products",
      "failure to prepare batch production and control records"
    ],
    "recommendations": [
      "Investigate and determine the causes of the violations identified",
      "Take prompt action to correct the violations",
      "Notify the FDA in writing within fifteen (15) working days of the specific steps taken to correct the violations",
      "Include documentation of the corrective actions taken or planned"
    ]
  },
  {
    "letter_name": "liveyon-labs-inc-588399-12052019",
    "violated_terms": [
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(4)",
      "21 CFR 1271.15",
      "21 CFR 1271.75(a)",
      "21 CFR 1271.80(c)",
      "21 CFR 211.113(b)",
      "21 CFR 211.192",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.42(c)(10)(v)",
      "21 CFR 211.100(a)",
      "21 CFR 211.84(a)",
      "21 CFR 211.198(a)",
      "FD&C Act",
      "PHS Act"
    ],
    "recommendations": [
      "Review FDA Guidance for Industry, Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products.",
      "Consult with third-party experts to implement comprehensive corrective action."
    ]
  },
  {
    "letter_name": "real-clean-distribuciones-sa-de-cv-608900-10272020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Provide a detailed investigation into how hand sanitizer drugs were substituted with methanol",
      "Provide a list of all raw materials used to manufacture all of your hand sanitizer drug products",
      "Provide a list of all batches of any hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of your entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "neoingenium-labs-sa-de-cv-610499-03312021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e)(1)(A), (c), (x), (b)(1), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under sections 301(d) and (a) of the FD&C Act",
      "failure to comply with CGMP requirements under section 501(a)(2)(B) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE) under section 201(p) of the FD&C Act",
      "not in conformity with the 1994 TFM and applicable requirements for nonprescription drugs",
      "failure to disclose the presence of methyl alcohol (methanol) in the product label",
      "failure to include the principal intended use of the drug as part of the statement of identity",
      "failure to provide a complete domestic address or telephone number for adverse event reporting"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "provide a detailed investigation into the substitution of ethanol with methanol",
      "provide a summary of findings regarding raw material suppliers",
      "provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "provide copies of complete batch records for all batches distributed to the U.S."
    ]
  },
  {
    "letter_name": "washington-homeopathic-products-inc-589823-06192020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to establish an adequate quality control unit",
      "failure to conduct identity testing for components",
      "failure to establish and document test method validation"
    ],
    "recommendations": [
      "Provide a complete reconciliation of all drug products released without adequate oversight",
      "Implement quality agreements with suppliers",
      "Conduct a comprehensive independent review of the material system",
      "Establish appropriate microbiological batch release specifications",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "saruhan-kimya-ve-temizlik-urunleri-sanayi-ticaret-anonim-sirketi-corlu-subesi-669487-11062023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to validate and establish the reliability of your component supplier’s test analyses.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products."
    ],
    "recommendations": [
      "Provide the chemical and microbiological quality control specifications for testing each incoming lot of components.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "List chemical and microbial specifications, including test methods, used to analyze each batch of drug products before a batch disposition decision.",
      "Develop a comprehensive CAPA plan to ensure the adequacy of your stability program, including stability indicating methods and ongoing stability studies.",
      "Engage a qualified consultant to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "pharmalab-enterprises-inc-588432-12102019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "adulterated within the meaning of section 402(g)(1) of the FD&C Act",
      "misbranded dietary supplements under section 403 of the FD&C Act",
      "misbranded foods under section 403 of the FD&C Act",
      "failed to establish laboratory controls",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failed to establish adequate written procedures for production and process control",
      "failed to establish product specifications for each dietary supplement",
      "failed to declare the common or usual names of each ingredient",
      "failed to identify the part of the plant from which each botanical dietary ingredient is derived",
      "failed to include a percent juice declaration",
      "failed to provide nutrition information as required by 21 CFR 101.9"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed corrective action and preventive action (CAPA) plan.",
      "Conduct a comprehensive assessment of the design and control of manufacturing operations.",
      "Perform complete investigations into all batches with potential objectionable microbial contamination.",
      "Establish appropriate microbiological batch release specifications.",
      "Provide a detailed action plan to remediate the system for investigating deviations and discrepancies.",
      "Provide a detailed summary of the validation program for ensuring a state of control throughout the product lifecycle.",
      "Engage a consultant qualified to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "premier-trends-llc-621313-03142022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug product",
      "misbranded drug product",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to test samples of each component for identity and conformity",
      "failure to routinely calibrate, inspect, or check equipment",
      "failure to establish and follow written procedures for master production and control records",
      "failure to ensure personnel are qualified for CGMP operations",
      "lack of a quality control unit",
      "failure to submit registration information annually",
      "failure to properly list drug products"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed remediation plan",
      "Ensure products in the market comply with appropriate specifications",
      "Conduct a comprehensive review of the material system and establish adequate incoming material controls",
      "Evaluate all manufacturing equipment and implement a CAPA plan for equipment management",
      "Implement procedures to assure production records are completed and reviewed",
      "Develop a training plan for staff to ensure proper CGMP training and oversight",
      "Engage a qualified consultant to assist in meeting drug CGMP requirements",
      "Inform FDA if discontinuing manufacturing or updating labels for Magic Heal"
    ]
  },
  {
    "letter_name": "ws-badger-company-inc-622318-04122022",
    "violated_terms": [
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192)."
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures.",
      "A detailed, independent assessment of all test methods to ensure they include specific instructions to ensure repeatability, are supported by adequate validation studies, and are appropriate for their intended use.",
      "A retrospective, independent review of all invalidated OOS results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis."
    ]
  },
  {
    "letter_name": "unipharma-llc-585388-11062019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranding",
      "failure to thoroughly investigate discrepancies",
      "objectionable microbiological contamination",
      "inadequate written procedures for production and process control",
      "failure to establish adequate written testing program for stability",
      "failure to provide adequate stability data",
      "failure to comply with Drug Facts labeling requirements"
    ],
    "recommendations": [
      "Comprehensive, independent assessment of overall system for investigating deviations",
      "Detailed CAPA plan to remediate the investigation system",
      "Comprehensive, independent assessment of laboratory practices and procedures",
      "Comprehensive, independent assessment of water system design and maintenance",
      "Thorough remediation plan for suitable water system operation",
      "Validation report for the water system after design issues are corrected",
      "Detailed summary of validation program for product lifecycle control",
      "Timeline for performing process performance qualification for marketed drug products",
      "Comprehensive, independent assessment and CAPA plan for stability program",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "walfer-corporation-dba-medicine-shoppe-pharmacy-611017-09172021",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products due to insanitary conditions",
      "Misbranded drug products under section 502(f)(1) of the FDCA",
      "Failure to maintain buildings in a clean and sanitary condition",
      "Failure to clean and sanitize equipment and utensils",
      "Presence of vermin in the production area",
      "Non-microbial contamination in production area",
      "Unsealed, loose ceiling tiles in production area",
      "Inadequate containment and cleaning of hazardous drug products"
    ],
    "recommendations": [
      "Take prompt action to correct the violations cited in the letter",
      "Notify the FDA in writing within fifteen (15) working days of receipt of the letter about specific steps taken to correct the violations",
      "Provide documentation regarding the cleaning schedule and pest remediation actions",
      "Maintain adequate oversight of contractors to ensure compliance with CGMP regulations",
      "Conduct a comprehensive assessment of operations before resuming production of sterile drugs",
      "Notify the FDA fifteen (15) working days prior to resuming production of any sterile drugs"
    ]
  },
  {
    "letter_name": "vida-international-inc-573082-05292019",
    "violated_terms": [
      "Failure to perform appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Failure to conduct at least one test to verify the identity of each component of a drug product.",
      "Failure to establish an adequate quality control unit.",
      "Failure to prepare batch production and control records with complete information."
    ],
    "recommendations": [
      "Plan for testing retain samples of all batches of drug product distributed to the U.S. market.",
      "Conduct a risk assessment of all drug product batches distributed to the U.S. market.",
      "Notify FDA prior to resuming manufacturing drugs for the U.S. market.",
      "Provide test methods and specifications for analyzing each batch of drug product before release.",
      "Establish a comprehensive assessment and corrective action and preventive action (CAPA) plan."
    ]
  },
  {
    "letter_name": "torrent-pharmaceuticals-limited-585255-10082019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to follow written procedures for production and process control",
      "failure to thoroughly investigate unexplained discrepancies or failures",
      "inadequate OOS investigations",
      "high percentage rate of invalidated OOS test results",
      "repeated failures at multiple sites"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide a timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.",
      "Provide a review of all data that supports your process validation for commercially distributed drug products.",
      "Conduct a retrospective, third-party review of all invalidated OOS results for products currently in the U.S. market.",
      "Provide a comprehensive review and remediation plan for your OOS result investigation systems.",
      "Engage a qualified consultant to assist in meeting CGMP requirements and provide a summary of their audit report.",
      "Investigate and determine the causes of violations and prevent their recurrence."
    ]
  },
  {
    "letter_name": "missouri-analytical-laboratories-inc-615319-09302021",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records (21 CFR 211.68(b)).",
      "Failure to document and explain any deviation and investigate all critical deviations."
    ],
    "recommendations": [
      "Provide a retrospective, independent review of all invalidated OOS results for products currently in the U.S. market and within expiry.",
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting, including interviews of current and former employees."
    ]
  },
  {
    "letter_name": "maison-terre-llc-610315-04012021",
    "violated_terms": [
      "Adulterated under section 501(a)(2)(A) of the FD&C Act",
      "Adulterated under section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drug under section 505(a) of the FD&C Act",
      "Misbranded drug under section 502 of the FD&C Act",
      "Failed to conduct appropriate laboratory testing (21 CFR 211.165(b))",
      "Failed to test before use each lot of a component (21 CFR 211.84(d)(6))",
      "Failed to establish a quality control unit (21 CFR 211.22(a))",
      "Failed to have separate or defined areas to prevent contamination (21 CFR 211.42(c))",
      "Failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "Failed to establish and follow appropriate written procedures to prevent objectionable microorganisms (21 CFR 211.113(a))",
      "Did not keep inventory or distribution records (21 CFR 211.150)",
      "Failed to establish written procedures to identify the drug product with a lot or control number (21 CFR 211.130(c))",
      "Failed to assure that the drug product bore an expiration date supported by stability testing (21 CFR 211.137(a))",
      "Misbranded under section 502(f)(1) of the FD&C Act"
    ],
    "recommendations": [
      "Remove the 'Goldenseal Root Powder Organic' drug product currently in distribution in the U.S. market",
      "Clarify whether you intend to resume manufacturing any drugs at this facility in the future"
    ]
  },
  {
    "letter_name": "maitland-labs-central-florida-610102-08062021",
    "violated_terms": [
      "section 503B of the FDCA",
      "section 505 of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 582 of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 502(a) of the FDCA",
      "section 503B(b)(5) of the FDCA",
      "section 503B(a)(10) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in conducting the comprehensive evaluation.",
      "Notify the FDA in writing of the specific steps taken to address the issues identified within 15 working days."
    ]
  },
  {
    "letter_name": "monarch-pcm-llc-620779-06102022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products under section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drugs under section 505(a) of the FD&C Act",
      "Failure to properly list drug products under section 510(j) of the FD&C Act",
      "Misbranding under section 301(p) and 502(o) of the FD&C Act",
      "Failure to investigate unexplained discrepancies (21 CFR 211.192)",
      "Failure to use appropriately designed equipment (21 CFR 211.63)",
      "Failure of quality control unit to ensure compliance with CGMP (21 CFR 211.22)",
      "Inadequate written testing program for stability characteristics (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Conduct detailed risk assessments addressing hazards posed by marketed drug products with microbiological contamination.",
      "Perform full microbiological testing of retain samples for all batches of drug products formulated with water.",
      "Provide a comprehensive, independent assessment of water system design, control, and maintenance.",
      "Develop a thorough remediation plan for the stability program.",
      "Provide a comprehensive independent assessment and remediation plan for the quality control unit.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Implement a management strategy to ensure reliability and completeness of all data generated."
    ]
  },
  {
    "letter_name": "lec-custom-products-inc-607838-09242020",
    "violated_terms": [
      "Failure to use appropriate equipment design and maintenance (21 CFR 211.63)",
      "Failure to establish written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to clean and maintain equipment to prevent contamination (21 CFR 211.67(a))",
      "Failure to establish a written testing program for stability characteristics (21 CFR 211.166(a))",
      "Failure to test samples of each component for identity and conformity (21 CFR 211.84(d)(1) and (2))",
      "Failure to establish an adequate quality unit (21 CFR 211.22(a)&(d))"
    ],
    "recommendations": [
      "Develop a comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.",
      "Establish a detailed process validation program with timelines for each marketed drug product.",
      "Implement a robust cleaning validation program focusing on worst-case scenarios.",
      "Create a stability program with stability indicating methods and ongoing studies.",
      "Conduct identity testing for all incoming components and establish a vendor qualification program.",
      "Ensure the quality unit has adequate authority and resources to oversee manufacturing processes."
    ]
  },
  {
    "letter_name": "sunstar-americas-inc-614058-12212021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Quality System (QS) regulations",
      "21 CFR 211.100(a) and (b)",
      "21 CFR 211.192",
      "21 CFR 211.160(b)",
      "21 CFR 820.75(a)",
      "21 CFR 820.100(a) & (b)",
      "21 CFR 820.70(g)",
      "21 CFR 820.30(c)"
    ],
    "recommendations": [
      "Provide a comprehensive independent assessment of your water system design, control, and maintenance, and corresponding corrective actions and preventative actions (CAPA).",
      "Provide a thorough remediation plan to install and operate a suitable water system.",
      "Conduct a retrospective, independent review of all invalidated OOS results.",
      "Provide a comprehensive retrospective review of all GMP documentation associated with distributed finished drug product batches.",
      "Explain whether you have reconsidered the sequence of the water system components in your current design.",
      "Conduct a detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry.",
      "Provide your updated procedures that ensure all activities performed by you and your contract manufacturers are adequate and approved by your quality unit.",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "sagent-pharmaceuticals-inc-636636-07272022",
    "violated_terms": [
      "Drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions.",
      "Failure to establish an adequate air supply in the aseptic processing areas.",
      "Failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas.",
      "Failure to ensure container closure systems provide protection against foreseeable external factors.",
      "Failure to use equipment that is of appropriate design and adequately located for its intended use.",
      "Failure to ensure that substances required for equipment operations do not come in contact with drug products.",
      "Failure to thoroughly investigate any unexplained discrepancy or failure of a batch.",
      "Failure to clean, maintain, and sanitize equipment and utensils at appropriate intervals.",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in the evaluation.",
      "Provide adequate supporting documentation for corrective actions taken in response to the Form FDA 483.",
      "Notify the FDA within fifteen working days of the specific steps taken to address the violations."
    ]
  },
  {
    "letter_name": "sanitizer-supply-llc-633583-09022022",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and (2)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive audit of operations.",
      "Establish an adequate quality unit with responsibilities to ensure oversight for the manufacture of drug products.",
      "Implement appropriate testing protocols for each batch of drug products and incoming components."
    ]
  },
  {
    "letter_name": "pure-source-llc-555240-02202019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "misbranded drugs",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to establish and document accuracy, sensitivity, specificity, and reproducibility of test methods",
      "failure to establish adequate written procedures for production and process control",
      "failure to validate manufacturing processes",
      "failure to properly list drug products",
      "failure to comply with CGMP as a contract manufacturer"
    ],
    "recommendations": [
      "Conduct a retrospective, independent review of all invalidated OOS results.",
      "Provide detailed final investigations with root cause analysis for all OOS results.",
      "Conduct a comprehensive, independent assessment of the overall system for investigations.",
      "Implement a corrective action plan to address manufacturing root causes.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Requalify the deionized water system and revise the monitoring and testing program.",
      "Increase the frequency of microbial testing for the water system.",
      "Provide a commitment to use valid test methods for all drug products until the system is qualified."
    ]
  },
  {
    "letter_name": "lcc-ltd-657336-08032023",
    "violated_terms": [
      "Failure to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))",
      "Failure to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))"
    ],
    "recommendations": [
      "Provide DEG and EG test results from testing retains for all lots of high-risk drug components used in the manufacture of drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination.",
      "Establish a comprehensive assessment and remediation plan to ensure the quality control unit is given the authority and resources to effectively function.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "sanitor-corporation-616232-11292021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products under section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drugs under section 505(a) of the FD&C Act",
      "Misbranded drug under section 502(c) of the FD&C Act",
      "Failure to properly list drug products under section 510(j) of the FD&C Act",
      "Inadequate investigations and lack of process control",
      "Failure to establish laboratory controls under 21 CFR 211.160(b)",
      "Failure to exercise appropriate controls over computer systems under 21 CFR 211.68(b)"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures.",
      "Complete investigations into all batches with potential objectionable microbial contamination.",
      "Conduct an independent retrospective review of all hand sanitizer drug products manufactured.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of the stability program.",
      "Provide a complete assessment of documentation systems used throughout manufacturing and laboratory operations.",
      "Provide a comprehensive assessment and remediation plan to ensure the quality unit is given the authority and resources to effectively function.",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records and reporting.",
      "Provide appropriate microbiological batch release specifications for each drug product.",
      "Engage a consultant with appropriate CGMP expertise in overall quality risk management, data integrity, and investigations."
    ]
  },
  {
    "letter_name": "trilogy-laboratories-llc-595087-03052020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranding",
      "failure to perform appropriate laboratory determination",
      "failure to conduct tests to verify identity of components",
      "failure to establish adequate written procedures for production and process control",
      "failure to comply with the Final Rule for Topical Acne Drug Products for Over-the-Counter Use",
      "failure to comply with the Tentative Final Monograph for Skin Bleaching Drug Products",
      "failure to include a Drug Facts panel",
      "failure to disclose a domestic address or telephone number"
    ],
    "recommendations": [
      "Take prompt actions to correct the violative conditions",
      "Notify FDA in writing before resuming operations if planning to manufacture drugs",
      "Investigate and determine the causes of the violations",
      "Prevent recurrence of the violations",
      "Respond in writing within 15 working days detailing corrective actions taken"
    ]
  },
  {
    "letter_name": "neobiosis-llc-662985-06052024",
    "violated_terms": [
      "Unapproved Drug and Biological Product Violations",
      "Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile",
      "Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area",
      "Failure to establish laboratory controls that include scientifically sound and appropriate specifications",
      "Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions",
      "Failure to establish written procedures for production and process controls",
      "Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products",
      "Introduction or delivery for introduction of adulterated drugs into interstate commerce",
      "Failure to obtain approved biologics license applications (BLAs) or investigational new drug applications (INDs)"
    ],
    "recommendations": [
      "Respond in writing within fifteen (15) working days outlining specific steps taken or planned to address violations",
      "Provide documentation necessary to show that matters have been addressed",
      "Submit evidence of completed corrective actions",
      "Ensure compliance with CGMP for the manufacturing activities performed",
      "Establish procedures for contract processing and require quality agreements with contract customers"
    ]
  },
  {
    "letter_name": "sunstar-guangzhou-ltd-592906-01222020",
    "violated_terms": [
      "Failure to perform appropriate laboratory determination of satisfactory conformance to final specifications for each batch of drug product (21 CFR 211.165(a))",
      "Failure to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1))",
      "Failure to establish laboratory controls that include scientifically sound specifications and test procedures (21 CFR 211.160(b))",
      "Failure to establish an adequate quality control unit and follow applicable procedures (21 CFR 211.22(a) and 211.22(d))"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each lot of drug products before disposition.",
      "Develop an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Conduct a comprehensive independent assessment of laboratory practices and provide a detailed remediation plan.",
      "Ensure that test methods performed by contract laboratories are properly validated before use.",
      "Conduct a comprehensive review of the material system to ensure all suppliers are qualified and materials are suitable for use.",
      "Implement a commitment to test each component lot for conformity with specifications and establish reliability of supplier results.",
      "Provide a detailed corrective action and preventive action (CAPA) plan for laboratory systems.",
      "Ensure quality control unit oversight throughout operations and a complete review of each batch before disposition."
    ]
  },
  {
    "letter_name": "novel-laboratories-inc-dba-lupin-613385-06112021",
    "violated_terms": [
      "21 CFR 211.67(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.22(d)",
      "section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Test all reserve samples of drug products for potential cross-contamination.",
      "Conduct a comprehensive, independent retrospective assessment of cleaning effectiveness.",
      "Develop a CAPA plan based on the retrospective assessment of cleaning and preventative maintenance programs.",
      "Improve the cleaning validation program with emphasis on worst-case conditions.",
      "Describe steps for change management before introducing new manufacturing equipment or drug products.",
      "Provide a summary of updated SOPs for verification and validation of cleaning procedures.",
      "Provide a detailed summary of the validation program for ensuring a state of control.",
      "Establish a timeline for performing appropriate process performance qualification.",
      "Enhance in-process testing and monitoring to detect variation during production.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit."
    ]
  },
  {
    "letter_name": "lupin-limited-572345-09102019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a))."
    ],
    "recommendations": [
      "Provide a retrospective, independent review of all invalidated OOS results for all U.S. drug products since July 1, 2016, and assess scientific justification for each.",
      "Conduct a comprehensive and independent assessment of manufacturing processes to determine the current state of control and identify necessary process remediation.",
      "Perform a comprehensive, independent retrospective assessment of cleaning processes to evaluate cross-contamination hazards and provide a CAPA plan based on findings."
    ]
  },
  {
    "letter_name": "lnk-international-inc-582253-09262019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b))."
    ],
    "recommendations": [
      "Provide a retrospective, independent review of all invalidated OOS results within expiry, including a thorough review of production and potential manufacturing root causes.",
      "Conduct a comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, focusing on microbiological hazards.",
      "Perform a detailed risk assessment addressing the hazard posed by distributing drug product lots with potentially objectionable microbial contamination.",
      "Complete investigations into all lots with data indicating potential objectionable microbial contamination.",
      "Develop a comprehensive review and remediation plan for your OOS result investigation systems, including revised procedures and quality unit oversight.",
      "Ensure your quality unit is given the authority and resources to effectively function, including oversight of investigations and adherence to appropriate practices."
    ]
  },
  {
    "letter_name": "new-england-life-care-inc-dba-advanced-compounding-solutions-659161-05162023",
    "violated_terms": [
      "Adulterated Drug Products",
      "Unapproved New Drug Products",
      "Misbranded Drug Products",
      "Insanitary conditions",
      "Current Good Manufacturing Practice (CGMP) violations",
      "Failure to meet conditions of section 503B of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise."
    ]
  },
  {
    "letter_name": "row1-inc-dba-regenative-labs-638823-06212023",
    "violated_terms": [
      "Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile",
      "Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess",
      "Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products"
    ],
    "recommendations": [
      "Respond in writing within fifteen (15) working days outlining specific steps taken or planned to address violations and prevent recurrence",
      "Include documentation necessary to show that the matters have been addressed",
      "If unable to address matters completely within fifteen (15) working days, explain the reason for the delay and the timeframe for completion"
    ]
  },
  {
    "letter_name": "yara-elena-de-la-garza-perez-nieto-608697-02222021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e)(1)(A), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Test every lot of ethanol received for methanol content using the USP method in a CGMP compliant laboratory",
      "Provide a detailed investigation into the substitution of methanol for ethanol",
      "List all raw materials used to manufacture hand sanitizer products, including suppliers' information",
      "Provide a list of all batches of hand sanitizer shipped to the U.S. and a full reconciliation of distributed materials",
      "Submit copies of complete batch records for all batches distributed to the U.S."
    ]
  },
  {
    "letter_name": "vitti-labs-llc-627699-07282022",
    "violated_terms": [
      "manufacture of products derived from human umbilical cord for allogeneic use",
      "products intended for clinical use in humans",
      "not regulated solely under section 361 of the PHS Act",
      "fail to meet the criterion in 21 CFR 1271.10(a)(2)",
      "not intended for homologous use",
      "fail to meet the minimal manipulation criterion in 21 CFR 1271.10(a)(1)",
      "no approved biologics license application (BLA)",
      "no investigational new drug application (IND) in effect",
      "significant deviations from current good manufacturing practice (CGMP)",
      "failure to establish and follow appropriate written procedures",
      "failure to have ceilings of smooth, hard surfaces that are easily cleanable",
      "failure to establish laboratory controls",
      "failure to establish and follow written procedures for production and process control",
      "failure to withhold from use each lot of components until tested",
      "failure to establish and follow a written testing program for stability characteristics"
    ],
    "recommendations": [
      "respond in writing within fifteen (15) working days",
      "outline specific steps taken or planned to address violations",
      "include documentation to show matters have been addressed",
      "explain reason for any delay in addressing matters"
    ]
  },
  {
    "letter_name": "sudesan-temizlik-urunleri-ve-ambalaj-sanaryi-ticaret-anomin-sirketi-666900-11132023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to validate and establish the reliability of your component supplier’s test analyses.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine supplier qualifications and material expiration dates.",
      "Provide the chemical and microbiological quality control specifications established to release each incoming lot of components for use in manufacturing.",
      "Describe how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "List chemical and microbial specifications used to analyze each lot of drug products before a lot disposition decision.",
      "Conduct a comprehensive assessment and CAPA plan to ensure the adequacy of your stability program."
    ]
  },
  {
    "letter_name": "samchundang-pharm-co-ltd-599255-05132020",
    "violated_terms": [
      "Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).",
      "Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).",
      "Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a))."
    ],
    "recommendations": [
      "Provide a comprehensive assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies, along with a detailed remediation plan.",
      "Conduct a comprehensive, independent and retrospective review of personnel and environmental monitoring data since 2018, including CAPA for environmental monitoring.",
      "Assess documentation systems and provide a CAPA plan to ensure accurate record-keeping, along with a comprehensive assessment and CAPA for the training program."
    ]
  },
  {
    "letter_name": "rxhomeo-private-limited-575889-06132019",
    "violated_terms": [
      "failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality",
      "failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced",
      "quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP"
    ],
    "recommendations": [
      "Provide a detailed description of how you plan to test each component, container, and closure for conformity with all appropriate written specifications for identity, purity, strength and quality",
      "Perform a global review of the production processes for all your drug products and establish appropriately detailed master batch records",
      "Provide a comprehensive assessment with corrective actions and preventive actions (CAPA) to ensure your QU is given the authority and resources to effectively and independently function"
    ]
  },
  {
    "letter_name": "tct-nutraceuticals-sdn-bhd-680743-06052024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Establish a robust testing program to verify the identity of each component and ensure adequate testing of active ingredients for impurities.",
      "Implement a stability testing program that assesses the chemical properties and microbiological attributes of drug products throughout their labeled expiry period."
    ]
  },
  {
    "letter_name": "safari-stem-cell-llc-661023-04052024",
    "violated_terms": [
      "marketing unapproved new animal drugs",
      "failure to establish written procedures for production and process control",
      "failure to establish and follow written procedures for in-process controls",
      "failure to perform appropriate laboratory testing for objectionable microorganisms",
      "failure to have a system for monitoring environmental conditions in an aseptic processing area",
      "failure to make appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to establish and follow written procedures for cleaning and maintenance of equipment",
      "failure to establish and follow written procedures for handling complaints",
      "failure to prepare batch production and control records"
    ],
    "recommendations": [
      "notify FDA in writing within 15 working days of receipt of this letter",
      "include an explanation of each step being taken to prevent the recurrence of violations",
      "provide copies of related documentation",
      "state the reason for any delay in completing corrective actions and the time within which they will be completed"
    ]
  },
  {
    "letter_name": "regenerative-processing-plant-llc-672154-08162024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to establish and follow appropriate written procedures",
      "failure to have an adequate system for monitoring environmental conditions",
      "failure to establish and follow an adequate written testing program",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to prepare batch production and control records",
      "failure to have an adequate system for cleaning and disinfecting",
      "failure to maintain production, control, or distribution records",
      "failure to retain an appropriately identified reserve sample",
      "failure to include required labeling statements",
      "failure to conduct growth promotion testing",
      "failure to provide adequate stability data",
      "failure to provide adequate documentation for corrective actions",
      "failure to comply with OTC Monograph M018"
    ],
    "recommendations": [
      "Voluntarily suspend manufacturing operations until corrective actions are completed",
      "Quarantine and hold all inventory of Regener-Eyes® products manufactured prior to corrective actions",
      "Retain a qualified consultant to assist in meeting CGMP requirements",
      "Provide documentation showing specific steps taken to address violations",
      "Conduct stability studies to support product claims",
      "Ensure all media fill studies are representative of the entire manufacturing process",
      "Implement adequate environmental monitoring procedures",
      "Conduct identity tests for all components used in drug products",
      "Maintain records pertaining to the manufacture and distribution of drug products"
    ]
  },
  {
    "letter_name": "medoffice-saglik-endustri-anonim-sirketi-687586-10232024",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for each batch of drug product (21 CFR 211.165(a) and 211.165(b)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each batch of drug products before a batch disposition decision.",
      "Conduct a comprehensive, independent review of your material system to determine whether all suppliers of components are qualified.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle."
    ]
  },
  {
    "letter_name": "mr-lulu-llc-650772-06012023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "21 CFR 211.165(a)",
      "21 CFR 211.84(d)(1) and (2)",
      "21 CFR 211.100 (a)",
      "21 CFR 211.188",
      "21 CFR 211.22"
    ],
    "recommendations": [
      "Provide a comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.",
      "Provide an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Provide a comprehensive review of your material system to determine whether all suppliers of components, containers, and closures are each qualified.",
      "Provide a summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "thibiant-international-inc-555921-03062019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to follow an adequate written testing program",
      "failure to establish the reliability of the component supplier’s analysis",
      "failure to establish adequate written responsibilities and procedures applicable to the quality control unit"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your system for investigating deviations, atypical events, complaints, OOS results, and failures.",
      "Conduct a retrospective, independent review of all OOS in-process and finished testing results for products currently on the U.S. market within expiry.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program.",
      "Provide the chemical and microbiological specifications you use to approve release of each incoming lot of components for use in manufacturing.",
      "Provide a comprehensive assessment, with CAPA, to ensure your quality unit (QU) is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "nephron-sc-inc-634647-10112022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failed to submit an NDA Field Alert Report within three working days",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failed to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas",
      "failed to adequately evaluate the scope of cross-contamination hazards",
      "failed to conduct adequate and timely investigations relating to products",
      "failed to establish appropriate environmental monitoring action levels"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Establish a procedure for your water system monitoring that provides for appropriate daily microbial testing.",
      "Conduct a comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities.",
      "Implement routine, vigilant operations management oversight of facilities and equipment.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Provide a detailed remediation plan with timelines to address contamination hazards.",
      "Conduct testing between lots of autoclaved drug products using sensitive testing techniques.",
      "Review and ensure EM/PM alert levels, action levels, procedures, and CAPA are robust and appropriate."
    ]
  },
  {
    "letter_name": "united-exchange-corporation-561814-03062019",
    "violated_terms": [
      "Your firm failed to establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products.",
      "Inadequate quality unit oversight of contract manufacturers.",
      "Inadequate batch review or release procedures.",
      "Inadequate procedures for handling investigations, deviations, and specification failures."
    ],
    "recommendations": [
      "Provisions for requalifying all suppliers you plan to use in the future.",
      "A risk assessment to determine whether all your drug products currently on the market within expiry conform to their specifications.",
      "Scientific justification of how you can be confident of the accuracy of your assessment.",
      "Your new procedures for your batch review and release process.",
      "An assessment of any risks to the quality of drug products released before implementing your new procedures and your mitigation plans.",
      "Your new procedure for deviation and investigation handling including specifics on the handling of all investigations."
    ]
  },
  {
    "letter_name": "luen-fook-medicine-sdn-bhd-572963-04042019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to establish written procedures for production and process control",
      "failure to clean, maintain, and sanitize equipment",
      "inadequate quality control unit",
      "repeated CGMP observations",
      "failure to validate the manufacturing process",
      "failure to perform cleaning validation",
      "failure to ensure appropriate finished product specifications",
      "failure to ensure process validation was reviewed and approved",
      "failure to ensure cleaning validation was performed",
      "failure to comply with the conditions proposed in the Oral Health Care TFM",
      "failure to have an approved new drug application"
    ],
    "recommendations": [
      "provide a summary of results obtained from testing retain samples",
      "provide a validation plan for ensuring a state of control",
      "provide a comprehensive plan to evaluate cleaning procedures",
      "provide a comprehensive assessment with corrective and preventive actions for the quality control unit",
      "engage a consultant qualified to assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "respond in writing within 15 working days detailing corrective actions taken"
    ]
  },
  {
    "letter_name": "stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023",
    "violated_terms": [
      "manufacture of products for allogeneic use",
      "failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile",
      "failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions",
      "failure to establish laboratory controls that include scientifically sound and appropriate specifications",
      "failure to establish written procedures for production and process control",
      "failure to thoroughly investigate any unexplained discrepancy",
      "failure to establish and follow a written testing program designed to assess the stability characteristics of drug products",
      "no approved biologics license application (BLA)",
      "no investigational new drug application (IND) in effect"
    ],
    "recommendations": [
      "respond in writing within fifteen (15) working days outlining specific steps taken or planned to address violations",
      "include documentation necessary to show that the matters have been addressed",
      "provide reasoning and supporting information if the products are believed to be in compliance"
    ]
  },
  {
    "letter_name": "red-mountain-inc-569406-03202019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug product",
      "misbranded drug",
      "failure to establish a quality control unit",
      "failure to approve or reject all procedures or specifications",
      "failure to provide supportive documentation for contract manufacturing organization (CMO)",
      "failure to establish robust supplier qualification",
      "failure to establish robust CMO qualification",
      "failure to include 'Rx only' on the label"
    ],
    "recommendations": [
      "Establish an adequate quality control unit (QU)",
      "Conduct a comprehensive assessment with corrective and preventive actions (CAPA)",
      "Perform a retrospective evaluation of homeopathic drug products on the U.S. market",
      "Establish a robust supplier qualification and auditing program",
      "Establish a robust CMO qualification and auditing program",
      "Revise the quality agreement to document responsibilities clearly",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "promise-pharmacy-llc-587148-07292019",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(B)",
      "section 502(f)(1)",
      "section 505 of the FDCA",
      "section 501(a)(2)(A)",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant aseptic drug manufacturing expertise.",
      "Ensure all ophthalmic solutions produced are free from particles and have a suitable pH level for administration.",
      "Ensure transfer occurs under ISO 5 airflow to prevent contamination.",
      "Maintain sufficient oversight of any contracted laboratory to ensure full CGMP compliance."
    ]
  },
  {
    "letter_name": "sterling-pharmaceutical-services-llc-629019-09272022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to thoroughly investigate discrepancies",
      "inadequate environmental monitoring program",
      "failure to establish adequate procedures to prevent microbiological contamination",
      "failure to follow appropriate written procedures",
      "ineffective quality system"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent risk assessment of contamination hazards",
      "Provide a detailed remediation plan with timelines",
      "Implement a CAPA plan for routine operations management oversight",
      "Conduct an independent assessment of ongoing use of rapid sterility testing methods",
      "Summarize the program for qualifying and overseeing contract laboratories",
      "Test retain samples of all drug product batches within expiry",
      "Conduct an independent assessment of the environmental monitoring program",
      "Ensure appropriate aseptic practices and cleanroom behavior during production"
    ]
  },
  {
    "letter_name": "similasan-ag-658878-09112023",
    "violated_terms": [
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act",
      "drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failed to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failed to establish laboratory controls that include scientifically sound and appropriate specifications",
      "failed to ensure that laboratory records included complete data derived from all tests",
      "failed to establish an adequate quality unit",
      "unapproved new drugs are not generally recognized as safe and effective",
      "failure to conduct 100% visual inspection of ophthalmic drug products",
      "failure to conduct retrospective reviews for tested products",
      "failure to ensure adequate procedures for microbiological contamination prevention",
      "failure to ensure adequate procedures to establish laboratory controls",
      "failure to ensure adequate procedures to include complete data in laboratory records"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "provide a comprehensive risk assessment of all contamination hazards",
      "provide a detailed remediation plan with timelines to address findings",
      "improve in-process testing and monitoring to enhance detection of variation",
      "conduct 100% visible inspection of retain samples",
      "provide data supporting that particle inspection system can detect particles",
      "conduct a complete assessment of documentation systems",
      "provide an action plan to address product quality or patient safety risks",
      "provide a comprehensive assessment and remediation plan for the quality unit"
    ]
  },
  {
    "letter_name": "petra-hygienic-systems-int-ltd-572769-05072019",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.",
      "Your firm released over-the-counter (OTC) drug products to the U.S. market without conducting finished product quality testing per National Formulary (NF) monograph requirements.",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment.",
      "Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures."
    ],
    "recommendations": [
      "Provide an action plan and timeline for testing reserve samples of all finished OTC drug products distributed to the United States within expiry.",
      "Describe in detail how you plan to test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality.",
      "Provide your cleaning validation summary report demonstrating the adequacy of your cleaning procedures.",
      "Provide your comprehensive plan for establishing, supporting, and sustaining a robust quality system consistent with CGMP regulations."
    ]
  },
  {
    "letter_name": "les-importations-herbasante-inc-668412-01312024",
    "violated_terms": [
      "Your firm failed to appropriately sample, test, or examine the components, containers or closures released for use in the manufacture of a drug product.",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified.",
      "Develop a remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products.",
      "Implement a comprehensive assessment and remediation plan to ensure your quality unit is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "marco-antonio-rodriguez-fierro-610110-03012021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements",
      "unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act",
      "does not conform to the 1994 TFM",
      "misbranded under section 502(a) of the FD&C Act because its labeling is false or misleading",
      "misbranded under section 502(ee) of the FD&C Act because it does not comply with the requirements for marketing under section 505G of the FD&C Act"
    ],
    "recommendations": [
      "engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions before pursuing resolution of your firm’s compliance status with FDA",
      "request a Regulatory Meeting to discuss corrective actions if you decide to manufacture drugs for the United States in the future"
    ]
  },
  {
    "letter_name": "westlab-pharmacy-inc-dba-westlab-pharmacy-585571-06262019",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products due to insanitary conditions",
      "Use of non-pharmaceutical grade components in drug production",
      "Failure to establish and follow written procedures for drug product components",
      "Failure to conduct appropriate laboratory determination for drug product specifications",
      "Failure to assure drug product expiration dates supported by stability testing",
      "Misbranding of drug products due to inadequate directions for use"
    ],
    "recommendations": [
      "Cease compounding and distributing drug products that do not meet section 503A conditions",
      "Implement corrective actions to ensure compliance with CGMP regulations",
      "Conduct a comprehensive assessment of operations with third-party consultant assistance",
      "Notify FDA prior to resuming high-risk sterile compounding",
      "Provide documentation to support the safety of the uncovered light fixture"
    ]
  },
  {
    "letter_name": "tarmac-products-inc-595993-11092020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to ensure laboratory records included complete data",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to follow an adequate written testing program for stability",
      "failure to routinely calibrate equipment",
      "failure to establish laboratory controls",
      "failure to adequately validate processes",
      "failure to establish procedures to control nonconforming product",
      "failure to establish and maintain procedures for design verification",
      "failure to establish and maintain design change procedures",
      "failure to ensure equipment meets specified requirements",
      "failure to establish calibration procedures",
      "failure to establish and maintain procedures for corrective and preventive action (CAPA)"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed remediation plan.",
      "Conduct a retrospective review of all out-of-specification results and summarize findings.",
      "Implement a comprehensive assessment and CAPA plan for the stability program.",
      "Develop a CAPA plan for routine equipment management and oversight.",
      "Perform an independent assessment of all test methods to ensure they are fit for intended use.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Correct the violations promptly and provide documentation of corrective actions."
    ]
  },
  {
    "letter_name": "quva-pharma-inc-675685-01262024",
    "violated_terms": [
      "Adulterated drug products due to insanitary conditions",
      "Failure to follow CGMP regulations",
      "Inadequate product evaluation and corrective actions",
      "Failure to monitor environmental conditions",
      "Inadequate investigation of discrepancies"
    ],
    "recommendations": [
      "Implement comprehensive assessments of operations, including facility design and aseptic processing operations",
      "Ensure adequate documentation and justification for corrective actions taken",
      "Engage a third-party consultant for a thorough evaluation of sterile drug manufacturing practices",
      "Establish a robust system for monitoring and investigating microbial contamination in critical areas"
    ]
  },
  {
    "letter_name": "natco-pharma-limited-672564-04082024",
    "violated_terms": [
      "Your firm failed to clean, maintain, and sanitize equipment and utensils at appropriate intervals (21 CFR 211.67(a)).",
      "Your firm failed to thoroughly investigate discrepancies or failures of a batch or its components (21 CFR 211.192)."
    ],
    "recommendations": [
      "Provide a comprehensive, independent retrospective assessment of cleaning effectiveness, including the identity of residues and an assessment of cross-contamination hazards.",
      "Develop a corrective action and preventive action (CAPA) plan based on the retrospective assessment, detailing improvements to cleaning processes and practices.",
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations and discrepancies, including a detailed action plan for remediation.",
      "Submit a full report of the holistic assessment for inadequacies in investigations and CGMP documentation control for all batches produced from January 2021 to the end of 2023."
    ]
  },
  {
    "letter_name": "tropical-seas-inc-562365-05152019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of section 505(a) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act",
      "failed to establish laboratory controls that include scientifically sound and appropriate specifications",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failure to validate the UV spectrophotometer test method",
      "failure to correct repeat violations",
      "misbranding due to lack of Drug Facts panel"
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of laboratory practices and a detailed corrective action and preventive action (CAPA) plan",
      "Provide appropriate microbiological batch release specifications for each drug product",
      "Provide microbiological testing methods that conform to USP <61> and <62>",
      "Conduct a retrospective investigation into the customer complaint for batch 1482",
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Conduct a comprehensive assessment of manufacturing operations with emphasis on microbiological controls",
      "Submit a written response specifying corrective actions taken and plans for preventing recurrence"
    ]
  },
  {
    "letter_name": "makra-kozmetika-doo-684125-09262024",
    "violated_terms": [
      "Failure to conduct appropriate laboratory testing for each batch of drug products (21 CFR 211.165(a) and 211.165(b))",
      "Failure to conduct quality control testing for over-the-counter (OTC) drug products",
      "Failure to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to validate the (b)(4) system and monitor its quality",
      "Failure to provide scientific data to validate equipment cleaning processes",
      "Failure to establish an adequate quality unit (21 CFR 211.22(a) and 211.22(d))"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed remediation plan",
      "List chemical and microbial specifications for testing each batch of drug products",
      "Conduct a risk assessment of products released without appropriate testing",
      "Establish a detailed validation program for manufacturing processes",
      "Implement a comprehensive cleaning validation program",
      "Develop and implement written procedures for the quality unit and ensure adherence to them"
    ]
  },
  {
    "letter_name": "plasticos-las-palmas-sa-de-cv-609475-03012021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the United States",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "shriram-institute-industrial-research-597629-04152020",
    "violated_terms": [
      "Failure to exercise appropriate controls over computer or related systems (21 CFR 211.68(a))",
      "Failure to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d))",
      "Failure to ensure that all test procedures are scientifically sound and appropriate for raw materials and API quality standards"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Conduct a retrospective, independent risk assessment of documentation systems.",
      "Perform system suitability testing on all analytical instruments prior to analysis.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Implement a detailed corrective action and preventive action (CAPA) plan to remediate documentation practices."
    ]
  },
  {
    "letter_name": "tender-corporation-599789-07232020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranding",
      "failure to ensure laboratory records included complete data",
      "failure to establish laboratory controls",
      "inadequate investigations into drug product complaints",
      "failure to follow adequate written procedures for handling complaints"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment and CAPA plan for computer system security and integrity.",
      "Establish and validate analytical methods and procedures.",
      "Conduct a comprehensive, independent assessment of laboratory practices.",
      "Implement a comprehensive review and remediation plan for OOS result investigation systems.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Conduct a retrospective review into the investigations of complaints."
    ]
  },
  {
    "letter_name": "shadow-holdings-dba-bocchi-labs-561273-02062019",
    "violated_terms": [
      "The microbial contamination of the Medline Remedy Essentials Cleanser No-Rinse Foam product causes this product to be adulterated within the meaning of section 601(a) of the Act [21 U.S.C. 361(a)].",
      "The cosmetic products you manufacture are adulterated within the meaning of section 601(c) of the Act [21 U.S.C. 361(c)] due to insanitary conditions.",
      "Your firm failed to establish an adequate quality control unit as required by 21 CFR 211.22(a)."
    ],
    "recommendations": [
      "Implement a comprehensive cleaning and sanitation program to address insanitary conditions.",
      "Establish a quality control unit with the authority to approve or reject all components and products.",
      "Engage a qualified consultant to assist in meeting drug CGMP requirements and perform a comprehensive audit."
    ]
  },
  {
    "letter_name": "legacy-pharmaceutical-packaging-llc-633735-10032022",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your drug products are adulterated under section 501(a)(2)(A) of the FD&C Act due to insanitary conditions.",
      "Operators were observed picking tablets off the floor and placing them into the feed hopper, violating section 501(a)(2)(B) of the FD&C Act (21 CFR 211.113(a))."
    ],
    "recommendations": [
      "Conduct a comprehensive, independent written evaluation of packaging and labeling operations, focusing on failure modes and human interactions with equipment.",
      "Implement a detailed action plan to remediate the system for investigating deviations, discrepancies, and complaints, ensuring all phases of investigations are appropriately conducted.",
      "Perform a retrospective assessment of cleaning effectiveness to evaluate cross-contamination hazards and identify any inadequacies in cleaning procedures.",
      "Develop an action plan to address product quality or patient safety risks, including a review of customer complaints and testing of retain samples."
    ]
  },
  {
    "letter_name": "orchid-lifesciences-663478-08032023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in manufacturing.",
      "Conduct a full risk assessment for drug products containing any ingredient at risk for DEG or EG contamination.",
      "Describe how each component lot will be tested for conformity with specifications for identity, strength, quality, and purity.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit to ensure effective functioning.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "omega-packaging-corp-649122-03202023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.100(a)",
      "21 CFR 211.22",
      "21 CFR 211.67(b)",
      "21 CFR 211.166(a)",
      "21 CFR 211.68(b)",
      "21 CFR 211.188"
    ],
    "recommendations": [
      "Provide a comprehensive investigation into the extent of the inaccuracies in data records and reporting.",
      "Include a current risk assessment of the potential effects of the observed failures on the quality of your drugs.",
      "Develop a management strategy that includes a global corrective action and preventive action (CAPA) plan.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Confirm whether you intend to continue manufacturing any drugs at this facility or any other facility in the future."
    ]
  },
  {
    "letter_name": "lex-inc-656056-08172023",
    "violated_terms": [
      "Failure of the quality control unit to ensure compliance with CGMP (21 CFR 211.22)",
      "Inadequate oversight of manufacturing processes and procedures",
      "Failure to withhold components from use until tested and released by the quality control unit (21 CFR 211.84)",
      "Inadequate identity testing for components (21 CFR 211.84(a), 211.84(d)(1), 211.84(d)(2))",
      "Lack of written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to calibrate and maintain equipment (21 CFR 211.68(a) and (b))",
      "Inadequate process validation and incomplete process performance qualification studies",
      "Failure to establish reliability of raw material suppliers"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit's authority and resources",
      "Implement appropriate identity testing for all components prior to use",
      "Establish written procedures for production and process control",
      "Complete process validation activities and ensure prospective PPQ studies are done before distribution",
      "Develop a detailed CAPA plan for equipment qualification and calibration",
      "Conduct a risk assessment for drug products produced using unqualified equipment",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "roque-plast-sa-de-cv-609492-04092021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Conduct a detailed investigation into how hand sanitizer drug products were substituted with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer drug products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the United States",
      "Test each component lot for conformity with specifications for identity, strength, quality, and purity",
      "Conduct at least one specific identity test for each incoming component lot",
      "Test every lot of ethanol received for methanol content using the USP method"
    ]
  },
  {
    "letter_name": "orean-personal-care-ltd-682813-08292024",
    "violated_terms": [
      "Failure to test samples of each component for identity and conformity with specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Inadequate identity testing for each component lot, including active pharmaceutical ingredients",
      "Failure to establish reliability of suppliers' certificates of analysis (COAs)",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a) and 211.67(b))",
      "Lack of process validation for manufacturing processes",
      "Inadequate cleaning validation for non-dedicated manufacturing equipment",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)",
      "Inadequate investigations into non-conformances (21 CFR 211.192)",
      "Insufficient documentation control and retention practices (21 CFR 211.188)",
      "Failure to establish an adequate ongoing stability program (21 CFR 211.166(a))",
      "Failure to conduct annual product quality reviews (21 CFR 211.180(e))",
      "Repeat violations from previous inspections"
    ],
    "recommendations": [
      "Test each component lot for conformity with specifications for identity, strength, quality, and purity",
      "Conduct a retrospective risk assessment for products in the market that lack adequate component identity testing",
      "Establish a comprehensive cleaning validation program for non-dedicated equipment",
      "Implement a robust quality control system with adequate authority and resources",
      "Perform training for employees on updated procedures and ensure effectiveness of training",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Provide timelines for corrective actions and ensure ongoing monitoring of compliance"
    ]
  },
  {
    "letter_name": "newton-laboratories-inc-dba-newton-homeopathics-559612-04232019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B)",
      "misbranded drugs under section 503(b)(4)",
      "unapproved new animal drugs",
      "failed to thoroughly investigate unexplained discrepancies",
      "failed to establish written procedures for production and process controls",
      "failed to clean, maintain, and sanitize equipment",
      "failed to maintain written records for annual product reviews",
      "failed to validate manufacturing processes",
      "failed to conduct annual product reviews",
      "failed to provide assurance that each batch can consistently meet quality characteristics"
    ],
    "recommendations": [
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Perform a thorough review of production for any OOS results",
      "Provide a CAPA plan that identifies manufacturing root causes",
      "Establish a data-driven program to control sources of variability in production processes",
      "Implement an improved sampling plan for microbiological contamination detection",
      "Evaluate cleaning procedures and practices for manufacturing equipment",
      "Provide a comprehensive plan for annual product quality reviews",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "proandre-sl-567234-02132019",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
      "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.",
      "Proandre Antibacterial Soap Liquid and Proandre Hand Sanitizer Liquid are misbranded under sections 502(c) and (x) of the FD&C Act."
    ],
    "recommendations": [
      "Provide an updated Standard Operating Procedure (SOP) for finished drug product release testing that includes tests for identity and strength as well as product specifications and test methods.",
      "Provide a full summary of stability data results for all batches within expiry, including time points, methods used for microbiological and chemical testing, and updated test data.",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records and reporting, including a risk assessment of the potential effects of observed failures on drug quality.",
      "Engage a qualified consultant to assist in meeting CGMP requirements and ensure ongoing compliance."
    ]
  },
  {
    "letter_name": "ultra-seal-corporation-624650-03142022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.67(b)",
      "21 CFR 211.192",
      "21 CFR 211.160(a)",
      "21 CFR 211.68(b)",
      "21 CFR 211.22(a)"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent, retrospective assessment of cleaning effectiveness to evaluate the scope of cross-contamination hazards.",
      "Implement appropriate improvements to the cleaning validation program.",
      "Provide a retrospective, independent review of all invalidated OOS results.",
      "Develop a comprehensive review and remediation plan for OOS result investigation systems.",
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a detailed action plan to remediate the quality control unit's authority and resources.",
      "Ensure that only test data from validated or verified test methods are used to make batch release decisions.",
      "Perform a comprehensive investigation into the extent of inaccuracies in data records and reporting."
    ]
  },
  {
    "letter_name": "zhejiang-tianyu-pharmaceutical-co-ltd-631054-08172022",
    "violated_terms": [
      "current good manufacturing practice (CGMP)",
      "adulterated API",
      "failure to extend investigations to other batches",
      "deficient investigation of impurities",
      "failure to establish an impurity profile",
      "failure to clean equipment at appropriate intervals",
      "failure to complete cleaning validation studies"
    ],
    "recommendations": [
      "Provide a comprehensive assessment of the overall system for investigating deviations and discrepancies.",
      "Provide a summary update on investigations and corrective action and preventive action plans.",
      "Provide an assessment and testing results for impurities in API batches manufactured prior to 2018.",
      "Conduct a retrospective review of batches released without appropriate testing for impurities.",
      "Provide specifications and test methods used to release the API.",
      "Provide improvements to procedures for performing a systemic evaluation for identifying impurities.",
      "Conduct a comprehensive, independent retrospective assessment of cleaning effectiveness.",
      "Provide a summary of updated SOPs for cleaning procedures.",
      "Provide a corrective action and preventive action plan for operations management oversight.",
      "Provide a risk assessment of batches manufactured without cleaning validation."
    ]
  },
  {
    "letter_name": "xian-livingbond-nonwoven-products-corp-ltd-574591-06102019",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to establish written procedures for production and process control.",
      "Your firm failed to establish an adequate quality control unit."
    ],
    "recommendations": [
      "Provide a list of all chemical and microbial test methods and specifications used to analyze each batch of your drug products.",
      "Provide a description of how you will test each component lot for conformity with all appropriate specifications.",
      "Provide your validation plan for ensuring a state of control throughout the product lifecycle.",
      "Provide new and updated procedures describing the roles and responsibilities of your quality unit."
    ]
  },
  {
    "letter_name": "sck-zeta-dis-ticaret-pazarlama-ltd-610432-07152021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), (c), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a product into interstate commerce prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate operations",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "suhan-aerosol-663489-08032023",
    "violated_terms": [
      "Failure to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))",
      "Failure to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))"
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in manufacturing",
      "Conduct a full risk assessment for drug products containing any ingredient at risk for DEG or EG contamination",
      "Establish a comprehensive assessment and remediation plan for the quality control unit to ensure effective oversight and authority",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "pt-megasurya-mas-604366-08242020",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including identity and strength of each active ingredient, prior to release.",
      "Inadequate method validation for analytical test methods used to determine acceptability of drug products before release.",
      "Failure to conduct at least one test to verify the identity of each component of a drug product.",
      "Failure to follow written procedures for production and process control.",
      "Quality control unit's failure to ensure compliance with CGMP.",
      "Inadequate written testing program for assessing stability characteristics of drug products."
    ],
    "recommendations": [
      "Conduct a comprehensive independent assessment of laboratory practices and provide a remediation plan.",
      "Implement a testing program for incoming components to ensure reliability of supplier analyses.",
      "Develop a detailed validation program for process control and performance qualification.",
      "Strengthen the quality control unit's authority and resources to ensure compliance.",
      "Establish a comprehensive stability program including accelerated and long-term testing.",
      "Engage a qualified consultant to assist in remediation efforts."
    ]
  },
  {
    "letter_name": "ohm-pharma-inc-586428-11192019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "adulterated within the meaning of section 402(g)(1) of the FD&C Act",
      "misbranded dietary supplements under section 403 of the FD&C Act",
      "failed to maintain the buildings used in the manufacture in a clean and sanitary condition (21 CFR 211.56(a))",
      "failed to establish laboratory controls (21 CFR 211.160(b))",
      "failed to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failed to establish product specifications for each dietary supplement (21 CFR 111.70(e))",
      "failed to establish adequate identity specifications (21 CFR 111.70(b)(1))",
      "failed to ensure that the tests and examinations are appropriate (21 CFR 111.75(h)(1))",
      "failed to include all elements of a master manufacturing record (21 CFR 111.210)",
      "failed to include all elements of a batch production record (21 CFR 111.260)",
      "failed to reject the Syzygium Jambolanum (Jambul Powder) Lot with out-of-specification result (21 CFR 111.113(b)(2))",
      "failed to approve and release a batch that did not meet established product specifications (21 CFR 111.123(b)(2))",
      "misbranded within the meaning of section 403(y) of the FD&C Act",
      "misbranded within the meaning of section 403(q)(5)(F) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34",
      "establish and follow written procedures for quality control operations",
      "maintain physical plant in a clean and sanitary condition (21 CFR 111.15(b)(1))",
      "ensure the water system is installed to prevent backflow and cross connection",
      "display net quantity of contents in the bottom 30% of the principal display panel (21 CFR 101.7(f))",
      "place the FDA disclaimer statement in accordance with 21 CFR 101.93(d)"
    ]
  },
  {
    "letter_name": "nowrez-ismail-shukri-company-682810-07112024",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2))."
    ],
    "recommendations": [
      "If your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations.",
      "The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status."
    ]
  },
  {
    "letter_name": "thai-nakorn-patana-co-ltd-672712-02272024",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements before resuming drug manufacturing operations.",
      "Perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action (CAPA)."
    ]
  },
  {
    "letter_name": "notarika-sa-de-cv-609174-10072021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (c), (f)(2), (i), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "not in conformity with the 1994 TFM",
      "misbranded under section 502(f)(2) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "misbranded under section 502(i)(1) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions",
      "Request a Regulatory Meeting to discuss corrective actions if intending to manufacture drugs for the U.S. market"
    ]
  },
  {
    "letter_name": "toyobo-co-ltd-614177-08192021",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies in batch specifications (21 CFR 211.192)",
      "Inadequate investigation of significant particulate defects in sterile drug products",
      "Insufficient data integrity investigation and lack of comprehensive assessment of breaches"
    ],
    "recommendations": [
      "Comprehensive assessment of the investigation system for deviations and discrepancies",
      "Updated risk assessment regarding marketed batches and potential impacts of contaminants",
      "Detailed remediation plan for aseptic practices and cleanroom behavior",
      "Comprehensive investigation into data integrity breaches with a focus on root causes and corrective actions"
    ]
  },
  {
    "letter_name": "pharmasol-corporation-570727-03142019",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Establishment of an adequate quality control unit (21 CFR 211.22(a) and (d))",
      "Adequate written testing program for stability characteristics (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Comprehensive investigations into root causes of leaking containers, including CAPA plans",
      "Retrospective review of invalidated OOS results and improvements to the OOS handling process",
      "Independent assessment and CAPA plan for the stability testing program, including specific attributes to be tested"
    ]
  },
  {
    "letter_name": "yuyao-yijia-daily-chemical-co-ltd-610487-01222021",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.",
      "Provide a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Provide a comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of your stability program.",
      "Provide a comprehensive assessment and remediation plan to ensure your quality unit is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "seoul-cosmetics-co-ltd-653882-10022023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "Misbranded under section 502(ee) of the FD&C Act",
      "Failure to establish an adequate quality unit (QU)",
      "Failure to validate test methods",
      "Inadequate stability data",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to adequately validate manufacturing processes",
      "Failure to qualify equipment used in manufacturing",
      "Failure to ensure drug products meet established specifications for identity, strength, quality, and purity"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Conduct a comprehensive assessment of laboratory practices and provide a remediation plan",
      "Develop a corrective action and preventive action (CAPA) plan for the stability program",
      "Provide DEG and EG test results within 30 calendar days",
      "Conduct a full risk assessment for drug products containing ingredients at risk for DEG or EG contamination",
      "Test each component lot for conformity with specifications",
      "Engage a qualified consultant to assist in meeting drug CGMP requirements",
      "Investigate and determine the causes of any violations and prevent their recurrence"
    ]
  },
  {
    "letter_name": "us-specialty-formulations-llc-659142-07262023",
    "violated_terms": [
      "section 503B of the FDCA",
      "section 505 of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 582 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "21 CFR 211.42(c)(10)(iii)",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)(v)",
      "21 CFR 211.42(a)",
      "21 CFR 211.167(a)",
      "21 CFR 211.28(a)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.192",
      "21 CFR 211.165(a)",
      "21 CFR 211.160(a)",
      "21 CFR 211.166(a)",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third party consultant with relevant sterile drug manufacturing expertise to assist in the comprehensive evaluation.",
      "Submit a corrective action with respect to labels lacking a list of active and inactive ingredients identified by established name and the quantity or proportion of each ingredient.",
      "Provide the agency with a revised procedure for reporting adverse events."
    ]
  },
  {
    "letter_name": "system-kosmetik-produktionsgesellschaft-fur-kosmetische-gmbh-632727-09092022",
    "violated_terms": [
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a) and 211.67(b))",
      "Lack of process validation for OTC drug products",
      "Inadequate batch records lacking critical production information",
      "Insufficient cleaning validation program for shared equipment",
      "Failure to establish laboratory controls (21 CFR 211.160(b))",
      "Inadequate testing for identity of incoming active pharmaceutical ingredients (21 CFR 211.84(d)(1))",
      "Inadequate controls over computer systems (21 CFR 211.68(b))"
    ],
    "recommendations": [
      "Detailed summary of validation program for product lifecycle control",
      "Timeline for process performance qualification for marketed drug products",
      "Risk assessment for drugs produced on shared equipment",
      "Comprehensive remediation plan for the design and maintenance of the (b)(4) system",
      "Management strategy for global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "maquiladora-miniara-sa-de-cv-609152-12152021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x) and (ee) of the FD&C Act",
      "prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "Perform a comprehensive audit of your entire operation for CGMP compliance",
      "Include the name 'alcohol gel' as part of the statement of identity on the product label"
    ]
  },
  {
    "letter_name": "remedyrepack-inc-649198-05112023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.67(b)",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.42(c)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Provide a comprehensive, independent retrospective assessment of your cleaning effectiveness.",
      "Develop a corrective action and preventive action (CAPA) plan based on the retrospective assessment.",
      "Implement appropriate improvements to your cleaning validation program.",
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations.",
      "Establish a timeline for performing appropriate process performance qualification (PPQ) for each marketed drug product.",
      "Provide a plan to fully dedicate your facility to beta-lactams or cease any beta-lactam production in the building.",
      "Perform environmental sampling of your facility for beta-lactam cross-contamination.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "tg-united-inc-577583-08012019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to conduct investigations",
      "inadequate investigations",
      "failure to use appropriate equipment",
      "failure to clean and maintain equipment",
      "failure to follow an adequate written testing program",
      "repeat violations"
    ],
    "recommendations": [
      "Conduct a retrospective review of all invalidated OOS results and water system monitoring failures.",
      "Provide a comprehensive, independent assessment of your water system design and maintenance.",
      "Evaluate cleaning procedures and practices for each piece of manufacturing equipment.",
      "Provide a table listing all drug products distributed to the U.S. market since 2016.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  
  {
    "letter_name": "denison-pharmaceuticals-llc-654226-07262023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to thoroughly investigate discrepancies",
      "failure to conduct adequate investigations for contamination",
      "failure to initiate investigations for microbiological excursions",
      "failure to conduct identity testing for drug components",
      "failure to establish accuracy and validation of test methods"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a detailed action plan to remediate the investigation system.",
      "Conduct an independent assessment and remediation plan for the CAPA program.",
      "Provide a comprehensive, independent assessment of the water system design, control, and maintenance.",
      "Install and operate a suitable water system with ongoing control and monitoring.",
      "Establish procedures for routine microbial testing of the water system.",
      "Perform a full risk assessment for drug products containing ingredients at risk for DEG or EG contamination.",
      "Provide updated validation protocols and reports for test methods.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "dercher-enterprises-inc-dba-gordon-laboratories-580346-09132019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drugs",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to thoroughly investigate discrepancies",
      "failure to conduct appropriate laboratory testing",
      "inadequate quality control unit",
      "failure to establish specifications for microbiological quality",
      "failure to follow standard operating procedures (SOP)",
      "failure to implement effective corrective actions and preventive actions (CAPA)",
      "failure to provide adequate supportive documentation",
      "failure to establish adequate directions for use"
    ],
    "recommendations": [
      "Revise SOPs and perform analytical testing of retained lots and new batches",
      "Conduct a retrospective evaluation of the quality of all lots of Monsel’s Solution",
      "Provide an investigation and CAPA plan identifying manufacturing root causes",
      "Establish appropriate microbiological batch release specifications",
      "Conduct a comprehensive assessment of manufacturing operations",
      "Provide a comprehensive, independent assessment of the quality control unit",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Provide a detailed description of testing for incoming components",
      "Conduct complete investigations into all lots with objectionable microbial contamination"
    ]
  },
  {
    "letter_name": "grupo-insoma-sapi-de-cv-608768-10232020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (f)(2), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "does not comply with the requirements for marketing under section 505G of the FD&C Act",
      "misbranded under section 502(f)(2) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing your firm’s hand sanitizer drug products currently in distribution in the U.S. market",
      "engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "provide a detailed investigation into the substitution of ethanol with methanol",
      "provide a list of all raw materials used to manufacture hand sanitizer products",
      "provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "provide copies of the complete batch records for all batches distributed to the U.S.",
      "provide a complete assessment of your laboratory practices and a detailed plan to remediate"
    ]
  },
  {
    "letter_name": "ingenue-care-574836-05312019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish and follow an adequate written testing program for stability",
      "failure to establish a quality control unit",
      "failure to provide adequate directions for use"
    ],
    "recommendations": [
      "Provide established procedures for testing all finished drug dosage products",
      "Provide completed chemical and microbial analytical method validation",
      "Provide a summary of test results from testing retain samples of all drug products",
      "Provide a procedure for incoming component testing",
      "Provide a comprehensive review of the materials system",
      "Provide standard operating procedure for ongoing stability program",
      "Provide stability data demonstrating compliance throughout expiry",
      "Establish an adequate quality control unit with appropriate authority",
      "Provide corrective actions to ensure compliance with CGMP",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "global-cosmetics-company-limited-677948-04302024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to establish an adequate quality control unit (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive six-system audit.",
      "Establish a robust testing program for incoming components, including testing for methanol in ethanol.",
      "Develop and implement a stability testing program that includes adequate chemical and microbiological testing.",
      "Ensure the quality control unit effectively oversees all aspects of drug manufacturing operations."
    ]
  },
  {
    "letter_name": "drivergent-inc-647234-05012023",
    "violated_terms": [
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "misbranded under sections 502(a), (i)(1), and (x) of the FD&C Act",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to maintain buildings in a good state of repair",
      "failure to establish an adequate quality unit",
      "failure to determine whether each component conformed with specifications for purity, strength, and quality"
    ],
    "recommendations": [
      "Consider removing any batches of drug product currently in distribution from the U.S. market",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance",
      "Confirm whether you intend to resume manufacturing any drugs at this facility or any other facility in the future",
      "Notify the FDA prior to resuming drug manufacturing operations"
    ]
  },
  {
    "letter_name": "firstcham-co-ltd-672903-04032024",
    "violated_terms": [
      "Current Good Manufacturing Practices (CGMP)",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "failure to conduct at least one test to verify the identity of each component of a drug product",
      "failure to validate and establish the reliability of your component supplier’s test analyses",
      "failure to ensure that laboratory records included complete data derived from all tests",
      "failure to establish adequate written procedures for production and process control",
      "failure to exercise responsibility to ensure drug products are in compliance with CGMP"
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in manufacture",
      "Conduct a full risk assessment for drug products within expiry that contain ingredients at risk for DEG or EG contamination",
      "Describe how you will test each component lot for conformity with specifications",
      "Conduct a comprehensive independent review of your material system",
      "Provide a detailed summary of your validation program for ensuring a state of control",
      "Provide a comprehensive assessment and remediation plan for your quality control unit",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "guangzhou-baiyunshan-jingxiutang-pharmaceutical-co-ltd-675823-08012024",
    "violated_terms": [
      "Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures (21 CFR 211.160(b))",
      "Drug products lacked appropriate release specifications and analytical testing procedures",
      "Inadequate testing for objectionable microorganisms on drug product components",
      "Failure to establish an adequate quality control unit with the authority to approve or reject all components and drug products (21 CFR 211.22(a))"
    ],
    "recommendations": [
      "Provide a comprehensive assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies",
      "List chemical and microbiological specifications, including test methods, used to analyze each lot of drug products",
      "Develop an action plan and timelines for conducting full chemical and microbiological testing of retain samples",
      "Establish a procedure for ongoing control, maintenance, and monitoring of drug product quality",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "deva-holding-577493-cerkezkoy-subesi",
    "violated_terms": [
      "Your firm failed to perform operations related to the manufacture, processing, and packing of penicillin in facilities separate from those used for other drug products for human use (21 CFR 211.42(d)).",
      "Penicillin cross contamination incidents and their implications for patient safety.",
      "Inadequate penicillin monitoring in non-penicillin areas.",
      "Lack of effectiveness data for penicillin cleaning methods.",
      "Failure to test non-penicillin drug products for penicillin contamination when reasonable possibility existed (21 CFR 211.176)."
    ],
    "recommendations": [
      "Provide a comprehensive decontamination plan for the non-beta-lactam portion of the facility.",
      "List all decontaminant solutions used, including validation data.",
      "Establish a future monitoring program for beta-lactam residue.",
      "Revise control plans for identified routes of beta-lactam contamination.",
      "Commit to validating and implementing FDA's analytical method for penicillin detection with an acceptable limit of detection.",
      "Engage a qualified CGMP consultant for a comprehensive audit and corrective action evaluation."
    ]
  },
  {
    "letter_name": "guangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of operations for CGMP compliance"
    ]
  },
  {
    "letter_name": "acino-products-llc-589471-02102020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failed to maintain buildings in a good state of repair (21 CFR 211.58)",
      "failed to clean, maintain, and sanitize equipment (21 CFR 211.67(a) and (b))",
      "failed to ensure laboratory records included complete data (21 CFR 211.194(a))"
    ],
    "recommendations": [
      "Provide checklist and related procedures for cleanliness",
      "Provide photographs of repairs made to facilities and equipment",
      "Provide CAPA plan for routine management oversight of facilities and equipment",
      "Provide qualification reports for manufacturing equipment",
      "Conduct a comprehensive assessment of cleaning effectiveness",
      "Provide a CAPA plan based on the retrospective assessment",
      "Provide a summary of updated SOPs for verification and validation of cleaning procedures",
      "Engage a qualified consultant to assist in remediation",
      "Conduct a comprehensive investigation into data record inaccuracies",
      "Provide a current risk assessment of observed failures",
      "Develop a management strategy including a global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "kc-pharmaceuticals-inc-654986-08032023",
    "violated_terms": [
      "Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that includes validation of all aseptic and sterilization processes (21 CFR 211.113(b)).",
      "Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.",
      "Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment.",
      "Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as critical in your drug manufacturing operation."
    ]
  },
  {
    "letter_name": "agropharma-laboratories-inc-623475-03252022",
    "violated_terms": [
      "Quality Control Unit Responsibilities: Failure to ensure drug products are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).",
      "Facility Maintenance: Failure to maintain buildings in a clean and sanitary condition (21 CFR 211.56(a)).",
      "Production and Process Control: Failure to establish written procedures for production and process control to assure drug products have the identity, strength, quality, and purity they represent (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure the Quality Control Unit is effective.",
      "Implement a corrective action and preventive action (CAPA) plan for routine oversight and maintenance of facilities.",
      "Submit a detailed summary of the validation program for manufacturing processes, including timelines and protocols for process performance qualification."
    ]
  },
  {
    "letter_name": "central-admixture-pharmacy-services-inc-674736-03292024",
    "violated_terms": [
      "Adulterated Drug Products under section 501(a)(2)(A) and 501(a)(2)(B) of the FDCA",
      "Failure to investigate discrepancies (21 CFR 211.192)",
      "Failure to establish laboratory controls (21 CFR 211.160(b))"
    ],
    "recommendations": [
      "Implement thorough investigations for microbial contamination with appropriate corrective actions.",
      "Provide current environmental and personnel monitoring results.",
      "Evaluate and demonstrate the suitability of rapid sterility test methods.",
      "Conduct a comprehensive assessment of operations with third-party consultant assistance."
    ]
  },
  {
    "letter_name": "anicare-pharmaceuticals-pvt-ltd-569251-02282019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drug products",
      "failure to establish and follow an adequate written testing program",
      "inadequate stability program",
      "failure to review and approve written procedures for production and process control",
      "inadequate validation of drug product manufacturing processes",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to provide a complete statement of identity on labels",
      "failure to include a 'Drug Facts' panel in Spanish",
      "failure to disclose a domestic address or telephone number on labels"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment and corrective action and preventative action (CAPA) plan for stability program",
      "Conduct a comprehensive review of manufacturing processes and validation studies",
      "Provide a comprehensive CAPA plan for the (b)(4) system design, control, and maintenance",
      "Evaluate cleaning procedures, practices, and validation study results for each piece of manufacturing equipment",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements",
      "Respond in writing within 15 working days detailing corrective actions taken"
    ]
  },
  {
    "letter_name": "brassica-pharma-pvt-ltd-679005-07112024",
    "violated_terms": [
      "Failure to ensure laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a))",
      "Failure to test every batch for sterility as required by procedures",
      "Fabrication of records for sterility testing and environmental monitoring",
      "Inadequate sterility test method validation",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination (21 CFR 211.113(b))",
      "Poor practices in aseptic processing areas",
      "Inadequate gowning for aseptic processing",
      "Inadequate media fill program",
      "Inadequate airflow visualization studies",
      "Deficient bulk drug product sterilization validation",
      "Failure to clean, maintain, and sanitize equipment at appropriate intervals (21 CFR 211.67(a) and 211.67(b))",
      "Inadequate cleaning validation"
    ],
    "recommendations": [
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting",
      "Perform a current risk assessment of the potential effects of observed failures on drug quality",
      "Develop a management strategy that includes a global corrective action and preventive action (CAPA) plan",
      "Implement a detailed corrective action plan to ensure reliability and completeness of all generated data",
      "Conduct a thorough retrospective review and risk assessment of how poor aseptic technique may have affected drug quality",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "genlabs-corporation-625479-05122022",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "misbranding under section 502(c) of the FD&C Act",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to establish adequate written procedures for production and process control",
      "failure of quality control unit to ensure compliance with CGMP",
      "failure to conduct stability testing",
      "failure to validate water system",
      "failure to perform adequate release testing"
    ],
    "recommendations": [
      "Conduct a risk assessment for all drugs produced on shared equipment.",
      "Provide plans for separating manufacturing areas for pharmaceutical and non-pharmaceutical products.",
      "Improve cleaning validation program with emphasis on worst-case conditions.",
      "List chemical and microbial specifications for each batch of drug products.",
      "Conduct full chemical and microbiological testing of retain samples.",
      "Perform a comprehensive independent third-party assessment of laboratory practices.",
      "Establish adequate written procedures for quality control unit responsibilities.",
      "Develop a comprehensive stability program.",
      "Implement a remediation plan for the water system design and maintenance.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "auto-chlor-system-llc-641808-12202022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranding",
      "failure to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "failure to test samples of each component for identity and conformity (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure of quality control unit to ensure compliance with CGMP (21 CFR 211.22)",
      "failure to ensure employees are trained in CGMPs (21 CFR 211.25(a))",
      "failure to perform appropriate testing for identity and strength (21 CFR 211.165(a))",
      "failure to test for objectionable microorganisms (21 CFR 211.165(b))",
      "failure to establish an adequate stability program (21 CFR 211.166(a))",
      "failure to perform annual product reviews (21 CFR 211.180(e))",
      "failure to prepare adequate batch control and production records (21 CFR 211.188)",
      "failure to conduct thorough investigations for out-of-specifications results (21 CFR 211.192)",
      "failure to comply with conditions for marketing under section 505G of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "notify the FDA before resuming or outsourcing the manufacturing of drugs"
    ]
  },
  {
    "letter_name": "health-pharma-usa-llc-588155-12182019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "quality control unit failed to ensure compliance with CGMP",
      "inadequate quality unit oversight",
      "shipping drug products before adequate review",
      "inadequate stability program",
      "failed to prepare batch production and control records with complete information",
      "failed to establish adequate written procedures for production and process control",
      "failed to test samples of each component for identity and conformity",
      "failed to validate and establish the reliability of component supplier’s test analyses"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Commit to discontinue the practice of allowing shipment of a drug batch before proper review",
      "Provide a list of all lots within distribution and historical stability data",
      "Provide a comprehensive assessment and remediation plan for the stability program",
      "Provide release test results for specific drug products",
      "Conduct a global review of production processes for all drug products",
      "Provide detailed master batch records for each drug product",
      "Establish a program for designing, validating, and monitoring manufacturing processes",
      "Provide a timeline for process performance qualification for marketed drug products",
      "Provide chemical and microbiological quality control specifications for testing components",
      "Summarize results obtained from testing components to evaluate reliability of COA",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "avaria-health-beauty-corp-685248-09032024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures.",
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "chemland-co-ltd-593158-02112020",
    "violated_terms": [
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide interim controls to prevent deletion and modification of data for all computerized systems used in CGMP-related operations at your facility.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures.",
      "A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program."
    ]
  },
  {
    "letter_name": "champaklal-maganlal-homeo-pharmacy-private-limited-652319-04102023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Failure to adequately test each shipment of glycerin for identity and safety limits for diethylene glycol (DEG) or ethylene glycol (EG).",
      "Inadequate testing methods for glycerin impurities and lack of evidence for analytical testing results."
    ],
    "recommendations": [
      "Provide results of tests for DEG and EG in retain samples of all glycerin lots used in production.",
      "Conduct a full risk assessment for drug products containing glycerin.",
      "Review material systems to ensure all suppliers are qualified and materials have appropriate expiration dates.",
      "Describe testing procedures for each component lot and establish reliability of supplier results.",
      "Detail chemical and microbiological quality control specifications for incoming lots.",
      "Assess laboratory practices and provide a remediation plan."
    ]
  },
  {
    "letter_name": "hubei-kangzheng-pharmaceutical-co-ltd-616581-11232021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug product",
      "unapproved new drug",
      "misbranding",
      "failure to establish and follow appropriate written procedures",
      "failure to demonstrate capability of preventing microbial contamination",
      "failure to establish and validate a process suitable for sterile drug product",
      "failure to establish and follow appropriate written procedures for sterilizing equipment",
      "failure to establish an adequate system for monitoring environmental conditions",
      "failure to conduct sterility testing",
      "failure to establish and follow an adequate written testing program for stability",
      "failure to thoroughly investigate unexplained discrepancies or failures",
      "failure to clean, maintain, and sanitize equipment and utensils"
    ],
    "recommendations": [
      "Provide a comprehensive risk assessment of all contamination hazards",
      "Provide a detailed remediation plan with timelines",
      "Provide a detailed summary of your validation program",
      "Include your process performance protocol(s) and written procedures for qualification and sterilization of equipment",
      "Provide a comprehensive summary of your media fill program",
      "Conduct smoke studies to evaluate air flow patterns",
      "Update environmental monitoring procedures",
      "Provide appropriate microbiological batch release specifications",
      "Provide all chemical, physical, and microbial test methods used",
      "Provide a comprehensive, independent assessment and CAPA plan for stability program",
      "Provide a CAPA plan for routine operations management oversight",
      "Conduct a retrospective assessment of cleaning effectiveness"
    ]
  },
  {
    "letter_name": "eosera-inc-605500-07132020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to thoroughly investigate discrepancies",
      "failure to follow a written testing program for stability",
      "failure to validate manufacturing processes",
      "inadequate quality control unit",
      "failure to establish appropriate expiration dates",
      "failure to conduct adequate investigations of OOS results"
    ],
    "recommendations": [
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Provide a comprehensive review and remediation plan for OOS result investigation systems",
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations",
      "Develop a comprehensive CAPA plan for the design, control, and maintenance of water systems",
      "Provide a comprehensive, independent assessment and CAPA plan for the stability program",
      "Provide a detailed summary of the validation program for ensuring a state of control",
      "Conduct a comprehensive assessment and remediation plan for the quality control unit",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "analytical-food-laboratories-inc-687513-10102024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "failed to establish and follow required laboratory control mechanisms",
      "lack of method validation",
      "inadequate system suitability",
      "inadequate growth promotion testing",
      "failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP",
      "failed to adequately control the issuance and reconciliation of uncontrolled loose forms",
      "failed to review laboratory records to ensure completeness"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Conduct a retrospective assessment of prior testing to assure suitability of all analytical methods for the last 3 years.",
      "Conduct a retrospective risk assessment of prior testing to assure suitability of all growth media for the last 3 years.",
      "Provide a comprehensive assessment and remediation plan to ensure the quality control unit is effective.",
      "Conduct a comprehensive independent assessment of documentation practices.",
      "Provide an independent assessment summarizing the potential impact on product quality of inadequate documentation.",
      "Conduct a comprehensive, independent assessment of the change management system.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "jiangsu-hengrui-pharmaceuticals-co-ltd-679790-07112024",
    "violated_terms": [
      "Quality control unit responsibilities (21 CFR 211.22)",
      "Inadequate physical separation between Grade A and Grade B areas (21 CFR 211.42(c)(10))",
      "Data integrity practices as per FDA guidance"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for QA department",
      "Detailed remediation plan addressing contamination hazards",
      "Comprehensive investigation into data integrity inaccuracies",
      "Management strategy for corrective actions and preventive measures"
    ]
  },
  {
    "letter_name": "cosmetic-specialty-labs-inc-671239-02292024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "drug products are adulterated",
      "not duly listed with FDA",
      "failure to properly list a drug product",
      "drug misbranded",
      "quality control unit failed to ensure compliance with CGMP",
      "inadequate quality unit oversight",
      "failure to perform thorough investigations into out-of-specifications results",
      "failure to establish an adequate stability program",
      "failure to perform periodic product reviews",
      "approved drug products for distribution without complete finished product testing",
      "failure to establish adequate written procedures for production and process control",
      "lack of appropriate process validation",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to validate and establish the reliability of component supplier’s test analyses",
      "failure to adequately test incoming components for identity",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to fulfill drug listing obligations"
    ],
    "recommendations": [
      "provide a comprehensive assessment and remediation plan for the quality unit",
      "provide a comprehensive, independent assessment of the overall system for investigating deviations",
      "provide a list of chemical and microbial specifications for testing each batch",
      "provide an action plan and timelines for conducting full chemical and microbiological testing",
      "provide a comprehensive, independent assessment and CAPA plan for the stability program",
      "provide a detailed summary of the validation program for ensuring a state of control",
      "provide a comprehensive, independent review of the material system for component suppliers",
      "provide a CAPA plan based on the retrospective assessment of the cleaning program",
      "engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "hangzhou-sunking-nonwovens-co-ltd-568546-01292019",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing.",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products."
    ],
    "recommendations": [
      "Provide test methods and specifications for analyzing each batch of drug product prior to release.",
      "Develop a plan for testing retains of all drug products distributed to the U.S. market within expiry.",
      "Establish batch release specifications for all incoming components.",
      "Conduct a risk assessment of all drug products distributed to the U.S. market within expiry.",
      "Develop and implement a complete drug stability program.",
      "Provide process performance qualification for drug products.",
      "Establish a corrective and preventive action (CAPA) plan for the quality control unit."
    ]
  },
  {
    "letter_name": "greenbrier-international-inc-dba-dollar-tree-574706-11062019",
    "violated_terms": [
      "Receipt of Adulterated Drugs from Contract Manufacturers and Suppliers",
      "Specific CGMP violations at Shanghai Weierya Daily Chemicals Factory and Hangzhou Zhongbo Industrial Company, Ltd.",
      "Failure to conduct component identity testing and test for objectionable microorganisms",
      "Pattern of using suppliers with significant CGMP violations"
    ],
    "recommendations": [
      "Detailed plan to ensure no receipt or delivery of adulterated drugs",
      "Full evaluation of supplier and contract manufacturer evaluation program",
      "Plan to audit suppliers and reconcile drugs from manufacturers listed in the letter",
      "Ensure testing conducted by Bureau Veritas meets FDA regulations"
    ]
  },
  {
    "letter_name": "higley-industries-inc-669170-02222024",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.",
      "You failed to adequately test your incoming ethanol for methanol contamination.",
      "You failed to adequately test your incoming glycerin for identity and contamination with diethylene glycol (DEG) or ethylene glycol (EG).",
      "Your firm has not demonstrated that the water is suitable for use and meets the USP water monograph.",
      "Your firm failed to establish adequate written procedures for production and process control.",
      "Your quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Include a commitment to conduct at least one specific identity test for each incoming component lot.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "A comprehensive assessment and remediation plan to ensure your quality unit is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "corporativo-bureli-sa-de-cv-610304-12012020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "misbranded under section 502(j) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing your firm’s hand sanitizer and rubbing alcohol drug products currently in distribution to the U.S. market",
      "provide a detailed investigation into how the drug product was substituted with methanol",
      "provide a list of all raw materials used to manufacture hand sanitizer and rubbing alcohol products",
      "provide a list of all batches of hand sanitizer and rubbing alcohol products shipped to the U.S.",
      "provide copies of the complete batch records for all batches distributed to the U.S.",
      "provide a complete assessment of laboratory practices and a detailed plan to remediate and evaluate the effectiveness of the laboratory system",
      "engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "art-beauty-company-inc-674144-05222024",
    "violated_terms": [
      "Quality control unit responsibilities and procedures (21 CFR 211.22)",
      "Testing for identity of drug components (21 CFR 211.84(d)(1))",
      "Microbial testing of drug products (21 CFR 211.165(b))",
      "Production and process control procedures (21 CFR 211.100(a))",
      "Cleaning and maintenance procedures (21 CFR 211.67(a) and (b))"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality control unit",
      "Independent review of material system and testing protocols for drug components",
      "List of chemical and microbial test methods for drug products",
      "Detailed plan for cleaning and maintenance procedures, including validation",
      "Engagement of a qualified CGMP consultant"
    ]
  },
  {
    "letter_name": "gadal-laboratories-inc-655929-08152023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.100(a)",
      "21 CFR 211.22(d)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Provide remaining test results for finished products and retains of high-risk components within 30 calendar days.",
      "Perform a full risk assessment for drug products within expiry containing any ingredient at risk for contamination.",
      "Conduct a risk assessment of components qualified and released for use without appropriate testing.",
      "Review the completion status and adequacy of microbial effectiveness testing studies for multi-use non-sterile drug products.",
      "Provide chemical and microbiological quality control specifications for testing incoming lots of components.",
      "Establish a detailed program for validating and maintaining manufacturing processes.",
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the system.",
      "Conduct a comprehensive assessment and remediation plan to ensure the quality control unit functions effectively.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "advanced-botanical-consulting-testing-inc-dba-abc-testing-572991-06042019",
    "violated_terms": [
      "Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).",
      "You did not use United States Pharmacopeia (USP) monograph methods to test multiple USP monograph drug products nor did you show method equivalency or superiority for your methods.",
      "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
      "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
      "Your firm failed to routinely calibrate, inspect, or check according to a written program designed to assure proper performance of and to maintain adequate written records of calibration checks and inspections (21 CFR 211.68(a))."
    ],
    "recommendations": [
      "Provide an independent assessment of all test methods used by your firm to ensure they have appropriate instructions, method suitability criteria, and appropriate validation.",
      "Provide a comprehensive independent review of your entire laboratory system, and a corrective action and preventive action (CAPA) plan that ensures full remediation of the laboratory operation.",
      "Perform a global review of all your notebooks and worksheets to determine if there are any additional missing information on other notebooks and worksheets.",
      "Provide a summary of your interim controls to prevent deletion and modification of data; define the roles and responsibilities of personnel who have access to analytical instruments and data.",
      "Establish a procedure requiring regular scheduling of calibration and validation for all equipment."
    ]
  },
  {
    "letter_name": "ismar-soluciones-dinamicas-s-de-rl-de-cv-609690-05042021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "bi-coastal-pharma-international-628196-06302022",
    "violated_terms": [
      "Failure to establish and follow adequate written procedures for handling complaints (21 CFR 211.198(a)).",
      "Inadequate investigation of a complaint regarding Chlordiazepoxide HCl and Clidinium Br.",
      "Failure to establish an adequate quality unit and written responsibilities for the quality control unit (21 CFR 211.22(a) and (d)).",
      "Lack of Quality Unit oversight over contract manufacturers.",
      "Failure to follow established procedures for batch record review and release.",
      "Inadequate training and qualifications of personnel overseeing quality functions (21 CFR 211.25(b))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of the system for investigating complaints and deviations.",
      "Conduct a retrospective review of all records that may constitute a complaint for U.S. products.",
      "Evaluate existing processes and procedures for quality and manufacturing controls, especially when a CMO is no longer in business.",
      "Establish written responsibilities for managing CMOs and ensure compliance with CGMP.",
      "Implement a comprehensive assessment and CAPA for the training program, including practices and staff competencies.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "absara-cosmetics-sapi-de-cv-612455-02182021",
    "violated_terms": [
      "Adulteration of hand sanitizer product due to subpotency (58% ethanol instead of 70%)",
      "Failure to provide adequate test methods and documentation for method validation",
      "Inadequate investigation into the root cause of subpotency and lack of thorough review of laboratory operations"
    ],
    "recommendations": [
      "Conduct a detailed follow-up investigation into the subpotency issue, identifying specific batches affected",
      "Provide a comprehensive list of raw materials used in the manufacturing process, including supplier details",
      "Submit complete batch records for all distributed hand sanitizer products",
      "List appropriate chemical and microbial test methods used for product analysis before lot disposition"
    ]
  },
  {
    "letter_name": "eyepoint-pharmaceuticals-inc-679747-07122024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.100(b)",
      "21 CFR 211.110(a)"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.",
      "Conduct a retrospective review of all investigations into OOS results and unexplained discrepancies for U.S. products for the last three years.",
      "Perform a retrospective review of historical release rate test results including those for in-process and finished product release.",
      "Implement routine, vigilant operations management oversight of facilities and equipment.",
      "Establish adequate written procedures for production and process control.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements.",
      "Investigate the impact of improper practices on release rate test results."
    ]
  },
  {
    "letter_name": "allerquest-llc-578557-06242019",
    "violated_terms": [
      "Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).",
      "Your aseptic processing line design is inadequate.",
      "You failed to ensure sufficient use of a sporicidal agent in your disinfection program.",
      "You did not adequately investigate the cause of multiple excursions above your action limit.",
      "You failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192)."
    ],
    "recommendations": [
      "Provide interim plans for the manufacture and distribution of sterile drug products while remediating the facility and equipment design.",
      "Comprehensive identification of all contamination hazards with respect to aseptic processes, equipment, and facilities, including an independent risk assessment.",
      "A detailed CAPA plan with timelines to address contamination hazards and improve aseptic processing operation design.",
      "Detailed supportive documentation of your CAPA, including updates on facility remediation plans and change-over procedures.",
      "A detailed procedure for routine shutdown and startup of aseptic production operations.",
      "An improved visual inspection program with acceptance and rejection limits based on statistical principles."
    ]
  },
  {
    "letter_name": "diora-kimya-sanayi-ve-ticaret-limited-sirketi-688271-10172024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Failure to conduct at least one test to verify the identity of each component of a drug product",
      "Failure to validate and establish the reliability of component supplier’s test analyses",
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product",
      "Failure to establish written procedures for production and process control",
      "Personal CARE Antibacterial Soap not duly listed with FDA",
      "Failure to provide listing information required by section 510(j) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance",
      "Develop and validate assay methods",
      "Revise standard operating procedures and retrain employees",
      "Implement process controls and complete process and cleaning validation",
      "Create new procedures and implement training for employees",
      "Ensure compliance with registration and listing requirements under section 510 of the FD&C Act"
    ]
  },
  {
    "letter_name": "king-bio-inc-567480-03202019",
    "violated_terms": [
      "Failure to establish an adequate quality control unit (21 CFR 211.22(a))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to validate manufacturing processes for homeopathic drug products",
      "Failure to use appropriately designed equipment for drug manufacturing (21 CFR 211.63)",
      "Misbranding of drugs under section 503(b) of the FD&C Act (21 U.S.C. 353(b))"
    ],
    "recommendations": [
      "Conduct an independent, retrospective review of all OOS results and complaints since Jan. 1, 2015.",
      "Develop a comprehensive assessment with corrective and preventive actions (CAPA) for the Quality Unit.",
      "Establish a data-driven program to identify and control sources of variability in manufacturing processes.",
      "Provide a risk assessment for distributed drug products manufactured using unvalidated processes.",
      "Implement a comprehensive evaluation and remediation plan for the purified water system."
    ]
  },
  {
    "letter_name": "healthy-foods-nutrition-lab-de-mexico-sa-de-cv-609608-09292021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements",
      "unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Provide a detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 70% ethanol, in fact contained an average of 13% ethanol",
      "Provide a list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information",
      "Provide a list of all batches of any hand sanitizer drug products shipped to the United States, and a full reconciliation of all material you distributed",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Provide a complete, comprehensive, independent assessment of your quality unit, including laboratory oversight, and procedures related to release decisions",
      "Provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system",
      "Provide process validation procedures and protocols for all drug products you plan to ship to the U.S. in the future",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "fancystage-unipessoal-lda-678453-06042024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products under section 501(a)(2)(B) of the FD&C Act",
      "Misbranding under section 502(f)(1) of the FD&C Act",
      "Failure to test samples of each component for identity and conformity",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to establish laboratory controls",
      "Quality control unit failure to ensure compliance with CGMP"
    ],
    "recommendations": [
      "Provide a description of how you will test each component lot for conformity",
      "Include a commitment to conduct at least one specific identity test for each incoming component lot",
      "Provide a comprehensive, independent review of your material system",
      "Provide a detailed summary of your validation program for ensuring a state of control",
      "Provide a complete assessment and remediation plan for your quality control unit",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "kilitch-healthcare-india-limited-672956-03282024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act",
      "failed to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failed to ensure that laboratory records included complete data",
      "failed to perform operations within specifically defined areas of adequate size",
      "failed to ensure drug products manufactured are in compliance with CGMP",
      "failed to follow approved, written production and process controls",
      "failed to ensure that adequate stability data supported drug expiration dates",
      "failed to ensure the accuracy and integrity of data"
    ],
    "recommendations": [
      "Provide a plan to ensure appropriate aseptic practices and cleanroom behavior during production.",
      "Conduct a thorough retrospective review and risk assessment evaluating the impact of poor aseptic technique.",
      "Perform a comprehensive, independent assessment of the design and control of manufacturing operations.",
      "Conduct complete investigations into all batches with potential objectionable microbial contamination.",
      "Implement a detailed remediation plan with timelines to address contamination hazards.",
      "Provide a comprehensive, independent assessment of laboratory practices and data integrity.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Provide a commitment to test for diethylene glycol (DEG) and ethylene glycol (EG) in high-risk drug components.",
      "Conduct a comprehensive assessment and remediation plan for the quality control unit.",
      "Implement a CAPA plan to ensure routine oversight of facilities and equipment."
    ]
  },
  {
    "letter_name": "imprimis-njof-llc-553322-06072019",
    "violated_terms": [
      "failure to meet the conditions of section 503B",
      "compounded drug products using gatifloxacin are not eligible for exemptions",
      "failure to submit a report to FDA identifying drug products compounded",
      "failure to submit adverse event reports as required",
      "CGMP violations causing drug products to be adulterated",
      "failure to establish an adequate system for monitoring environmental conditions",
      "failure to establish and follow appropriate procedures for testing incoming materials",
      "failure to establish an adequate quality control unit",
      "failure to thoroughly investigate discrepancies",
      "introduction of adulterated drugs into interstate commerce",
      "marketing unapproved new drug products",
      "failure to provide adequate directions for use causing misbranding",
      "failure to report drugs compounded during the previous 6-month period",
      "failure to report adverse events"
    ],
    "recommendations": [
      "undertake a comprehensive assessment of operations",
      "assess aseptic processing operations",
      "engage a third-party consultant with sterile drug manufacturing expertise",
      "ensure all components used to produce finished drug products are appropriate for the intended route of administration"
    ]
  },
  {
    "letter_name": "kadesh-international-570947-05022019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded drugs in violation of section 503(b)(4) of the FD&C Act",
      "unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&C Act",
      "failed to establish an adequate quality control unit (21 CFR 211.22(a))",
      "failed to prepare batch production and control records (21 CFR 211.188)",
      "failed to establish time limits for the completion of each phase of production (21 CFR 211.111)"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34",
      "perform a comprehensive audit of your drug production operation for CGMP compliance",
      "provide written clarification of whether you plan to manufacture drugs required to be sterile in the future",
      "provide detailed supporting documentation of your CAPA",
      "provide interim plans for the manufacture and distribution of drug products while you remediate your violations",
      "conduct a retrospective evaluation of your drug products that remain on the U.S. market",
      "ensure your QU is given the needed authority and resources to effectively discharge its function",
      "establish a robust supplier qualification program"
    ]
  },
  {
    "letter_name": "fill-it-pack-it-inc-570946-05022019",
    "violated_terms": [
      "Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile.",
      "Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas necessary to prevent contamination or mix-ups in aseptic processing areas.",
      "Your filling suite is not suitable for filling sterile drugs.",
      "You lacked a system for monitoring environmental conditions.",
      "You failed to establish procedures for the sterilization of a drug product that is required to be sterile.",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products.",
      "You did not ensure that containers and closures used in the aseptic manufacture of an ophthalmic drug product were sterile."
    ],
    "recommendations": [
      "Provide detailed supporting documentation of your CAPA, including bulk hold times, cleaning validation, and screening criteria for drugs that may require sterility.",
      "Implement routine management oversight of manufacturing to ensure appropriate facilities and capable equipment.",
      "Conduct a retrospective evaluation of any drug product that remains on the U.S. market to assess quality or patient safety risks.",
      "Engage a consultant qualified to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "ctx-lifesciences-private-ltd-577416-07122019",
    "violated_terms": [
      "Failure to ensure that water used in the manufacturing steps of a non-sterile API intended for a sterile drug product is monitored and controlled for total microbial counts, objectionable organisms, and endotoxins.",
      "Failure to adequately investigate out-of-specification results and implement appropriate corrective actions."
    ],
    "recommendations": [
      "Commitment to monitor and control water for endotoxins for API intended for sterile drug products, including detailed corrective actions and preventive actions (CAPA).",
      "Retrospective review of all invalidated OOS results and a thorough investigation of potential manufacturing causes for OOS results with inconclusive or no root cause identified."
    ]
  },
  {
    "letter_name": "bella-pharmaceuticals-inc-572550-02112019",
    "violated_terms": [
      "Failure to meet the conditions of section 503B of the FDCA",
      "Drug products compounded using Fluorescein Sodium are not eligible for exemptions",
      "Labeling does not include required statements",
      "Failure to submit reports to FDA upon initial registration and in June 2017",
      "Drug products prepared under insanitary conditions",
      "Drug products adulterated under section 501(a)(2)(A) of the FDCA",
      "CGMP violations causing drug products to be adulterated under section 501(a)(2)(B) of the FDCA",
      "No FDA-approved applications on file for compounded drug products",
      "Drug products misbranded under section 502(f)(1) of the FDCA",
      "Failure to report drugs as required under section 503B(b)(2) of the FDCA"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems",
      "Engage a third-party consultant with sterile drug manufacturing expertise for evaluation",
      "Take prompt action to correct the violations cited in the letter",
      "Notify the FDA 15 days prior to resuming production of any sterile drugs",
      "Provide documentation of corrective actions taken"
    ]
  },
  {
    "letter_name": "cg-laboratorios-sa-de-cv-610782-04262021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "bershtel-enterprises-llc-dba-wepackitall-570885-05022019",
    "violated_terms": [
      "Your firm failed to establish and follow appropriate written procedures to prevent microbiological contamination (21 CFR 211.113(b) & 211.42(c)(10)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancies (21 CFR 211.192).",
      "Your firm failed to maintain written records for annual product reviews (21 CFR 211.180(e))."
    ],
    "recommendations": [
      "Provide detailed supporting documentation of corrective actions and preventive actions (CAPA) related to microbiological contamination controls.",
      "Conduct a comprehensive assessment of your investigation system for deviations and ensure adequate procedures are in place.",
      "Establish and implement annual product review procedures with supporting documentation."
    ]
  },
  {
    "letter_name": "beijing-xinggu-lvsan-technology-co-ltd-formerly-known-beijing-lvsan-technology-co-ltd-633904",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under section 502(c) and (ee) of the FD&C Act",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to conduct appropriate laboratory testing for objectionable microorganisms",
      "failure to establish written procedures for production and process control",
      "failure of the quality control unit to ensure compliance with CGMP"
    ],
    "recommendations": [
      "Provide a retrospective risk assessment on the impact of the lack of adequate tests for incoming components",
      "Provide chemical and microbiological quality control specifications for testing incoming lots",
      "Describe how each component lot will be tested for conformity with specifications",
      "Summarize results obtained from testing all components to evaluate the reliability of COA",
      "Provide a risk assessment for drugs produced on shared equipment",
      "Provide plans for separating areas for pharmaceutical and non-pharmaceutical manufacturing",
      "Provide updated SOPs for verification and validation of cleaning procedures",
      "List chemical and microbial specifications used to analyze drug products before lot disposition",
      "Provide a detailed summary of the validation program for manufacturing processes",
      "Provide a comprehensive assessment and remediation plan for the quality control unit",
      "Conduct a comprehensive investigation into data integrity issues",
      "Engage a qualified consultant for CGMP compliance assistance"
    ]
  },
  {
    "letter_name": "aurolife-pharma-llc-607087-10162020",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Maintenance of buildings in good repair (21 CFR 211.58)",
      "Written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "Written procedures for production and process control (21 CFR 211.100(a))"
    ],
    "recommendations": [
      "Provide the identity of impurities and conduct root cause analysis for OOS results.",
      "Implement a CAPA plan for routine operations management oversight of facilities.",
      "Conduct a retrospective review of drugs potentially impacted by facility leaks.",
      "Establish effective powder control systems and assess cross-contamination hazards.",
      "Develop a detailed validation program for ensuring a state of control throughout the product lifecycle."
    ]
  },
  {
    "letter_name": "contacare-ophthalmics-diagnostics-570360-04232019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to perform operations within specifically defined areas",
      "failure to establish and follow appropriate written procedures",
      "failure to maintain equipment used to control aseptic conditions",
      "failure to thoroughly investigate unexplained discrepancies",
      "introduction or delivery for introduction of new drugs without FDA approval",
      "failure to provide adequate directions for use"
    ],
    "recommendations": [
      "Conduct smoke studies under static and dynamic conditions to evaluate airflow patterns",
      "Perform a retrospective risk assessment of all drug products produced in the filling room",
      "Establish and follow appropriate written procedures to prevent microbiological contamination",
      "Provide a retrospective assessment of all media fills conducted since November 2015",
      "Provide evidence and justification for the source of discoloration on HEPA filters",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Implement a detailed corrective action and preventive action (CAPA) plan",
      "Provide a management strategy that includes a global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "bell-international-laboratories-inc-669736-02152024",
    "violated_terms": [
      "Failure to establish an adequate quality unit with documented responsibilities (21 CFR 211.22(a) and (d))",
      "Inadequate investigations into non-conformances (21 CFR 211.192)",
      "Inadequate investigations into complaints (21 CFR 211.198(a))",
      "Inadequate document control and retention (21 CFR 211.188)",
      "Failure to test samples of each component for identity and conformity (21 CFR 211.84(d)(1))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for the quality unit's authority and resources",
      "Complete assessment of documentation systems with a detailed CAPA plan",
      "Independent assessment and remediation plan for the CAPA program",
      "Comprehensive review and remediation plan for the investigation systems",
      "Commitment to provide test results for DEG and EG from high-risk drug components",
      "Detailed program for designing and validating manufacturing processes"
    ]
  },
  {
    "letter_name": "guangzhou-youxing-cosmetic-co-ltd-610709-09302021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements",
      "unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act",
      "contains ethanol in a concentration that is less than the 75% v/v stated on its product label",
      "misbranded under section 502(a) of the FD&C Act because its labeling is false or misleading",
      "does not comply with the requirements for marketing under section 505G of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions before pursuing resolution of your firm’s compliance status with FDA",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "apollo-health-and-beauty-care-inc-593033-12232019",
    "violated_terms": [
      "Failure to routinely calibrate, inspect, or check equipment (21 CFR 211.68(a))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to thoroughly investigate unexplained discrepancies or failures (21 CFR 211.192)"
    ],
    "recommendations": [
      "Conduct a comprehensive investigation into data record inaccuracies and root causes",
      "Perform a current risk assessment of the effects of observed failures on drug quality",
      "Develop a management strategy including a global corrective action and preventive action plan",
      "Establish a detailed validation program for manufacturing processes",
      "Implement a comprehensive assessment and remediation plan for the quality unit and CAPA program"
    ]
  },
  {
    "letter_name": "cosmetic-science-laboratories-llc-645558-03102023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to validate and establish the reliability of your component supplier’s test analyses.",
      "Your firm failed to establish adequate written procedures for production and process control.",
      "Your firm lacked adequate batch records and process validation documents.",
      "Your firm could not provide evidence of cleaning validation and equipment qualification.",
      "Your firm did not establish that the water system is adequately designed and controlled.",
      "Your firm’s quality control unit failed to ensure compliance with CGMP.",
      "Your firm failed to fulfill establishment registration and drug listing obligations."
    ],
    "recommendations": [
      "Provide a comprehensive review of your material system to determine supplier qualifications.",
      "Establish and document adequate written procedures for production and process control.",
      "Implement a robust quality control unit with oversight of all manufacturing operations.",
      "Provide a detailed summary of your validation program for ensuring a state of control.",
      "Submit a comprehensive assessment and remediation plan for your quality control unit.",
      "Clarify your intentions regarding future drug manufacturing at the facility.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "botanicals-internacional-sa-de-cv-609774-02032021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide an updated investigation into the methanol contamination and CGMP failures",
      "List all batches of hand sanitizer shipped to the U.S. and reconcile all distributed material",
      "Submit complete batch records for all batches distributed to the U.S.",
      "List all raw materials used to manufacture hand sanitizer products and explain quality system failures",
      "Engage a qualified GMP consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "first-royal-care-co-llc-dba-red-mountain-compounding-pharmacy-610384-09082020",
    "violated_terms": [
      "Failed to meet the conditions of section 503A of the FDCA.",
      "Produced drug products without valid prescriptions for individually-identified patients.",
      "Drug products were prepared, packed, or held under insanitary conditions.",
      "Adulterated drug products due to insanitary conditions under section 501(a)(2)(A) of the FDCA.",
      "Significant CGMP violations including failure to establish and follow appropriate written procedures.",
      "Failure to conduct appropriate laboratory testing for drug products."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design and aseptic processing operations.",
      "Engage a third-party consultant with sterile drug manufacturing expertise.",
      "Establish and follow appropriate written procedures to prevent microbiological contamination.",
      "Implement a quality oversight and controls system over the manufacture of drugs."
    ]
  },
  {
    "letter_name": "atlantic-management-resources-ltd-dba-claire-ellen-products-642082-01202023",
    "violated_terms": [
      "Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).",
      "Your firm failed to store drug products under appropriate conditions of temperature, humidity, and light so that the identity, strength, quality, and purity are not affected (21 CFR 211.142(b)).",
      "Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b))."
    ],
    "recommendations": [
      "Establish a quality unit with defined responsibilities and written procedures to ensure compliance with CGMP.",
      "Implement monitoring systems for storage conditions to maintain the integrity of drug products.",
      "Develop and maintain batch production and control records for all drug products manufactured."
    ]
  },
  {
    "letter_name": "harmonic-nature-s-de-rl-mi-609367-11162020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "guangzhou-minghui-cosmetics-co-ltd-610575-07062021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (c), (f)(2), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions",
      "consider removing all of your firm’s hand sanitizer drug products currently in distribution from the U.S. market",
      "initiate a recall of the affected products"
    ]
  },
  {
    "letter_name": "coral-pharmaceuticals-ltd-586576-10092019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug product",
      "failure to establish adequate written procedures for production and process control",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to validate and establish the reliability of component supplier’s test analyses",
      "failure to establish an adequate quality control unit"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation plan for ensuring a state of control throughout the product lifecycle",
      "Provide a timeline for performing appropriate process performance qualification (PPQ) for each drug product",
      "Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each manufacturing process",
      "Provide chemical and microbiological quality control specifications for testing and releasing each incoming lot of components",
      "Conduct at least one specific identity test for each incoming component lot",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive audit of your entire operation for CGMP compliance",
      "Provide comprehensive corrective actions including systemic remediation and global assessment of all manufacturing operations"
    ]
  },
  {
    "letter_name": "cerci-kozmetik-ve-otel-ekipmanlari-pazarlama-ic-ve-dis-ticaret-limited-sirketi-669488-11162023",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).",
      "You did not provide evidence of identity testing for each lot of components (21 CFR 211.84(d)(1) and (d)(2))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.",
      "Provide an action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry.",
      "Provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Provide a comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program.",
      "Engage a qualified consultant to assist your firm in meeting CGMP requirements and perform a comprehensive audit of your entire operation for CGMP compliance."
    ]
  },
  {
    "letter_name": "health-plus-inc-616877-12292021",
    "violated_terms": [
      "21 CFR 211.204",
      "21 CFR 211.100(a)",
      "21 CFR 211.165(e)",
      "21 CFR 211.166(a)",
      "21 CFR 211.22(c)"
    ],
    "recommendations": [
      "A comprehensive, independent assessment and remediation plan to ensure the adequacy of your returned drug product handling and processing for redistribution.",
      "Provide your action plan to address any product quality risks associated with the redistributed batches in the United States.",
      "A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "A timeline for performing appropriate process performance qualification for your marketed drug product.",
      "A comprehensive assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program.",
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "bodywell-natural-skin-care-inc-677099-03272024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to validate and establish the reliability of component supplier’s test analyses",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failure to establish adequate written procedures for production and process control",
      "failure to prepare batch production and control records"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34",
      "perform a comprehensive six-system audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of all CAPAs before pursuing resolution of compliance status"
    ]
  },
  {
    "letter_name": "anazaohealth-corporation-613214-08182021",
    "violated_terms": [
      "section 503B of the FDCA",
      "section 505 of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 582 of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 503B(b)(5) of the FDCA",
      "section 301(d) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Take prompt action to correct any violations cited in this letter.",
      "Notify the FDA in writing of the specific steps taken to address any violations within fifteen (15) working days.",
      "Include an explanation of each step being taken to prevent the recurrence of any violations.",
      "Provide copies of related documentation.",
      "If unable to completely address the matter within fifteen (15) working days, state the reason for the delay and the time within which it will be addressed."
    ]
  },
  {
    "letter_name": "chemical-services-group-incroyal-chemical-company-648378-04052023",
    "violated_terms": [
      "Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Failure to validate and establish the reliability of component supplier’s test analyses (21 CFR 211.84(d)(2)).",
      "Failure to establish acceptance criteria for sampling and testing conducted by the quality control unit (21 CFR 211.165(d)).",
      "Quality control unit's failure to ensure compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Confirmation of discontinuation of manufacturing drugs on shared equipment.",
      "Risk assessment for drugs produced on shared equipment.",
      "Comprehensive retrospective assessment of cleaning effectiveness.",
      "CAPA plan for routine oversight of facilities and equipment.",
      "CAPA plan for cleaning processes and practices.",
      "Summary of updated SOPs for cleaning verification and validation.",
      "Confirmation that ethanol meets USP standards.",
      "Chemical and microbiological quality control specifications for incoming lots.",
      "Testing procedures for component lots.",
      "Control procedures for incoming raw materials.",
      "List of ethanol grades, lots, and manufacturers.",
      "Action plan for non-compliant hand sanitizer products.",
      "Traceability controls for ethanol lots.",
      "Chemical and microbiological specifications for batch testing.",
      "Action plan for testing retain samples.",
      "Independent assessment of laboratory practices.",
      "Comprehensive assessment and remediation plan for the quality control unit.",
      "Assessment of drug product processes for variability control.",
      "Independent assessment of the investigation system.",
      "Assessment of documentation systems and CAPA plan for documentation practices."
    ]
  },
  {
    "letter_name": "asesores-en-mantenimiento-hidraulico-e-industrial-sa-de-cv-610108-02222021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "does not comply with the requirements for marketing under section 505G of the FD&C Act",
      "misbranded under section 502(j) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing all of your firm’s hand sanitizer drug products currently in distribution from the U.S. market",
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "huaian-zongheng-bio-tech-co-ltd-590789-01092020",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a))",
      "Failure to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1))",
      "Failure to establish and follow an adequate written testing program for stability characteristics of drug products (21 CFR 211.166(a))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to use equipment of appropriate design, adequate size, and suitably located for its intended use (21 CFR 211.63)"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each lot of drug products before disposition.",
      "Develop an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Conduct a comprehensive independent assessment of laboratory practices and provide a remediation plan.",
      "Establish a written testing program for stability characteristics and ensure ongoing stability studies.",
      "Provide a detailed summary of the validation program for ensuring control throughout the product lifecycle."
    ]
  },
  {
    "letter_name": "gordon-laboratories-inc-631432-08172022",
    "violated_terms": [
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications",
      "failed to adequately investigate the root cause of the benzene, acetal, and acetaldehyde impurities",
      "failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality",
      "failed to establish adequate written procedures for production and process control",
      "inadequate investigations",
      "quality systems are inadequate"
    ],
    "recommendations": [
      "provide a comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures",
      "provide a summary of all available water system results from all parties",
      "provide a summary of all results including methanol, benzene, acetal, and acetaldehyde for all hand sanitizer batches released and distributed",
      "provide a description of how you will test each component lot for conformity with all appropriate specifications",
      "provide a detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug products currently in U.S. distribution",
      "engage a consultant qualified to assist your firm in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "haw-par-healthcare-limited-578581-08192019",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies and OOS results",
      "Establishment of laboratory controls with appropriate specifications",
      "Complete laboratory records with all necessary data",
      "Use of appropriately designed equipment for drug manufacturing",
      "Misbranding of 'TIGER BALM LINIMENT' under section 502(f)(2)"
    ],
    "recommendations": [
      "Retrospective review of all invalidated OOS results and CAPA plan",
      "Drug product specifications and degradation protocols",
      "Comprehensive review of data systems and CAPA for data integrity",
      "Validation protocol and risk assessment for manufacturing systems",
      "Engagement of a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "david-cosmetic-co-ltd-627408-05022022",
    "violated_terms": [
      "Adulteration of CALA Advanced Hand Sanitizer due to benzene contamination",
      "Failure to conduct impurity testing as required under 21 CFR 211.160(b) and 21 CFR 211.165",
      "Quality assurance deficiencies indicating non-compliance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the benzene contamination",
      "Provide a comprehensive list of raw materials and suppliers",
      "Submit complete batch records for all distributed batches",
      "Engage a qualified CGMP consultant for compliance evaluation and corrective action assessment"
    ]
  },
  {
    "letter_name": "betone-sa-de-cv-674299-03212024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.165(a)",
      "21 CFR 211.101(a)",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.137(a)"
    ],
    "recommendations": [
      "Provide a comprehensive assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Provide a list of chemical and microbial test methods and specifications used to analyze each lot of drug product.",
      "Develop a remediation plan to assure ongoing management oversight throughout the manufacturing lifecycle.",
      "Conduct identity testing on each shipment of high-risk components.",
      "Provide test results for DEG and EG from all lots of high-risk drug components.",
      "Perform a full risk assessment for drug products containing ingredients at risk for DEG or EG contamination.",
      "Establish and maintain an ongoing stability testing program to support labeled expiry.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "farmville-discount-drug-inc-dba-best-value-drug-574044-07092019",
    "violated_terms": [
      "section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)",
      "current good manufacturing practices (CGMP)",
      "labeling with adequate directions for use",
      "FDA approval prior to marketing",
      "section 501(a)(2)(A) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Notify the FDA in writing of the specific steps taken to correct violations within fifteen (15) working days."
    ]
  },
  {
    "letter_name": "aspire-pharmaceuticals-inc-630328-11222022",
    "violated_terms": [
      "21 CFR 111.75(h)(1)",
      "21 CFR 111.113(a)(1)",
      "21 CFR 111.110(c)",
      "21 CFR 211.194(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.192",
      "21 CFR 211.22",
      "21 CFR 211.165",
      "21 CFR 211.194",
      "21 U.S.C. § 342(g)(1)",
      "21 U.S.C. § 343",
      "21 U.S.C. § 343(q)(1)(A)",
      "21 U.S.C. 351(a)(2)(B)"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "Develop, validate, and implement an analytical method to detect and quantify impurities by September 2022.",
      "Establish interim controls to ensure product quality and mitigate risk to patients.",
      "Conduct a retrospective, independent review of all invalidated OOS results for products currently in the U.S. market.",
      "Retain a consultant highly qualified in data integrity assessment to assist in remediation.",
      "Implement a detailed corrective action plan to ensure the reliability and completeness of all generated data.",
      "Notify customers, recall product, conduct additional testing, and enhance complaint monitoring as interim measures."
    ]
  },
  {
    "letter_name": "ignacio-reyes-gonzalez-609718-01252021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "does not comply with the requirements for marketing under section 505G of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions if intending to manufacture drugs for the U.S. market"
    ]
  },
  {
    "letter_name": "imprimisrx-ca-inc-dba-imprimisrx-541375-03262019",
    "violated_terms": [
      "section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)",
      "section 501(a)(2)(B)",
      "section 502(f)(1)",
      "section 505",
      "section 501(a)(2)(A)",
      "section 501(c)",
      "section 501(d)",
      "Title 21, Code of Federal Regulations (CFR), parts 210 and 211",
      "section 301(d)",
      "section 502(a)"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in the evaluation.",
      "Investigate the cause of the sub potency and take appropriate corrective actions to prevent recurrence.",
      "Provide detail regarding the current policy for drug component selection and the use of non-pharmaceutical-grade ingredients.",
      "Ensure that the labeling includes all inactive ingredients and warnings associated with potential serious adverse reactions."
    ]
  },
  {
    "letter_name": "family-pharmacy-statesville-inc-611664-11062020",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products due to insanitary conditions",
      "Failure to establish an adequate system for cleaning and disinfecting",
      "Failure to adequately design the facility to prevent contamination",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "Failure to use appropriate air filtration systems",
      "Misbranded drug products due to inadequate directions for use"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design and procedures.",
      "Engage a third-party consultant with sterile drug manufacturing expertise.",
      "Implement corrective actions for insanitary conditions and CGMP violations.",
      "Provide evidence of retraining on cleaning procedures and other corrective actions.",
      "Submit supporting documentation for all corrective actions taken."
    ]
  },
  {
    "letter_name": "glenmark-pharmaceuticals-limited-582701-10032019",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies and batch failures (21 CFR 211.192)",
      "Identification of appropriate root causes and implementation of sustainable CAPA",
      "Investigation of complaints regarding product grittiness and inadequate response to ongoing formulation issues",
      "Investigation of temperature excursions during shipping and lack of timely actions",
      "Investigation of OOS test results for critical product attributes and failure to identify root causes",
      "Investigation of consumer complaints related to container/closure system defects"
    ],
    "recommendations": [
      "Comprehensive assessment of the investigation system for deviations, discrepancies, complaints, and failures",
      "Independent assessment and remediation plan for the CAPA program",
      "Detailed review of the robustness of the new formulation for (b)(4) cream USP",
      "Independent review of the material system for supplier qualification and material controls",
      "Review of manufacturing processes to ensure state of control and qualification of equipment and facility"
    ]
  },
  {
    "letter_name": "intas-pharmaceuticals-limited-652067-07282023",
    "violated_terms": [
      "current good manufacturing practice (CGMP)",
      "adulterated drug products",
      "failure to ensure reliability of data",
      "failure to assure integrity of analytical testing data",
      "failure to exercise appropriate controls over computerized systems",
      "failure to have adequate oversight of laboratory investigations",
      "failure to establish and follow required laboratory control mechanisms",
      "failure to establish adequate written procedures for production and process control",
      "failure to establish the accuracy, sensitivity, specificity, and reproducibility of test methods"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the QA department",
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Develop a comprehensive, independent assessment and CAPA plan for computer system security and integrity",
      "Complete assessment of documentation systems used throughout manufacturing and laboratory operations",
      "Conduct a comprehensive independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies",
      "Provide a comprehensive, independent assessment of the validation program for ensuring an ongoing state of control",
      "Conduct a detailed, independent assessment of all test methods to evaluate their validation and appropriateness for intended use",
      "Implement interim measures to protect patients and ensure drug quality"
    ]
  },
  {
    "letter_name": "fancystage-unipessoal-lda-657341-08032023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide (b)(4) and (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products.",
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "kvk-tech-inc-608236-10082020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "21 CFR 211.67(b)",
      "21 CFR 211.188",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Improvements to the cleaning validation program with emphasis on worst-case conditions",
      "Complete assessment of documentation systems used throughout manufacturing and laboratory operations",
      "CAPA plan for improving management oversight of operations",
      "Comprehensive, independent assessment of the change management system",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Clarify intentions regarding the resumption of drug manufacturing at the facility"
    ]
  },
  {
    "letter_name": "glenmark-pharmaceuticals-limited-637314-11222022",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies (21 CFR 211.192)",
      "Inadequate written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to establish laboratory control mechanisms (21 CFR 211.160(a))",
      "Incomplete batch production and control records (21 CFR 211.188)"
    ],
    "recommendations": [
      "Comprehensive independent assessment of investigation systems and action plans for improvements.",
      "Detailed program for designing, validating, and monitoring manufacturing processes.",
      "Independent assessment of laboratory practices and management strategy for data reliability.",
      "Remediation plan for ongoing management oversight of manufacturing lifecycle."
    ]
  },
  {
    "letter_name": "amlion-toothpaste-mfg-sdn-bhd-665879-11172023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP.",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products.",
      "Your firm failed to establish adequate written procedures for production and process control."
    ],
    "recommendations": [
      "Provide DEG and EG test results from testing retains for all lots of high-risk drug components.",
      "Conduct a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Establish a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle."
    ]
  },
  {
    "letter_name": "grupo-asimex-de-mexico-sa-de-cv-609759-11062020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing hand sanitizer drug products currently in distribution to the U.S. market",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Confirm that the firm is no longer manufacturing or distributing hand sanitizers for the U.S. market"
    ]
  },
  {
    "letter_name": "cga-limited-589028-12192019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to test samples of each component for identity and conformity",
      "failure to adequately test incoming components",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to use equipment of appropriate design and adequate size"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of your material system",
      "Provide chemical and microbiological quality control specifications for testing incoming lots",
      "Describe testing procedures for each component lot",
      "Submit a standard operating procedure (SOP) for COA validation program",
      "Provide a summary of the program for qualifying and overseeing contract facilities",
      "Conduct a comprehensive, independent assessment of laboratory practices",
      "Develop and implement a complete drug stability program",
      "Implement a corrective actions and preventive actions (CAPA) plan for equipment cleaning",
      "Conduct a detailed risk assessment of the (b)(4) system deficiencies",
      "Engage a qualified consultant for CGMP compliance assistance"
    ]
  },
  {
    "letter_name": "deqing-jiarou-daily-chemical-co-ltd-677928-03182024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive six-system audit.",
      "Implement a testing program to verify the identity of each component and ensure that active ingredients are tested for impurities.",
      "Establish a robust quality control unit to oversee all aspects of drug manufacturing operations.",
      "Develop a comprehensive stability testing program that includes appropriate chemical and microbiological testing."
    ]
  },
  {
    "letter_name": "accu-bio-chem-laboratories-619450-02242022",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Establishment and documentation of test method accuracy (21 CFR 211.165(e))",
      "Appropriate controls over electronic data systems (21 CFR 211.68(b))"
    ],
    "recommendations": [
      "Retrospective review of all invalidated OOS results and a comprehensive remediation plan for OOS investigation systems.",
      "Independent assessment of chemical and microbiological test methods with a plan for method verification or validation.",
      "Complete assessment of documentation systems and a detailed CAPA plan for documentation practices."
    ]
  },
  {
    "letter_name": "dermapharm-596662-03102020",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and (2)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies, along with a detailed remediation plan.",
      "Conduct full chemical and microbiological testing of retained samples to determine the quality of all batches of drug product distributed to the United States.",
      "Establish a detailed summary of the validation program for ensuring a state of control throughout the product lifecycle, including timelines for performing process performance qualification (PPQ) for each marketed drug product.",
      "Engage a qualified consultant to assist in meeting CGMP requirements and perform a comprehensive audit of the entire operation for CGMP compliance."
    ]
  },
  {
    "letter_name": "cangene-biopharma-llc-dba-emergent-biosolutions-630316-08102022",
    "violated_terms": [
      "Failure to clean, maintain, and sanitize equipment and utensils at appropriate intervals (21 CFR 211.67(a) and (b))",
      "Deficient system for ensuring suitable design and adequate control of equipment",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination of drug products (21 CFR 211.113(b))",
      "Poor aseptic technique during production runs",
      "Repeated failures demonstrating inadequate executive management oversight and control over drug manufacturing",
      "Ineffective quality system not in accordance with CGMP"
    ],
    "recommendations": [
      "Implement a corrective action and preventive action (CAPA) plan for routine operations management oversight of facilities and equipment",
      "Conduct a thorough retrospective review and risk assessment of aseptic techniques and cleanroom behavior",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements",
      "Revise procedures to include identification and tracking of all tray units for maintenance and suitability",
      "Provide a comprehensive assessment and remediation plan for the quality unit (QU) to ensure effective functioning"
    ]
  },
  {
    "letter_name": "formology-lab-inc-644745-03012023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish written procedures for production and process control (21 CFR 211.100(a)).",
      "Your firm failed to establish an adequate quality unit (21 CFR 211.22(a) and (d))."
    ],
    "recommendations": [
      "Provide a comprehensive review of your material system to ensure all suppliers are qualified and materials have appropriate expiration or retest dates.",
      "Detail your validation program for ensuring a state of control throughout the product lifecycle, including timelines for completion.",
      "Submit a comprehensive assessment and remediation plan to ensure your quality unit is effective and has the necessary authority and resources."
    ]
  },
  {
    "letter_name": "green-wave-analytical-llc-630965-08192022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drugs",
      "failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods",
      "failure to ensure that laboratory records included complete data",
      "failure to exercise appropriate controls over computer or related systems",
      "failure to establish a system for monitoring environmental conditions in aseptic processing areas",
      "failure to establish an adequate quality unit",
      "delaying, denying, limiting, or refusing a drug inspection"
    ],
    "recommendations": [
      "Provide the quality unit with appropriate authority and sufficient resources",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Investigate and determine the causes of any violations and prevent their recurrence",
      "Respond in writing within 15 working days to address violations and prevent recurrence"
    ]
  },
  {
    "letter_name": "gfa-production-xiamen-co-ltd-678364-06132024",
    "violated_terms": [
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a) and 211.100(b)).",
      "Lack of Process Validation: Failure to provide adequate data for process performance qualification.",
      "Inadequate Cleaning Validation: Failure to demonstrate adequate cleaning validation for manufacturing equipment.",
      "Inadequate Equipment Controls: Failure to monitor and acknowledge equipment alarms as per established procedures.",
      "Your firm failed to ensure laboratory records included complete data from all tests (21 CFR 211.194(a)).",
      "Your firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a))."
    ],
    "recommendations": [
      "Provide a remediation plan for ongoing management oversight throughout the manufacturing lifecycle.",
      "Submit a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Include a timeline for performing appropriate process performance qualification for each marketed drug product.",
      "Develop a comprehensive assessment of the design and control of manufacturing operations, including microbiological hazards.",
      "Conduct complete investigations into all batches with potential objectionable microbial contamination.",
      "Implement a corrective action and preventive action (CAPA) plan for routine operations management oversight."
    ]
  },
  {
    "letter_name": "hangzhou-linkeweier-daily-chemicals-co-ltd-595492-03132020",
    "violated_terms": [
      "Failure to conduct appropriate laboratory testing for objectionable microorganisms (21 CFR 211.165(b)).",
      "Inadequate testing of incoming components for identity and conformity (21 CFR 211.84(d)(1) and (2)).",
      "Lack of adequate written procedures for production and process control (21 CFR 211.100(a)).",
      "Inadequate stability testing program (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Comprehensive independent assessment of manufacturing operations and microbiological hazards.",
      "Detailed risk assessment for drug products with potential contamination.",
      "Establishment of appropriate microbiological batch release specifications.",
      "Development of a robust stability testing program with specific protocols."
    ]
  },
  {
    "letter_name": "cord-life-inc-572770-03292019",
    "violated_terms": [
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(4)",
      "section 201(g) of the FD&C Act",
      "section 351(i) of the PHS Act",
      "21 CFR 211.113(b)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.67(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice.",
      "Submit a written response outlining specific steps taken to correct the noted violations and prevent their recurrence."
    ]
  },
  {
    "letter_name": "green-pharmaceuticals-inc-635162-12162022",
    "violated_terms": [
      "adulterated under section 501(a)(1) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505 of the FD&C Act",
      "violates section 301 of the FD&C Act",
      "failure to test these products for objectionable microorganisms",
      "CGMP regulations for finished pharmaceuticals, 21 CFR 211.165(b)",
      "gross microbial contamination",
      "not generally recognized as safe and effective for use",
      "failure to promptly and adequately address any violations"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements.",
      "Conduct a comprehensive, independent assessment of the design and control of your firm’s manufacturing operations.",
      "Perform a detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination.",
      "Complete investigations into all batches with potential objectionable microbial contamination.",
      "Establish appropriate microbiological batch release specifications for each of your drug products.",
      "Provide all microbial test methods used to analyze each of your drug products.",
      "Summarize results from testing retain samples of all drug product batches within the expected period of marketing."
    ]
  },
  {
    "letter_name": "dollar-tree-inc-629509-11082022",
    "violated_terms": [
      "Adulterated Human Foods and Dietary Supplements: Specific violations under 21 CFR Part 117 including pest control failures and insanitary conditions.",
      "Adulterated Cosmetics: Violations related to insanitary conditions affecting cosmetic products.",
      "Adulterated Animal Foods: Violations under 21 CFR Part 507 regarding contamination and pest control.",
      "Adulterated Human Drugs: Violations under 21 U.S.C. § 351(a)(2)(B) and § 351(a)(2)(A) regarding insanitary conditions.",
      "Adulterated Devices: Violations under 21 U.S.C. § 351(a)(2)(A) related to device contamination."
    ],
    "recommendations": [
      "Implement effective pest control measures to exclude rodents and prevent contamination.",
      "Enhance sanitation practices to maintain clean and sanitary conditions in all areas of the facility.",
      "Conduct thorough inspections and maintenance of the facility to prevent pest entry and harborage.",
      "Establish a comprehensive recall and destruction plan for affected products.",
      "Provide ongoing training for staff on sanitation and pest control protocols."
    ]
  },
  {
    "letter_name": "herbal-doctor-remedies-583205-10042019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs",
      "misbranded drugs under sections 502(f)(1) and 505(a) of the FD&C Act",
      "failure to register an establishment as required by section 510",
      "failure to list a drug as required under section 510(j)",
      "insanitary conditions",
      "failure to establish an adequate quality unit",
      "failure to establish a system for drug distribution",
      "failure to clean and maintain equipment",
      "failure to prepare batch production and control records",
      "failure to promptly correct violations"
    ],
    "recommendations": [
      "Review all information on websites, product labels, and promotional materials to ensure compliance with the FD&C Act",
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Clarify intentions regarding the resumption of manufacturing dietary supplements or drugs",
      "Notify the FDA prior to resuming operations if planning to use a contract manufacturer"
    ]
  },
  {
    "letter_name": "chameleon-beverage-co-inc-dba-chameleon-sanitizer-corporation-615066-09242021",
    "violated_terms": [
      "Adulteration under section 501(a)(2)(A) of the FD&C Act due to insanitary conditions",
      "Adulteration under section 501(a)(2)(B) of the FD&C Act due to CGMP violations",
      "Misbranding under section 502(i) of the FD&C Act due to misleading packaging"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality control unit oversight",
      "List of chemical and microbial test methods and specifications for lot disposition",
      "Detailed cleaning and maintenance procedures for equipment to prevent cross-contamination",
      "Retrospective assessment of cleaning effectiveness and CAPA plan for cleaning processes"
    ]
  },
  {
    "letter_name": "cetylite-industries-inc-622823-04142022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.160(b)",
      "21 CFR 211.192",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Commitment to using current USP compendial methods until alternative methods have been demonstrated to be equivalent or better than the USP methods.",
      "Comprehensive study to determine whether test methods for drug products are equivalent to, or better than, the USP method.",
      "Updated test results using a validated test method of all reserve samples for all drugs released to the market within expiry.",
      "Action plan to address any product quality or patient safety risks for drug products in U.S. distribution.",
      "Retrospective, independent review of all invalidated OOS results for US products currently in the U.S. market.",
      "Thorough review of production for all OOS results found to have inconclusive or no root cause identified in the laboratory.",
      "Comprehensive review and remediation plan for OOS result investigation systems.",
      "Revised OOS investigation procedures."
    ]
  },
  {
    "letter_name": "cosmelab-co-ltd-590480-01092020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "21 CFR 211.22(a)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "FDA Import Alert 66-40"
    ],
    "recommendations": [
      "Establish a comprehensive quality unit with authority and resources",
      "Conduct a comprehensive independent assessment and remediation plan for the quality unit",
      "Perform a retrospective evaluation of drug products on the U.S. market",
      "Provide a list of chemical specifications and test methods for drug products",
      "Develop a detailed plan for ongoing assessments of each lot of components used in production",
      "Engage a qualified consultant to assist in meeting drug CGMP requirements"
    ]
  },
  {
    "letter_name": "k-boeun-pharmaceutical-co-ltd-665099-08142023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in manufacturing.",
      "Conduct a full risk assessment for drug products within expiry that contain any ingredient at risk for DEG or EG contamination.",
      "Describe how each component lot will be tested for conformity with specifications for identity, strength, quality, and purity.",
      "Provide a comprehensive, independent review of the material system to ensure all suppliers are qualified and materials are assigned appropriate expiration or retest dates.",
      "Summarize the program for qualifying and overseeing contract facilities that test the drug products manufactured.",
      "Summarize results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer."
    ]
  },
  {
    "letter_name": "jg-atlas-comercios-sa-de-cv-609415-11062020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "does not conform to the 1994 TFM",
      "not an active ingredient permitted for use in consumer antiseptic hand washes",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a detailed investigation into how the consumer antiseptic drug product was substituted with methanol",
      "List all raw materials used to manufacture consumer antiseptic drug products, including suppliers’ names, addresses, and contact information",
      "List all batches of any consumer antiseptic drug products shipped to the United States and reconcile all material distributed",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status"
    ]
  },
  {
    "letter_name": "inopak-ltd-667411-12152023",
    "violated_terms": [
      "Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).",
      "Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a))."
    ],
    "recommendations": [
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function, including a determination of whether procedures used by your firm are robust and appropriate.",
      "Your plan for continuing stability studies for your drug products through expiry, including detailed timelines and an assessment of the stability of drug product currently on the U.S. market."
    ]
  },
  {
    "letter_name": "infusion-options-inc-612459-08262021",
    "violated_terms": [
      "Drug products produced failed to meet the conditions of section 503B of the FDCA.",
      "Drug products did not include required labeling statements such as 'This is a compounded drug' and 'Not for resale'.",
      "Failure to submit reports to FDA identifying compounded drug products.",
      "Drug products prepared, packed, or held under insanitary conditions.",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination.",
      "Failure to follow written procedures regarding storage and warehousing of drug products.",
      "Failure to establish an adequate system for maintaining equipment used to control aseptic conditions.",
      "Failure to ensure appropriate clothing for manufacturing personnel.",
      "Failure to follow written procedures for production and process control.",
      "Failure to establish an adequate system for cleaning and disinfecting.",
      "Failure to perform operations within defined areas to prevent contamination.",
      "Failure to ensure authorized personnel access to limited-access areas.",
      "Failure to ensure aseptic processing areas have cleanable surfaces.",
      "Failure to establish an adequate system for monitoring environmental conditions.",
      "Failure to investigate discrepancies or failures of batches."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with sterile drug manufacturing expertise for evaluation.",
      "Implement quality oversight and controls over drug manufacturing processes.",
      "Ensure compliance with CGMP requirements and FDA regulations.",
      "Notify FDA 15 working days prior to resuming production, holding, or distribution of drug products."
    ]
  },
  {
    "letter_name": "cross-brands-contract-filling-llc-589295-12172019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "failed to conduct at least one test to verify the identity of each component of a drug product",
      "failed to validate and establish the reliability of your component supplier's test analyses",
      "lacks an adequate quality control unit",
      "failed to conduct microbiological testing before use of each lot of a component with potential for objectionable microbiological contamination",
      "quality system does not adequately ensure the accuracy and integrity of data",
      "unapproved new drug charges"
    ],
    "recommendations": [
      "Provide the chemical and microbiological quality control specifications for testing and releasing each incoming lot of component.",
      "Describe how you will test each component lot for conformity with specifications.",
      "Provide a summary of results obtained from testing all components to evaluate the reliability of the COA.",
      "Provide a comprehensive assessment and remediation plan for your Quality Unit.",
      "Conduct a retrospective evaluation of your drug product batches on the U.S. market within expiry.",
      "Conduct a comprehensive, independent assessment of your water system design, control, and maintenance.",
      "Retain a qualified consultant to assist in your remediation.",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records and reporting.",
      "Develop a management strategy that includes a global CAPA plan."
    ]
  },
  {
    "letter_name": "colgin-inc-670332-01252024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.100(a)",
      "21 CFR 211.22",
      "21 CFR 211.165(b)",
      "21 CFR 211.192",
      "21 CFR 211.67(a)",
      "21 CFR 211.137(a)",
      "21 CFR 211.180(e)",
      "21 CFR 211.25(a)"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of your material system",
      "Provide chemical and microbiological quality control specifications",
      "Describe how you will test each component batch for conformity",
      "Summarize results obtained from testing all components",
      "Summarize your program for qualifying and overseeing contract facilities",
      "Provide a detailed risk assessment addressing hazards of expired components",
      "Provide a detailed summary of your validation program",
      "Include a timeline for performing appropriate process performance qualification",
      "Provide written procedures for qualification of equipment and facilities",
      "Provide a detailed program for designing, validating, maintaining, controlling and monitoring manufacturing processes",
      "Provide a comprehensive assessment and remediation plan for your quality control unit",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "grupo-quimico-srl-674010-04302024",
    "violated_terms": [
      "Laboratory records did not include all testing data to support drug product analysis (21 CFR 211.194(a))",
      "Failure to establish laboratory controls with appropriate specifications and standards (21 CFR 211.160(b))",
      "Inadequate controls over computer systems to prevent unauthorized data changes (21 CFR 211.68(b))",
      "Failure to ensure the integrity and reliability of analytical data"
    ],
    "recommendations": [
      "Retain an independent third-party qualified consultant for remediation",
      "Conduct a comprehensive investigation into data inaccuracies",
      "Perform a current risk assessment of the effects of observed failures on drug quality",
      "Develop a management strategy including a global corrective action and preventive action (CAPA) plan",
      "Implement a comprehensive assessment and remediation plan for laboratory practices and documentation systems"
    ]
  },
  {
    "letter_name": "acella-pharmaceuticals-llc-604438-08142020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "failure to conform to compendial standards for strength, quality, or purity",
      "failed to establish laboratory controls",
      "failed to establish an adequate quality control unit",
      "no long-term stability data to support the batches",
      "drugs must be manufactured in conformance with CGMP",
      "distributing NP Thyroid, a biological product, without FDA approval or a valid biologics license"
    ],
    "recommendations": [
      "Review all other products to determine whether their specifications are appropriate and justifiable",
      "Conduct a risk assessment for any products lacking appropriate specifications",
      "Indicate corrective actions for products outside of compendial standards",
      "Provide an action plan with timelines for testing retain samples of all NP Thyroid batches",
      "Conduct a comprehensive assessment and remediation plan for the quality control unit",
      "Improve procedures for conducting audits of contract manufacturers",
      "Contact FDA's unapproved drugs coordinator for assistance with the application process"
    ]
  },
  {
    "letter_name": "akan-biosciences-inc-654674-04302024",
    "violated_terms": [
      "Failure to test a specimen from a donor of cells or tissue for evidence of infection due to relevant communicable disease agents",
      "Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery",
      "Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests",
      "Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors",
      "Failure to clearly identify an HCT/P that is in quarantine pending completion of a donor-eligibility determination",
      "Failure to ship in quarantine a pre-distribution shipment of HCT/Ps",
      "Failure to establish written procedures for production and process control",
      "Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area"
    ],
    "recommendations": [
      "Take prompt action to correct any violations and prevent their recurrence",
      "Respond in writing within fifteen (15) working days outlining specific steps taken or planned to address violations",
      "Include any documentation necessary to show that the matters have been addressed"
    ]
  },
  {
    "letter_name": "global-treat-srl-596638-03312020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to perform appropriate laboratory determination of satisfactory conformance",
      "failure to test samples of each component for identity and conformity",
      "failure to establish an adequate quality control unit"
    ],
    "recommendations": [
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Provide a list of chemical and microbial specifications for testing drug products",
      "Conduct full chemical and microbiological testing of retain samples",
      "Provide a comprehensive independent assessment of laboratory practices",
      "Establish procedures for testing each component lot for conformity",
      "Conduct a complete assessment of documentation systems used throughout operations",
      "Ensure oversight and approval of investigations and discharging of all other quality control unit duties"
    ]
  },
  {
    "letter_name": "cbd-american-shaman-llc-628753-11162022",
    "violated_terms": [
      "adulterated under section 402(a)(2)(C)(i) of the FD&C Act",
      "prohibited act under section 301(ll) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "unapproved new animal drugs under section 201(g)(1) of the FD&C Act",
      "unsafe under section 512(a) of the FD&C Act",
      "adulterated under section 501(a)(5) of the FD&C Act",
      "prohibited act under section 301(d) of the FD&C Act",
      "prohibited act under section 301(a) of the FD&C Act",
      "not generally recognized as safe and effective under section 201(p) of the FD&C Act",
      "food additive under section 201(s) of the FD&C Act",
      "not approved for use in any conventional food",
      "not GRAS for use in conventional foods",
      "not GRAS for use in animal food",
      "does not conform to the conditions of use specified in M020"
    ],
    "recommendations": [
      "Investigate and determine the causes of any violations",
      "Prevent recurrence of violations",
      "Notify FDA in writing within fifteen working days of receipt of this letter regarding specific steps taken to correct violations",
      "Include an explanation of each step being taken to prevent recurrence of violations",
      "Provide copies of related documentation"
    ]
  },
  {
    "letter_name": "kor-chem-inc-661280-09112023",
    "violated_terms": [
      "Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Failure to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).",
      "Failure to conduct appropriate laboratory testing for objectionable microorganisms (21 CFR 211.165(b)).",
      "Inadequate quality control unit oversight (21 CFR 211.22)."
    ],
    "recommendations": [
      "Confirmation to discontinue manufacturing drugs on shared equipment with non-drug products.",
      "Plan to maintain dedicated manufacturing equipment and separate areas for pharmaceutical and industrial products.",
      "Risk assessment for all drugs previously produced on shared equipment.",
      "Corrective action and preventive action (CAPA) plan for operations management oversight.",
      "Commitment to provide test results for high-risk drug components.",
      "Comprehensive review of material systems and supplier qualifications."
    ]
  },
  {
    "letter_name": "global-pharma-healthcare-private-limited-657325-10202023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "Adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act",
      "Misbranded under section 502(j) of the FD&C Act",
      "Misbranded under section 502(a) of the FD&C Act",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "Lack of adequate scientific evidence for aseptic filling machine suitability",
      "Failure to validate methods intended to render ophthalmic drug products sterile",
      "Inadequate airflow pattern studies for aseptic processing lines",
      "Lack of evidence of reliable container closure integrity",
      "Failure to perform antimicrobial effectiveness studies",
      "Failure to establish a system for monitoring environmental conditions",
      "Failure to adequately sterilize and clean equipment",
      "Failure to establish the accuracy, sensitivity, specificity, and reproducibility of test methods",
      "Failure to establish an adequate quality unit (QU)"
    ],
    "recommendations": [
      "Perform a comprehensive risk assessment of all contamination hazards",
      "Develop a detailed remediation plan with timelines",
      "Implement a CAPA plan for ongoing management oversight",
      "Ensure inspection and quality control methods for container-closure systems",
      "Conduct a comprehensive, independent review of material systems and supplier qualifications",
      "Establish a system for monitoring environmental conditions in aseptic processing areas",
      "Conduct a comprehensive, independent assessment of laboratory practices and methods",
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Engage a qualified consultant to assist in meeting drug CGMP requirements"
    ]
  },
  {
    "letter_name": "dsp-skin-care-llc-622549-07192022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products under section 501(a)(2)(B)",
      "Unapproved new drug under section 505(a)",
      "Misbranded under sections 502(a), (c), and (ee)",
      "Not duly registered with FDA under section 510",
      "Not duly listed with FDA under section 510(j)",
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications (21 CFR 211.165(a))",
      "Failure to establish and follow an adequate written testing program (21 CFR 211.166(a))",
      "Quality control unit failed to ensure compliance with CGMP (21 CFR 211.22)",
      "Misbranding under section 502(a)",
      "Misbranding under section 502(c)",
      "Misbranding under section 502(ee)",
      "Failure to properly list a drug product under section 301(p)",
      "Failure to register establishment under section 510(b)",
      "Failure to certify drug listing under 21 CFR 207.57"
    ],
    "recommendations": [
      "Provide a list of chemical and microbiological specifications used to analyze each lot of drug products before lot disposition.",
      "Submit an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of the stability program.",
      "Establish written procedures detailing the roles, responsibilities, and duties of the quality unit.",
      "Provide a comprehensive assessment and remediation plan to ensure the quality unit is given the authority and resources to function effectively.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "duren-health-mart-pharmacy-595524-11012019",
    "violated_terms": [
      "section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA)",
      "current good manufacturing practice (CGMP) under section 501(a)(2)(B)",
      "labeling with adequate directions for use under section 502(f)(1)",
      "FDA approval prior to marketing under section 505",
      "adulterated under section 501(a)(2)(A)",
      "misbranded under section 502(f)(1)",
      "prohibited act under section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Take prompt action to correct the violations cited in this letter.",
      "Notify the FDA in writing within fifteen (15) working days of receipt of this letter about specific steps taken to correct the violations.",
      "Include an explanation of each step being taken to prevent the recurrence of violations if intending to resume production of drugs.",
      "Notify the FDA 15 days prior to resuming production of any drugs in the future."
    ]
  },
  {
    "letter_name": "genuine-virgin-aloe-corp-dba-triderma-679744-07012024",
    "violated_terms": [
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Failure to establish written procedures for production and process control (21 CFR 211.100(a))",
      "Failure to establish an adequate written testing program for stability characteristics (21 CFR 211.166(a))",
      "Failure to establish an adequate quality unit and written procedures applicable to the quality control unit (21 CFR 211.22(a) and (d))"
    ],
    "recommendations": [
      "Provide DEG and EG test results for high-risk drug components within 30 days",
      "Conduct a full risk assessment for drug products containing ingredients at risk for DEG or EG contamination",
      "Establish a comprehensive stability program with stability indicating methods and ongoing studies",
      "Create a remediation plan to ensure the quality unit has adequate authority and resources"
    ]
  },
  {
    "letter_name": "cadila-healthcare-limited-584856-10292019",
    "violated_terms": [
      "Failure to clean, maintain, and sanitize equipment and utensils at appropriate intervals (21 CFR 211.67(a))",
      "Inadequate investigation of unexplained discrepancies or failures (21 CFR 211.192)",
      "Failure to follow written procedures to prevent microbiological contamination (21 CFR 211.113(b))",
      "Inadequate monitoring of environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv))"
    ],
    "recommendations": [
      "Implement a CAPA plan for routine oversight of facilities and equipment.",
      "Conduct a comprehensive independent retrospective assessment of cleaning effectiveness.",
      "Establish a risk assessment of contamination hazards in aseptic processes.",
      "Provide a detailed update on CAPAs and their current status."
    ]
  },
  {
    "letter_name": "eucyt-laboratories-llc-607182-06042020",
    "violated_terms": [
      "manufacture of products derived from human umbilical cord blood and umbilical cord",
      "products are drugs as defined in section 201(g) of the FD&C Act",
      "biological products as defined in section 351(i) of the PHS Act",
      "HCT/Ps that do not meet all the criteria in 21 CFR 1271.10(a)",
      "HCT/Ps are not regulated solely under section 361 of the PHS Act",
      "failure to determine and document the eligibility of a cell or tissue donor",
      "failure to screen a donor of human cells or tissue",
      "failure to establish and maintain procedures for donor eligibility",
      "failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failure to have an adequate system for monitoring environmental conditions",
      "failure to establish written procedures for production and process controls",
      "failure to establish and follow written procedures for cleaning and maintenance of equipment",
      "failure to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failure to establish and follow a written testing program for stability characteristics",
      "failure to establish and follow written procedures for handling complaints",
      "failure to test non-penicillin drug products for the presence of penicillin",
      "failure to prepare batch production and control records"
    ],
    "recommendations": [
      "take prompt action to correct these violations",
      "respond in writing within fifteen (15) working days outlining specific steps taken or planned to correct violations",
      "include documentation necessary to show that correction has been achieved",
      "if unable to complete all corrections within fifteen (15) working days, explain the reason for the delay and timeframe for completion"
    ]
  },
  {
    "letter_name": "clinical-resolution-laboratory-inc-615236-03012022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "failure to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product (21 CFR 211.165(a))",
      "failure of the quality control unit to ensure compliance with CGMP (21 CFR 211.22)"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.",
      "Include your process performance protocols, and written procedures for qualification of equipment and facilities.",
      "Appropriate improvements to your cleaning validation program.",
      "A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures.",
      "A CAPA plan based on the retrospective assessment of your cleaning program.",
      "A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.",
      "An updated list of chemical and microbiological specifications used to analyze each batch of your drug products.",
      "A comprehensive independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a consultant to assist your firm in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "accupack-midwest-inc-680228-08152024",
    "violated_terms": [
      "Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the water system.",
      "Submit a purified water system validation report, including a summary of improvements made to system design and ongoing control and maintenance.",
      "Establish a procedure for water system monitoring that specifies routine microbial testing.",
      "Define current action/alert limits for total counts and objectionable organisms for the Purified Water system.",
      "Create a procedure for ongoing control, maintenance, and monitoring to ensure compliance with Purified Water, USP monograph specifications.",
      "Conduct a detailed risk assessment addressing the effects of water system failures on drug product quality.",
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures."
    ]
  },
  {
    "letter_name": "glint-cosmetics-pvt-ltd-573468-05312019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to exercise responsibility of quality control unit",
      "failure to clean and maintain equipment",
      "failure to exercise appropriate controls over computer systems",
      "failure to ensure accuracy and integrity of data",
      "failure to provide a complete statement of identity on labels",
      "failure to disclose a domestic address or telephone number on labels"
    ],
    "recommendations": [
      "Provide a comprehensive assessment with corrective actions and preventive actions (CAPA) for quality control unit oversight.",
      "Submit a comprehensive plan to evaluate cleaning procedures and practices.",
      "Provide a summary of updated standard operating procedures for cleaning verification and validation.",
      "Conduct a comprehensive investigation into data record inaccuracies.",
      "Perform a current risk assessment of the effects of observed failures on drug quality.",
      "Develop a management strategy that includes a global corrective action and preventive action plan.",
      "Review cosmetic manufacturing processes for compliance with applicable laws and regulations."
    ]
  },
  {
    "letter_name": "aromas-para-el-alma-sa-672728-09102024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug introduced or delivered for introduction into interstate commerce",
      "misbranded under section 502(ee) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "failed to establish adequate written production and control procedures",
      "failed to prepare batch production and control records",
      "failed to test samples of each component for identity and conformity",
      "failed to ensure drug products manufactured are in compliance with CGMP"
    ],
    "recommendations": [
      "Provide a list of all batches of any drug product distributed in the United States",
      "Conduct full chemical and microbiological testing of retain samples",
      "Update the formulation for drug products including process validation",
      "Provide master production and control records for drug products",
      "Implement procedures to ensure production records are completed and reviewed",
      "Conduct a comprehensive, independent review of the material system",
      "Test each component lot for conformity with specifications",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Include the name 'alcohol gel' and 'alcohol spray' on product labels"
    ]
  },
  {
    "letter_name": "guangzhou-tinci-materials-technology-co-ltd-592199-01232020",
    "violated_terms": [
      "Failure to use equipment that is of appropriate design, adequate size, and suitably located (21 CFR 211.63)",
      "Inadequate monitoring of (b)(4) system for total aerobic microbial count (TAMC) and total yeast and molds count (TYMC)",
      "Failure to conduct appropriate laboratory testing for each batch of drug product (21 CFR 211.165(b))",
      "Inadequate quality control unit procedures (21 CFR 211.22(a) and (d))"
    ],
    "recommendations": [
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system",
      "Submit a (b)(4) system validation report and summarize improvements made",
      "List chemical and microbial specifications used to analyze each lot of drug products",
      "Conduct a comprehensive, independent assessment of laboratory practices and provide a remediation plan",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "asiaticon-sa-de-cv-609162-10292020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "new drug introduced in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market",
      "Engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of your entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "cosmetic-solutions-llc-670486-05312024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to establish adequate written responsibilities and procedures",
      "failure to follow stability testing procedure",
      "failure to establish reliability of component suppliers’ test analyses",
      "failure to follow written change control procedure",
      "failure to establish adequate written procedures for production and process control",
      "lack of Water System Qualification and Validation",
      "lack of Cleaning Validation"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Provide a comprehensive independent assessment and CAPA plan for the stability program",
      "Conduct a comprehensive independent review of the material system",
      "Conduct a comprehensive assessment of the change management system",
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the water system",
      "Provide a detailed risk assessment addressing the potential effects of the observed water system failures",
      "Provide a procedure for water system monitoring",
      "Provide a validation study of the microbiological testing system",
      "Implement appropriate improvements to the cleaning validation program",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "dr-retter-ec-wladyslaw-retter-619881-03142022",
    "violated_terms": [
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a) and (b)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to prepare batch production and control records (21 CFR 211.188(b)).",
      "Your firm failed to establish laboratory controls (21 CFR 211.160(b)).",
      "Your firm lacks a process validation program.",
      "Your firm does not have an adequate ongoing program for monitoring process control."
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide the chemical and microbiological quality control specifications for testing each incoming lot of components.",
      "Provide your master production and control records for your drug products.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your finished product testing.",
      "Provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "aire-master-america-inc-622546-05232022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drugs under section 505(a) of the FD&C Act",
      "Misbranded under sections 502(ee) of the FD&C Act",
      "Failure to establish laboratory controls (21 CFR 211.160(b))",
      "Failure to thoroughly investigate discrepancies (21 CFR 211.192)",
      "Failure to conduct appropriate laboratory testing (21 CFR 211.165(b))",
      "Failure to clean and maintain equipment (21 CFR 211.67(a))",
      "Failure to conduct identity testing for components (21 CFR 211.84(d)(1))"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your water system design, control, and maintenance.",
      "Develop a thorough remediation plan for your water system.",
      "Conduct a detailed risk assessment addressing the potential effects of water system failures.",
      "Establish a procedure for ongoing control, maintenance, and monitoring of the water system.",
      "Conduct a comprehensive, independent assessment of your overall system for investigating deviations.",
      "Provide an independent assessment and remediation plan for your CAPA program.",
      "Conduct appropriate laboratory testing for each batch of drug product.",
      "Provide a comprehensive, independent assessment of your laboratory practices.",
      "Conduct a retrospective assessment of your cleaning effectiveness.",
      "Develop a CAPA plan based on the assessment of your cleaning and disinfection program.",
      "Ensure appropriate identity testing for incoming components.",
      "Conduct a full risk assessment for drug products containing glycerin."
    ]
  },
  {
    "letter_name": "izeen-pharma-inc-565311-05162019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "introduction or delivery for introduction into interstate commerce of levothyroxine and liothyronine in violation of sections 505(a) and 301(d) of the FD&C Act",
      "misbranded under section 502(f)(1) of the FD&C Act",
      "failed to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "failed to establish adequate written procedures for production and process control",
      "failed to establish laboratory controls",
      "failed to establish an adequate written testing program for stability characteristics",
      "failed to exercise appropriate controls over computer or related systems",
      "data integrity lapses",
      "unapproved new drug violations",
      "misbranded drugs violations"
    ],
    "recommendations": [
      "Provide a retrospective, independent review of all invalidated OOS results",
      "Provide a fully remediated OOS investigation procedure",
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations",
      "Evaluate drug manufacturing operations to determine improvements needed",
      "Provide a detailed CAPA plan to remediate the laboratory system",
      "Provide a comprehensive assessment and CAPA plan to ensure the adequacy of the stability program",
      "Engage a qualified consultant to assist in remediation",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records",
      "Provide a current risk assessment of the potential effects of observed failures",
      "Provide a management strategy that includes a global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "dunagin-pharmaceuticals-inc-dba-massco-dental-644335-02222023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.42(c)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.100(a)",
      "21 CFR 211.22(a)",
      "21 CFR 211.160(b)"
    ],
    "recommendations": [
      "Discontinue manufacturing drugs on shared equipment.",
      "Provide a plan to separate areas for pharmaceutical and nonpharmaceutical manufacturing.",
      "Conduct a risk assessment for drugs produced on shared equipment.",
      "Perform comprehensive, independent review of material system and supplier reliability.",
      "Establish written procedures for production and process control.",
      "Provide a detailed summary of the validation program for manufacturing processes.",
      "Implement a comprehensive independent assessment and remediation plan for the quality control unit.",
      "Conduct a retrospective review of all invalidated OOS results.",
      "Establish adequate laboratory controls and specifications.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Conduct a comprehensive investigation into data integrity issues."
    ]
  },
  {
    "letter_name": "cohere-beauty-675475-04152024",
    "violated_terms": [
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a list of (b)(4) drug product batches remaining in the U.S. market and within expiry including, but not limited to, batch/lot numbers, distribution dates, and expiration dates.",
      "Provide a comprehensive plan on the oversight of (b)(4) drug product remaining in the U.S. market including, but not limited to, responsibilities for reserved samples collection and storage, stability program, and complaint receipt and handling.",
      "Provide your action plan to address any product quality risks associated with batches within expiry on the U.S. market, including potential customer notifications and recalls."
    ]
  },
  {
    "letter_name": "carsgen-therapeutics-corporation-686504-07262024",
    "violated_terms": [
      "Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition.",
      "Your firm failed to establish an adequate system for preventing contamination and monitoring environmental conditions in aseptic processing areas.",
      "Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions.",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."
    ],
    "recommendations": [
      "Implement a cleaning and sanitation program that ensures all areas are free from contamination and pests.",
      "Establish and follow written procedures for monitoring environmental conditions in aseptic processing areas.",
      "Conduct validation studies for cleaning processes to ensure they effectively remove contaminants.",
      "Develop and implement procedures for visual inspection of final drug products to ensure quality and purity.",
      "Ensure thorough investigations of discrepancies and implement corrective actions in a timely manner."
    ]
  },
  {
    "letter_name": "akorn-inc-568173-06132019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records (21 CFR 211.68(b)).",
      "Your firm failed to follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile (21 CFR 211.113(b)).",
      "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188)."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your system for investigating deviations, atypical events, complaints, OOS results, and failures, including a CAPA plan.",
      "Conduct a comprehensive, independent review of your laboratory practices, procedures, methods, equipment, and analyst competencies, and provide a detailed CAPA plan.",
      "Implement a detailed CAPA plan to address contamination hazards identified in your aseptic processes, equipment, and facilities.",
      "Review and remediate your overall system for investigating OOS results, ensuring enhanced quality unit oversight and identification of adverse laboratory control trends."
    ]
  },
  {
    "letter_name": "aaa-cosmetica-sa-de-cv-609083-02032021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide an updated investigation into how the drug product was substituted with methanol",
      "List all raw materials used to manufacture hand sanitizer drug products",
      "List all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of complete batch records for all batches distributed to the U.S.",
      "Commit to test every lot of ethanol received for methanol content using the USP method",
      "Provide a comprehensive, independent assessment of laboratory practices and a detailed plan to remediate and evaluate the effectiveness of the laboratory system",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "invitrx-therapeutics-inc-581182-03162020",
    "violated_terms": [
      "Failure to determine and document the eligibility of a cell or tissue donor",
      "Failure to determine a donor to be ineligible whose specimen tests reactive on a screening test for a communicable disease agent",
      "Failure to screen a donor of human cells or tissue by reviewing the donor’s relevant medical records for risk factors",
      "Failure to establish and maintain procedures for all steps performed in testing, screening, and determining donor eligibility",
      "Failure to retain the accompanying records with the HCT/Ps at all times following a donor eligibility determination",
      "Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products",
      "Failure to reject drug products that do not meet established standards or specifications",
      "Failure to establish and follow written procedures for cleaning and maintenance of equipment",
      "Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet specifications",
      "Failure to establish written procedures for production and process control",
      "Failure to have separate or defined areas or control systems for operations to prevent contamination",
      "Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area",
      "Failure to test products for the presence of penicillin",
      "Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product",
      "Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products",
      "Failure to establish and follow written procedures describing in sufficient detail the control procedures for the issuance of labeling",
      "Failure to withhold from use each lot of components, drug product containers, and closures until tested or examined"
    ],
    "recommendations": [
      "Review FDA Guidance for Industry, Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus",
      "Provide a timeline for completion of all necessary corrective actions",
      "Include documentation to demonstrate that you have corrected your violations"
    ]
  },
  {
    "letter_name": "dmm-vission-sa-de-cv-609797-06032021",
    "violated_terms": [
      "adulterated within the meaning of section 501(d)(2) of the FD&C Act",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (f)(2), (x) and (ee) of the FD&C Act",
      "misbranded under section 502(i) of the FD&C Act",
      "introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "episciences-inc-631902-08252022",
    "violated_terms": [
      "Failure to thoroughly investigate unexplained discrepancies or failures of batches to meet specifications (21 CFR 211.192)",
      "Inadequate investigations into out-of-specification (OOS) laboratory results",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a) & 211.100(b))",
      "Inadequate validation of drug manufacturing processes",
      "Failure to perform appropriate laboratory determination of satisfactory conformance to final specifications (21 CFR 211.165(a) & 211.165(b))",
      "Failure to conduct identity testing on each component of a drug product (21 CFR 211.84(d)(1) & 211.84(d)(2))"
    ],
    "recommendations": [
      "Conduct a retrospective, independent review of all invalidated OOS results for the last three years",
      "Develop a comprehensive review and remediation plan for OOS result investigation systems",
      "Perform adequate release testing for each batch of drug products prior to distribution",
      "Establish a detailed plan to ensure supplier reliability and conduct identity testing for each component lot",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "blaine-labs-inc-598733-05052020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to thoroughly investigate discrepancies",
      "inadequate investigation of out-of-specification (OOS) test results",
      "failure to establish adequate written procedures for production and process control",
      "failure to validate drug product manufacturing processes",
      "failure to conduct microbiological testing",
      "failure to establish an adequate quality unit"
    ],
    "recommendations": [
      "Implement an OOS system for bulk products",
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations",
      "Provide a detailed summary of the validation program for ensuring a state of control",
      "Establish a comprehensive remediation plan for the design, control, and maintenance of the water system",
      "Provide a comprehensive assessment and remediation plan to ensure the quality unit is effective",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "kari-gran-inc-640035-11302022",
    "violated_terms": [
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products.",
      "Failure to establish and follow a written testing program for stability characteristics of drug products.",
      "Failure to conduct adequate release testing for each batch of drug product prior to distribution.",
      "Failure to perform microbiological testing on each batch of finished drug product.",
      "Failure to conduct identity testing for each component of a drug product.",
      "Failure to validate and establish the reliability of component supplier’s test analyses.",
      "Failure to establish adequate written procedures for production and process control.",
      "Failure to prepare complete batch production and control records.",
      "Inadequate oversight by the quality control unit."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each batch of drug products.",
      "Submit an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Provide a comprehensive independent assessment of laboratory practices and a detailed remediation plan.",
      "Establish a detailed validation program for manufacturing processes and documentation practices.",
      "Ensure the quality control unit has adequate authority and resources to function effectively."
    ]
  },
  {
    "letter_name": "adamson-analytical-laboratories-inc-614644-08172021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP)",
      "21 CFR 211.68(b)",
      "21 CFR 211.160(a)",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Retain a qualified consultant to assist in your remediation.",
      "Perform a comprehensive investigation into the extent of any inaccuracies in data records and reporting.",
      "Conduct a current risk assessment of the potential effects of the observed failures on the quality of your drugs.",
      "Develop a management strategy that includes a global corrective action and preventive action plan.",
      "Update your change control form and written procedure governing change control over laboratory operations.",
      "Provide a comprehensive, independent assessment of your change management system."
    ]
  },
  {
    "letter_name": "jose-miguel-gutierrez-salas-609983-07212022",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e)(1)(A), and (ee) of the FD&C Act",
      "failure to register establishment under section 510(i) of the FD&C Act",
      "failure to list drugs with FDA under section 510(j) of the FD&C Act",
      "misbranded under section 502(o) of the FD&C Act",
      "failure to comply with CGMP requirements under section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer products shipped to the U.S.",
      "Submit copies of complete batch records for all batches distributed to the U.S.",
      "Provide full formulation for hand sanitizer products including target ethanol content",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "ddi-multinacional-sa-de-cv-608864-06272022",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "not in conformance with the 1994 TFM",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(e)(1)(A) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "provide a detailed investigation into the substitution of ethanol with methanol",
      "provide a list of all raw materials used to manufacture hand sanitizer products",
      "provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "provide copies of complete batch records for all batches distributed to the U.S.",
      "provide a detailed plan to remediate and evaluate the effectiveness of the laboratory system"
    ]
  },
  {
    "letter_name": "frenda-corporation-642267-02152023",
    "violated_terms": [
      "Insanitary conditions under section 501(a)(2)(A) of the FD&C Act",
      "Failure to maintain separate areas for drug and industrial chemical production (21 CFR 211.42(c))",
      "Inadequate cleaning and maintenance of equipment (21 CFR 211.67(a))",
      "Lack of written procedures for production and process control (21 CFR 211.100(a) and (b))",
      "Failure to conduct identity testing on components (21 CFR 211.84(d)(1) and (2))",
      "Inadequate quality control unit oversight (21 CFR 211.22)"
    ],
    "recommendations": [
      "Implement strict separation of drug manufacturing from industrial chemical production to prevent cross-contamination.",
      "Establish and maintain cleaning procedures and equipment logs for all manufacturing equipment.",
      "Develop and validate written procedures for production and process control, ensuring water system compliance.",
      "Conduct identity testing for all components used in drug production and establish reliability of supplier's test analyses.",
      "Strengthen the quality control unit's authority and responsibilities to ensure compliance with CGMP."
    ]
  },
  {
    "letter_name": "gaza-proveedora-de-servicios-de-hospedaje-y-alimentacion-611881-03012021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "ardil-comercial-srl-612018-09222021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (c), (i)(1), (x) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act",
      "misleading labeling under section 502(a) of the FD&C Act",
      "misbranding under section 502(c) of the FD&C Act",
      "misbranding under section 502(i)(1) of the FD&C Act",
      "misbranding under section 502(x) of the FD&C Act",
      "misbranding under section 502(ee) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "provide an updated investigation into how the drug product was substituted in part with ethanol",
      "provide a list of all raw materials used to manufacture all hand sanitizer drug products",
      "provide a list of all batches of any hand sanitizer drug products shipped to the U.S.",
      "provide copies of the complete batch records for all batches distributed to the United States",
      "provide a commitment to test every lot of IPA and ethanol for methanol content using the USP method"
    ]
  },
  {
    "letter_name": "greco-gas-inc-683090-08122024",
    "violated_terms": [
      "Failure to conduct identity testing for each component lot used in medical gas manufacturing.",
      "Inadequate testing of finished batches for impurities and identity and strength of active ingredients.",
      "Failure to routinely calibrate and maintain equipment used in manufacturing.",
      "Inadequate investigation of manufacturing and testing discrepancies.",
      "Failure to establish an adequate quality control unit with authority to approve or reject components and drug products."
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of material systems and supplier qualifications.",
      "Implement a detailed corrective action and preventive action (CAPA) plan for equipment calibration.",
      "Establish robust procedures for investigating discrepancies and ensuring accurate documentation.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Develop a management strategy to ensure data integrity and compliance with CGMP."
    ]
  },
  {
    "letter_name": "allay-pharmaceuticals-llc-609023-01272021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "adulterated under section 501(b) of the FD&C Act",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure to thoroughly investigate any unexplained discrepancy or failure of a batch (21 CFR 211.192)",
      "failure to establish and follow an adequate written testing program for stability (21 CFR 211.166(a))",
      "failure of the quality control unit to ensure compliance with CGMP (21 CFR 211.22)",
      "distributing unapproved new drugs"
    ],
    "recommendations": [
      "Provide a data-driven and scientifically sound analysis identifying all sources of variability and a CAPA plan to reduce process variation.",
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Provide a timeline for performing appropriate process performance qualification (PPQ) for each of your tablet drug products.",
      "Conduct a review of all other products to determine whether their specifications are appropriate and justifiable.",
      "Provide updated procedures to ensure that product specifications undergo a routine review.",
      "Conduct a comprehensive, independent assessment of your overall system for investigating deviations and discrepancies.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program.",
      "Conduct a comprehensive independent review of your material system to determine whether all suppliers are qualified.",
      "Provide a detailed description of how your firm will implement an effective system to ensure retention and review of laboratory data.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "elemental-herbs-inc-dba-all-good-654879-10202023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to establish an adequate quality unit (21 CFR 211.22(a) and 211.22(d))",
      "failure to follow an adequate written testing program (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Describe how top management supports quality assurance and reliable operations",
      "Develop a comprehensive review and remediation plan for OOS result investigation systems",
      "Establish an adequate stability program for OTC drug products",
      "Provide updated stability protocols to ensure all unique product types are included in the stability program"
    ]
  },
  {
    "letter_name": "ap-deauville-llc-586306-11082019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your quality unit (QU) failed to identify and investigate deviations from manufacturing instructions of batches released for distribution (21 CFR 211.22(a)&(d)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "You failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals (21 CFR 211.67(a))."
    ],
    "recommendations": [
      "Provide a detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution and within expiry.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes.",
      "Provide appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation."
    ]
  },
  {
    "letter_name": "b-jain-pharmaceuticals-private-limited-567957-03212019",
    "violated_terms": [
      "Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition (21 CFR 211.56(a)).",
      "Your firm failed to clean, maintain, and sanitize equipment and utensils at appropriate intervals (21 CFR 211.67(a)).",
      "Your firm failed to establish an adequate quality control unit (21 CFR 211.22(a)).",
      "Your firm’s products are misbranded drugs under section 503(b) of the FD&C Act (21 U.S.C. 353(b))."
    ],
    "recommendations": [
      "Provide a retrospective review for the (b)(4) material batch, including the disposition of the batch or batches of finished product that this component was used in.",
      "Review pest control and manufacturing procedures to ensure drug manufacturing areas are free from insects or other vermin.",
      "Provide a comprehensive CAPA plan for remedying design, control, and maintenance of the (b)(4) system.",
      "Conduct a comprehensive assessment with CAPA to ensure your quality unit is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "fresh-farms-llc-623723-04192022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.22(a)",
      "21 CFR 211.22(d)",
      "21 CFR 211.84(a)",
      "21 CFR 211.165(a)",
      "21 CFR 211.188",
      "section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.",
      "Investigate and determine the causes of any violations and prevent their recurrence.",
      "Correct any violations promptly."
    ]
  },
  {
    "letter_name": "4e-global-sapi-de-cv-608940-10232020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (f)(2), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drugs prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider removing hand sanitizer drug products currently in distribution to the U.S. market",
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Provide a detailed investigation into how hand sanitizer drug products were substituted with methanol",
      "List all raw materials used to manufacture hand sanitizer drug products, including suppliers' information",
      "List all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of complete batch records for all batches distributed to the U.S.",
      "Describe the scope of operations the consultant will be reviewing",
      "Provide revised test methods for testing raw materials and hand sanitizer drug products",
      "Discuss corrective action for not testing all drug products prior to release"
    ]
  },
  {
    "letter_name": "akorn-inc-558914-02042019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to follow appropriate written procedures",
      "poor aseptic practices",
      "failure to perform operations within specifically defined areas",
      "deficient environmental monitoring program",
      "deficient cleaning program",
      "failure to follow a written testing program for stability characteristics",
      "inadequate quality systems",
      "failure to ensure data integrity"
    ],
    "recommendations": [
      "Comprehensive independent identification of all contamination hazards",
      "Detailed corrective action and preventative action (CAPA) plan",
      "Plan to ensure appropriate aseptic practices and cleanroom behavior",
      "Thorough risk assessment of poor aseptic technique",
      "Description of missing batch record entries for interventions",
      "Review of supplier qualification and monitoring program",
      "Copy of new smoke study recordings and assessment",
      "Comprehensive independent retrospective review of personnel and environmental monitoring program",
      "Investigations and CAPAs initiated in response to cleaning and disinfection observations",
      "Comprehensive assessment and CAPA to ensure adequacy of stability program",
      "Management strategy for overseeing improvements in manufacturing operations",
      "Comprehensive investigation into data integrity inaccuracies",
      "Current risk assessment of observed failures on drug quality",
      "Global CAPA plan management strategy"
    ]
  },
  {
    "letter_name": "kvk-tech-inc-592387-02112020",
    "violated_terms": [
      "Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b))."
    ],
    "recommendations": [
      "Provide appropriate methods and procedures that are sufficiently detailed to prevent integration practices that are not scientifically sound.",
      "Conduct a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate."
    ]
  },
  {
    "letter_name": "jamol-laboratories-inc-654464-07132023",
    "violated_terms": [
      "Adulterated drug products under section 501(a)(2)(A) of the FD&C Act due to insanitary conditions.",
      "Failure to comply with Current Good Manufacturing Practice (CGMP) regulations.",
      "Lack of an adequate quality control unit as per 21 CFR 211.22.",
      "Failure to establish laboratory controls as required by 21 CFR 211.160(b) and 211.165(b).",
      "Inadequate written procedures for production and process control as per 21 CFR 211.100(a)."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment with CAPA to ensure the quality control unit is effective.",
      "Perform retroactive identification tests for potentially compromised batches and commit to recalls if necessary.",
      "Establish a detailed action plan for conducting full chemical and microbiological testing of retain samples.",
      "Develop a data-driven program to control variability in manufacturing processes.",
      "Provide timelines for process performance qualification for each marketed drug product."
    ]
  },
  {
    "letter_name": "iso-tex-diagnostics-inc-655666-07202023",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "jhs-svendgaard-hygiene-products-ltd-593473-02132020",
    "violated_terms": [
      "Your firm failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(2)).",
      "Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100 (a) and (b)).",
      "Your firm's quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP (21 CFR 211.22)."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine supplier qualifications and material controls.",
      "Provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.",
      "Submit a remediation plan that assures ongoing management oversight throughout the manufacturing lifecycle.",
      "Provide a comprehensive assessment and remediation plan for your quality control unit's oversight and investigation processes."
    ]
  },
  {
    "letter_name": "dr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023",
    "violated_terms": [
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "violates sections 301(d) and 505(a) of the FD&C Act",
      "misbranded drugs under section 502(o) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&C Act",
      "not generally recognized as safe and effective (GRASE)",
      "new drugs under section 201(p) of the FD&C Act",
      "not properly listed with FDA",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations",
      "include an explanation of each step being taken to prevent the recurrence of violations",
      "include copies of related documentation",
      "if you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration",
      "if you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction"
    ]
  },
  {
    "letter_name": "incredible-products-sa-de-cv-609503-05272021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "baxter-healthcare-corporation-654136-07252023",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a) and (b)).",
      "Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design (21 CFR 211.63)."
    ],
    "recommendations": [
      "Provide a written commitment to analyze all lots of finished products for endotoxins by a qualified laboratory until thorough investigations into each endotoxin test invalidation event are completed.",
      "Conduct a comprehensive independent assessment and remediation plan for visual inspection systems of sterile injectable drugs.",
      "Establish a CAPA plan based on a retrospective assessment of the cleaning program to address cross-contamination hazards.",
      "Perform a comprehensive independent assessment of the design and condition of sterile drug production lines and equipment."
    ]
  },
  {
    "letter_name": "coupler-enterprises-607662-09152020",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.130(e)",
      "21 CFR 211.67(b)",
      "21 CFR 211.22",
      "Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act"
    ],
    "recommendations": [
      "Provide SOP for line clearance and a comprehensive written evaluation of packaging and labeling operation.",
      "Improve cleaning validation program with emphasis on worst-case conditions.",
      "Summarize updated SOPs for verification and validation of cleaning procedures.",
      "Conduct a risk analysis on the quality impact of inadequate equipment qualification.",
      "Develop a comprehensive assessment and remediation plan for the quality control unit."
    ]
  },
  {
    "letter_name": "clean-cosmetics-llc-643205-01302023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "List chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.",
      "Provide a comprehensive assessment and remediation plan to ensure your quality control unit is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "dong-yuan-technology-co-ltd-568292-03182019",
    "violated_terms": [
      "Failure to establish and follow laboratory controls",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to ensure that laboratory records included complete data"
    ],
    "recommendations": [
      "Provide commitment to using current USP compendial methods until any alternative methods have been qualified.",
      "Provide a validation plan for ensuring a state of control throughout the product lifecycle.",
      "Provide a comprehensive review of laboratory practices and a detailed CAPA plan."
    ]
  },
  {
    "letter_name": "invitrx-therapeutics-inc-630712-11092022",
    "violated_terms": [
      "Failure to determine and document the eligibility of a cell or tissue donor",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "Failure to satisfy general biological products standards for sterility testing",
      "Failure to establish written procedures for production and process control",
      "Failure to establish laboratory controls that include specifications and standards",
      "Failure to withhold from use each lot of components until tested and released",
      "Failure to establish a written testing program for stability characteristics",
      "Failure to follow written procedures for handling complaints regarding drug products",
      "Failure to prepare batch production and control records",
      "Equipment used in manufacturing is not of appropriate design",
      "Failure to have an approved biologics license application (BLA)",
      "Failure to have an investigational new drug application (IND) in effect"
    ],
    "recommendations": [
      "Respond in writing within fifteen (15) working days outlining specific steps taken to address violations",
      "Include documentation showing that matters have been addressed",
      "Clarify whether manufacturing will continue at other locations",
      "Attend a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "centaur-pharmaceuticals-private-ltd-655231-07252023",
    "violated_terms": [
      "Your firm failed to clean, maintain, and sanitize equipment and utensils at appropriate intervals (21 CFR 211.67(a)).",
      "Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards.",
      "Develop a corrective action and preventive action (CAPA) plan based on the retrospective assessment of your cleaning program.",
      "Implement appropriate improvements to your cleaning validation program, focusing on worst-case conditions.",
      "Conduct a comprehensive assessment and remediation plan to ensure your quality unit is effective.",
      "Provide a detailed action plan to remediate your system for investigating deviations, discrepancies, and failures."
    ]
  },
  {
    "letter_name": "biomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024",
    "violated_terms": [
      "Adulterated Human Drugs: The drug product is adulterated due to gross microbial contamination.",
      "Drug CGMP Violations: Failure to conduct appropriate laboratory testing for objectionable microorganisms.",
      "Adulterated & Misbranded Dietary Supplements: Serious violations of Emergency Permit Control regulations and CGMPs for dietary supplements."
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Establish identity specifications for each component and product specifications for dietary supplements.",
      "Implement adequate procedures for calibrating instruments and controls used in manufacturing or testing."
    ]
  },
  {
    "letter_name": "ct-dream-co-ltd-678300-04112024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58)."
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements, including a comprehensive six-system audit.",
      "Clarify intentions regarding resuming manufacturing drugs for the U.S. market.",
      "Promptly correct all violations and provide a written response to the FDA within 15 working days."
    ]
  },
  {
    "letter_name": "delta-kozmetik-sanayi-ve-ticaret-selim-yesil-614402-07082021",
    "violated_terms": [
      "Adulteration of hand sanitizer due to subpotency (59% ethanol instead of labeled percentage)",
      "Failure to conduct appropriate identity testing for ethanol and methanol",
      "Inadequate assay testing for finished product",
      "Non-compliance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the ethanol content discrepancy",
      "Provide a comprehensive list of raw materials and suppliers",
      "Submit batch records for all distributed hand sanitizers",
      "Perform an independent assessment of laboratory practices and provide a remediation plan",
      "Engage a qualified CGMP consultant for compliance evaluation and corrective action assistance"
    ]
  },
  {
    "letter_name": "fei-fah-medical-manufacturing-pte-ltd-633084-01302023",
    "violated_terms": [
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to establish laboratory controls that include scientifically sound specifications and test procedures (21 CFR 211.160(b)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and 211.84(d)(2))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment and CAPA plan for the stability program, including stability indicating methods and ongoing stability studies.",
      "Submit a detailed plan to remediate laboratory practices, including validation reports for test methods and specifications for impurities.",
      "Conduct a comprehensive review of the material system for supplier qualification and establish a robust testing plan for incoming raw materials."
    ]
  },
  {
    "letter_name": "integradose-compounding-services-llc-592187-05062020",
    "violated_terms": [
      "Adulterated Drug Products: Specific instances of insanitary conditions and CGMP violations.",
      "Misbranded Drug Products: Lack of adequate directions for use.",
      "Failure to Report Adverse Events: Inadequate procedures for reporting adverse events."
    ],
    "recommendations": [
      "Implement comprehensive corrective actions addressing all cited violations, including detailed SOP revisions.",
      "Conduct a thorough review of labeling practices to ensure compliance with section 503B requirements.",
      "Establish robust adverse event reporting procedures that align with FDA guidelines."
    ]
  },
  {
    "letter_name": "dibar-nutricional-s-de-rl-de-cv-610444-03102021",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to perform, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63)."
    ],
    "recommendations": [
      "Provide chemical and microbiological quality control specifications for each incoming lot of components.",
      "List chemical and microbial specifications used to analyze each lot of drug products before disposition.",
      "Submit a comprehensive assessment and corrective actions plan for the stability program.",
      "Implement a CAPA plan for routine oversight of facilities and equipment."
    ]
  },
  {
    "letter_name": "fresenius-kabi-ag-657085-09142023",
    "violated_terms": [
      "failure to follow established, approved written procedures",
      "failure to thoroughly investigate any unexplained discrepancy",
      "failure to test in-process materials for identity, strength, quality, and purity",
      "failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failure to clean, maintain, and sanitize equipment and utensils",
      "failure to maintain buildings in a good state of repair",
      "failure to establish laboratory controls with appropriate specifications"
    ],
    "recommendations": [
      "take prompt action to correct these violations",
      "respond in writing within fifteen (15) working days outlining specific steps taken or planned to address violations",
      "include documentation necessary to show that the matters have been addressed"
    ]
  },
  {
    "letter_name": "ecometics-inc-569167-04162019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "misbranded under section 502(o) of the FD&C Act",
      "failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "failed to conduct appropriate laboratory testing for each batch of drug product (21 CFR 211.165(b))",
      "failed to use equipment of appropriate design and maintenance (21 CFR 211.63)",
      "failed to follow an adequate written testing program for stability characteristics of drug products (21 CFR 211.166(a))",
      "failed to fulfill registration and listing obligations under section 510 of the FD&C Act",
      "distributing unapproved prescription drugs"
    ],
    "recommendations": [
      "discontinue manufacturing drugs on shared equipment with non-pharmaceuticals",
      "provide a plan to separate areas for dedicated manufacturing equipment",
      "conduct a risk assessment for drugs previously manufactured on shared equipment",
      "provide microbiological batch release specifications for each drug product",
      "provide a comprehensive, independent assessment of the water system design and maintenance",
      "provide a CAPA plan to ensure the adequacy of the stability program",
      "engage a qualified consultant to assist in meeting CGMP requirements",
      "correct the violations promptly and respond to the FDA within 15 working days"
    ]
  },
  {
    "letter_name": "dental-kosmetik-gmbh-co-kg-591351-01162020",
    "violated_terms": [
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Inadequate Control of Manufacturing Processes: You have not performed process performance qualification studies, nor do you have an ongoing program for monitoring process control.",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and (2))."
    ],
    "recommendations": [
      "Provide an assessment of drug product processes to ensure a data-driven and scientifically sound program that identifies and controls all sources of variability.",
      "A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "A remediation plan to install and operate a suitable (b)(4) system with ongoing control, maintenance, and monitoring.",
      "A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified."
    ]
  },
  {
    "letter_name": "dextrum-laboratories-inc-666442-12072023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to conduct microbiological testing before use of each lot of a component with potential for objectionable microbiological contamination (21 CFR 211.84(d)(6)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a commitment to perform identity testing for each drug product component.",
      "Conduct retrospective testing of aqueous-based finished drug product retains to ensure microbiological quality.",
      "Engage a qualified third-party to perform an independent review and oversight of all validation activities."
    ]
  },
  {
    "letter_name": "kalchem-international-inc-607098-08272020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drugs",
      "unapproved new drug",
      "misbranding",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to review and approve batch records before release",
      "failure of quality unit to ensure API compliance with CGMP",
      "failure to maintain and review records for relabeled API",
      "failure to adequately review re-packaging batch records",
      "misbranding due to false and misleading labels",
      "failure to comply with conditions of applicable rulemakings",
      "failure to provide adequate procedures for operations",
      "failure to correct repeat deviations"
    ],
    "recommendations": [
      "Perform a full and prompt batch review by the Quality Unit prior to product release",
      "Conduct full chemical and microbiological testing of retain samples",
      "Provide a comprehensive, independent assessment of laboratory practices",
      "Ensure Quality Unit has authority and resources to function effectively",
      "Create new procedures for relabeling API and revise re-packaging procedures",
      "Conduct a risk assessment addressing hazards posed by inadequate documentation",
      "Engage a qualified consultant to evaluate operations for CGMP compliance",
      "Investigate and determine causes of violations and prevent recurrence"
    ]
  },
  {
    "letter_name": "grace-analytical-lab-inc-586510-11192019",
    "violated_terms": [
      "Failure to ensure laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a))",
      "Quality control unit failed to approve or reject all procedures or specifications impacting the identity, strength, quality, and purity of the drug product (21 CFR 211.22(d))",
      "Failure to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records (21 CFR 211.68(b))",
      "Failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e))",
      "Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures (21 CFR 211.160(b))"
    ],
    "recommendations": [
      "Provide investigation into the missing entries of media test data and stability chamber humidity records, including an impact assessment.",
      "Provide updated copies of procedures for issuance, use, and reconciliation of all forms used to support CGMP operations.",
      "Provide action plan with timelines for enabling audit trails for electronic laboratory data systems.",
      "Provide assessment of each analytical method used to test compendial material to ensure compliance with compendial test procedures.",
      "Provide analysis of method suitability for all test methods used for drug products and investigation into employee adherence to change control procedures."
    ]
  },
  {
    "letter_name": "colonial-dames-company-ltd-659151-12052023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products",
      "Unapproved new drugs",
      "Misbranded drugs",
      "Failure to fulfill drug listing obligations",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to clean, maintain, and sanitize equipment",
      "Failure to use appropriately designed equipment",
      "Quality control unit failures",
      "Failure to establish an adequate written testing program for stability",
      "Failure to comply with OTC monograph requirements"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle",
      "Provide a corrective action and preventative action (CAPA) plan for cleaning processes",
      "Provide a comprehensive, independent assessment of your water system design, control, and maintenance",
      "Provide a comprehensive assessment and remediation plan for your quality control unit",
      "Provide a comprehensive, independent assessment and CAPA plan for your stability program",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "indoco-remedies-limited-575313-07162019",
    "violated_terms": [
      "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a))."
    ],
    "recommendations": [
      "Provide procedures that establish use of appropriate AWC and other control procedures in your compression operation.",
      "Conduct a retrospective, independent evaluation comparing process control values manually recorded within the batch records and the values recorded electronically within the PLC for all strengths of (b)(4) batches manufactured for the U.S. market.",
      "Perform a retrospective, independent review of all invalidated OOS results for all products since June 1, 2016."
    ]
  },
  {
    "letter_name": "kumar-organic-products-limited-598683-04232020",
    "violated_terms": [
      "Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and (2))."
    ],
    "recommendations": [
      "Provide a comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.",
      "Conduct a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates."
    ]
  },
  {
    "letter_name": "b-j-group-641099-01192023",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a) and (b)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.",
      "Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.",
      "Provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient."
    ]
  },
  {
    "letter_name": "carolina-infusion-659408-05222023",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including establishing product endotoxin limit, facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Notify the FDA in writing of the specific steps taken to address any violations within fifteen (15) working days.",
      "Include an explanation of each step being taken to prevent the recurrence of violations and copies of related documentation."
    ]
  },
  {
    "letter_name": "amnio-technology-llc-646460-10012024",
    "violated_terms": [
      "sections 301(d) of the FD&C Act",
      "505(a) of the FD&C Act",
      "section 351(a)(1) of the PHS Act",
      "current good manufacturing practice (CGMP) requirements",
      "section 501(a)(2)(B) of the FD&C Act",
      "21 CFR Parts 210 and 211",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)",
      "21 CFR 211.198(a)",
      "21 CFR 1271.10(a)",
      "21 CFR 1271.3(c)",
      "21 CFR 1271.3(d)"
    ],
    "recommendations": [
      "Establish written procedures for production and process control.",
      "Establish and follow a written testing program for stability characteristics.",
      "Follow written procedures for handling complaints regarding drug products.",
      "Provide supporting data to demonstrate that the manufacturing process can consistently yield expected product characteristics.",
      "Address the inventory at the facility and specific plans for product disposition.",
      "Address the lack of an approved BLA to lawfully market the products."
    ]
  },
  {
    "letter_name": "arg-laboratories-inc-670899-06112024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs in violation of sections 505(a) and 301(d) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to establish an adequate quality unit (21 CFR 211.22(a) and (d))",
      "failure to conduct at least one test to verify the identity of each component (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "failure to follow a written testing program for stability characteristics (21 CFR 211.166(a))"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Provide DEG and EG test results from testing reserve samples of all lots of high-risk drug components",
      "Conduct a full risk assessment for drug products containing ingredients at risk for DEG or EG contamination",
      "Provide a detailed summary of the validation program for ensuring a state of control throughout the product lifecycle",
      "Submit a comprehensive assessment and CAPA plan for the stability program",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "emcure-pharmaceuticals-limited-576961-08022019",
    "violated_terms": [
      "failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications",
      "inadequate investigation of sterility failures",
      "lack of sufficient data to support conclusions in sterility failure investigations",
      "failure to address potential manufacturing root causes",
      "insufficient review of environmental data",
      "failure to adequately assess container-closure integrity hazards",
      "repeated failures in microbiological investigations"
    ],
    "recommendations": [
      "provide an assessment of the overall system for investigations of deviations, atypical events, complaints, out-of-specification results, and failures",
      "conduct a comprehensive, third-party evaluation of records relating to discrepancies, deviations, complaints, maintenance, detailed batch defect history, and investigations related to potential sealing variability and container-closure integrity issues",
      "ensure that future sterility failure investigations include a comprehensive evaluation of potential vulnerabilities in the manufacturing operation",
      "provide a comprehensive third-party review of sterility test methods with emphasis on improving method robustness",
      "conduct a third-party review of sterilizer reliability, with emphasis on uniformity of heat distribution and lethality"
    ]
  },
  {
    "letter_name": "industrias-cklass-s-de-rl-de-cv-610275-06222022",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "acrx-specialty-pharmacy-inc-609518-07242020",
    "violated_terms": [
      "Failure to meet the conditions of section 503A of the FDCA",
      "Adulterated drug products due to insanitary conditions",
      "Failure to perform adequate smoke studies under dynamic conditions",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "Failure to monitor environmental conditions in aseptic processing areas",
      "Failure to maintain equipment used to control aseptic conditions",
      "Failure to establish a written testing program for stability characteristics",
      "Failure to conduct laboratory testing for sterility and pyrogen-free requirements",
      "Misbranding of drug products under section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems",
      "Engage a third-party consultant with sterile drug manufacturing expertise to assist in the evaluation",
      "Provide documentation of corrective actions taken to address insanitary conditions and CGMP violations",
      "Cease compounding and distributing drug products that do not meet the conditions of section 503A"
    ]
  },
  {
    "letter_name": "altaire-pharmaceuticals-inc-586153-03122020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations for finished pharmaceuticals",
      "adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act",
      "failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas",
      "failed to establish laboratory controls that include scientifically sound and appropriate specifications",
      "falsified laboratory data used to make batch release decisions",
      "failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination",
      "failed to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design",
      "failed to adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs"
    ],
    "recommendations": [
      "A complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations",
      "A comprehensive, independent assessment of your firm’s environmental monitoring and personnel monitoring programs",
      "A retrospective review of microbiology test results",
      "A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures",
      "Provide comprehensive remediation to address each item listed in the section entitled 'Data Integrity Remediation'",
      "A comprehensive, independent review of your laboratory practices, procedures, methods, equipment, and analyst competencies",
      "A comprehensive third-party report that thoroughly evaluates all microbiological test methods",
      "A commitment to notify FDA when or if your firm’s laboratory resumes sterility testing of your products",
      "Provide your plan to ensure appropriate aseptic practices and cleanroom behavior during production",
      "A comprehensive, third-party risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities",
      "A detailed CAPA plan with timelines to address the findings of the contamination hazards risk assessment",
      "A management strategy that describes how your production and quality management will better oversee design and execution of manufacturing",
      "A comprehensive investigation into the extent of the inaccuracies in data records and reporting",
      "A current risk assessment of the potential effects of the observed failures on the quality of your drugs",
      "A management strategy for your firm that includes the details of your global corrective action and preventive action plan"
    ]
  },
  {
    "letter_name": "8046255-canada-inc-dba-viatrexx-596178-06112020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to establish and follow appropriate written procedures",
      "failure to validate aseptic manufacturing processes",
      "failure to establish appropriate procedures for media fills",
      "failure to qualify the use of an appropriate filter",
      "failure to ensure appropriate aseptic technique",
      "failure to ensure appropriate gowning for manufacturing personnel",
      "failure to establish a system for monitoring environmental conditions",
      "failure to establish laboratory controls"
    ],
    "recommendations": [
      "Comprehensive risk assessment of all contamination hazards",
      "Detailed remediation plan with timelines",
      "Plan to ensure appropriate aseptic practices and cleanroom behavior",
      "Plan to ensure robust sterilization processes",
      "List of gowning materials intended for use",
      "Gowning qualification program",
      "Role of the quality unit in gown supplier selection",
      "Details on establishing adequate gowning and training",
      "CAPA plan for cleaning and disinfection program",
      "Comprehensive environmental monitoring program",
      "Comprehensive personnel monitoring program",
      "Independent assessment of laboratory practices"
    ]
  },
  {
    "letter_name": "distribuidora-lagunera-del-norte-sa-de-cv-610939-03232021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (c), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status with FDA",
      "request a Regulatory Meeting to discuss corrective actions if intending to manufacture drugs for the United States in the future"
    ]
  },
  {
    "letter_name": "choice-all-natural-inc-dba-om-botanical-685615-10212024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "drug products are adulterated",
      "unapproved new drug",
      "misbranded under section 502(ee)",
      "not duly registered with FDA",
      "not listed with FDA",
      "failure to maintain buildings in a clean and sanitary condition",
      "failure to conduct appropriate laboratory testing",
      "failure to assure that the drug product bore an expiration date supported by stability testing",
      "failure to register in accordance with section 510",
      "failure to provide listing information in accordance with 510(j)"
    ],
    "recommendations": [
      "Provide a corrective action and preventive action (CAPA) plan for facilities and equipment management",
      "Demonstrate procedures to maintain buildings free from pests",
      "Conduct a comprehensive assessment of laboratory practices and provide a remediation plan",
      "List chemical and microbial test methods for batch analysis",
      "Investigate all batches with potential microbial contamination",
      "Establish an ongoing stability testing program",
      "Engage a qualified consultant for CGMP compliance evaluation"
    ]
  },
  {
    "letter_name": "custom-research-labs-inc-616184-07082022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to test samples of each component",
      "failure to validate and establish the reliability of component supplier's test analyses",
      "inadequate API testing",
      "inadequate component water testing",
      "failure to establish adequate written procedures for production and process control",
      "failure to establish and follow an adequate written testing program for stability characteristics",
      "failure of quality control unit to ensure compliance with CGMP"
    ],
    "recommendations": [
      "Test each component lot for conformity with specifications",
      "Establish chemical and microbiological quality control specifications",
      "Conduct a comprehensive review of material system and supplier qualifications",
      "Implement a water system monitoring procedure",
      "Perform a comprehensive assessment of the water system design and maintenance",
      "Provide a detailed summary of the validation program for drug products",
      "Establish a stability program for each drug product",
      "Ensure quality control unit has authority and resources to function effectively",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "diamond-chemical-co-inc-687078-09062024",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity and quality.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product.",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products."
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Perform comprehensive six-system audit of the entire operation for CGMP compliance.",
      "Establish a robust testing program for identity and strength of active ingredients prior to release.",
      "Implement adequate stability testing programs to ensure drug products meet specifications throughout their shelf lives."
    ]
  },
  {
    "letter_name": "hou-fu-biotech-611644-jiangsu-co-ltd",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (f)(2), and (ee) of the FD&C Act",
      "introduction or delivery for introduction prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "consider removing all of your firm’s hand sanitizer drug products currently in distribution from the U.S. market",
      "provide a detailed investigation into how the hand sanitizer drug product contained an average of 45% ethanol",
      "provide a list of all raw materials used to manufacture all of your hand sanitizer drug products",
      "provide a list of all batches of any hand sanitizer drug products shipped to the United States",
      "provide copies of the complete batch records for all batches distributed to the U.S.",
      "engage a consultant qualified to evaluate your operations and assist in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "azurity-pharmaceuticals-inc-656489-09202024",
    "violated_terms": [
      "sections 301(d) and 505(a) of the FD&C Act",
      "21 U.S.C. 331(d) and 355(a)",
      "section 501(a)(2)(B) of the FD&C Act",
      "21 U.S.C. 351(a)(2)(B)",
      "21 CFR 211.192",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.",
      "Provide an independent assessment of your CAPA program.",
      "Provide an independent, retrospective review of all complaints and associated investigations for your drug products.",
      "Provide an independent, comprehensive review of your company’s complaint handling program that identifies deficiencies and a corresponding CAPA.",
      "Provide a management strategy including interim measures to protect patients and ensure the quality of your drugs.",
      "Provide a comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program.",
      "Conduct a retrospective risk assessment of the stability of all batches of your drug product on the U.S. market within expiry."
    ]
  },
  {
    "letter_name": "actavis-laboratories-fl-inc-567857-02012019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to establish adequate written procedures for production and process control",
      "failure to adequately validate critical parameters",
      "failure to adequately evaluate changes to visual inspection systems",
      "failure to establish control procedures to monitor output and validate performance",
      "failure to adequately qualify operators",
      "failure to establish an adequate quality control unit",
      "failure to thoroughly investigate unexplained discrepancies or failures"
    ],
    "recommendations": [
      "Provide a validation plan for ensuring a state of control throughout the drug product lifecycle",
      "Conduct a comprehensive, independent evaluation of the change management system",
      "Provide a scientific justification for the remaining laser drill's capability",
      "Characterize the vision system used on the laser drill and discuss similarities and differences",
      "Details of a proposed qualification program for QA inspectors",
      "Evaluate the ability of inspectors to determine the presence of laser drilled holes",
      "Provide data trends for laser drilled drug products",
      "Conduct a comprehensive, independent assessment with CAPA for the quality control unit",
      "Provide results of investigations into drug product failures",
      "Improve identification of potential human error risks in future process designs",
      "Engage a qualified third-party consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "andapharm-llc-566492-02282019",
    "violated_terms": [
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).",
      "Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).",
      "Your firm failed to follow written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to document at the time of performance (21 CFR 211.100(b))."
    ],
    "recommendations": [
      "Provide clarification on daily quality assurance walkthroughs and a comprehensive plan for cleaning procedures.",
      "Summarize all accelerated and long-term stability data, including out-of-specification results and CAPA for stability program adequacy.",
      "Conduct a risk assessment on drug products exposed to inappropriate environmental conditions and summarize material segregation procedures.",
      "Provide a complete assessment of documentation systems and a detailed CAPA plan to ensure accurate record-keeping."
    ]
  },
  {
    "letter_name": "albek-de-mexico-sa-de-cv-609202-03112021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the U.S.",
      "Provide copies of complete batch records for all batches distributed to the U.S.",
      "Provide test methods for testing raw materials and hand sanitizer products",
      "Discuss corrective action to test all drug products prior to release",
      "Provide a comprehensive independent assessment of laboratory practices and procedures",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "aruba-aloe-balm-nv-674911-05132024",
    "violated_terms": [
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and 211.84(d)(2))",
      "Use of ethanol contaminated with methanol in drug products",
      "Failure to adequately test incoming components for diethylene glycol (DEG) or ethylene glycol (EG) contamination",
      "Failure to demonstrate that (b)(4) water is suitable for use in drug manufacturing",
      "Failure to have appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a) and 211.165(b))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Misbranding of ISLAND REMEDY ALL-DAY REVITALIZING MOISTURIZER under section 502(f)(2) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Conduct a comprehensive six-system audit of the entire operation for CGMP compliance",
      "Provide a comprehensive review of the material system to ensure all suppliers are qualified",
      "Implement a detailed program for testing and validating all incoming components",
      "Establish a robust stability testing program for drug products",
      "Develop a remediation plan for the design, control, and maintenance of the water system",
      "Ensure full release testing for identity, strength, impurities, and microbiological assessment prior to drug release"
    ]
  },
  {
    "letter_name": "delta-kozmetik-sanayi-ve-ticaret-selim-yesil-645478-02132023",
    "violated_terms": [
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your firm failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide a comprehensive, independent review of your material system to determine supplier qualifications and material expiration dates.",
      "Develop a remediation plan for ongoing management oversight throughout the manufacturing lifecycle.",
      "Implement a comprehensive stability program with stability indicating methods and ongoing stability studies."
    ]
  },
  {
    "letter_name": "guangzhou-shiruoni-cosmetics-co-ltd-613170-12072021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "misbranded under sections 502(a) and (e)(1)(A) of the FD&C Act",
      "introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&C Act",
      "misbranding under section 502(a) of the FD&C Act",
      "misbranding under section 502(e)(1)(A) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "kaylaan-llc-681977-08192024",
    "violated_terms": [
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.",
      "Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.",
      "Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a batch disposition decision.",
      "Conduct a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Develop a comprehensive assessment and remediation plan to ensure your quality unit is given the authority and resources to effectively function.",
      "Provide a remediation plan that assures ongoing management oversight throughout the manufacturing lifecycle of all drug products.",
      "Implement a CAPA plan to ensure routine operations management oversight of facilities and equipment."
    ]
  },
  {
    "letter_name": "fuller-industries-inc-654425-06282023",
    "violated_terms": [
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).",
      "Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
      "Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures (21 CFR 211.160(b))."
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Conduct a comprehensive review of your material system to determine whether all suppliers of components, containers, and closures are qualified.",
      "Provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies."
    ]
  },
  {
    "letter_name": "cosmobeauti-laboratories-manufacturing-inc-657682-08112023",
    "violated_terms": [
      "Quality control unit responsibilities and oversight (21 CFR 211.22)",
      "Laboratory testing for objectionable organisms (21 CFR 211.165(b) and 21 CFR 211.166(b))",
      "Written procedures for production and process control (21 CFR 211.100(a) and 21 CFR 211.188)",
      "Validation of water systems and cleaning processes"
    ],
    "recommendations": [
      "Comprehensive assessment of documentation systems and CAPA plan for quality control oversight",
      "Independent assessment and CAPA plan for stability program and laboratory practices",
      "Detailed summary of validation programs for production processes and water systems",
      "Engagement of a qualified consultant for CGMP compliance evaluation"
    ]
  },
  {
    "letter_name": "ammd-labs-llc-568180-05072019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to perform appropriate laboratory determination of satisfactory conformance",
      "lack of adequate testing for microbial attributes",
      "failure to establish adequate written procedures for production and process control",
      "failure to validate the processes used to manufacture drugs",
      "inadequate control of water system",
      "failure to establish and follow an adequate written testing program for stability",
      "lack of adequate stability data",
      "failure to establish a quality control unit with appropriate authority",
      "failure to adequately test or evaluate raw materials",
      "misbranding and unapproved drugs"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "provide a list of chemical and microbial test methods and specifications",
      "provide a comprehensive review of laboratory practices and a detailed CAPA plan",
      "provide a data-driven program to control sources of variability in production processes",
      "provide timelines for performing prospective process qualification",
      "provide a comprehensive evaluation of the water system design and a CAPA plan",
      "provide a remediated SOP describing the stability program",
      "provide a full list of procedures applicable to the quality control unit",
      "provide a detailed risk assessment addressing the potential effects of the deficient water system"
    ]
  },
  {
    "letter_name": "hybrid-pharma-llc-629021-06072022",
    "violated_terms": [
      "section 503B of the FDCA",
      "CGMP violations",
      "section 501(a)(2)(B) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 301(ccc)(3) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise."
    ]
  },
  {
    "letter_name": "aerosol-and-liquid-packaging-inc-676746-07242024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products under section 501(a)(2)(B) of the FD&C Act",
      "Unapproved new drug under section 505(a) of the FD&C Act",
      "Misbranding under section 502(ee) of the FD&C Act",
      "Failure to conduct identity testing for each component",
      "Failure to validate supplier test analyses",
      "Failure to establish written procedures for production and process control",
      "Failure to clean and maintain equipment",
      "Failure of quality control unit to ensure compliance with CGMP"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of material system and supplier qualifications",
      "Establish chemical and microbiological quality control specifications for testing incoming lots",
      "Implement a remediation plan for water system design and maintenance",
      "Establish written procedures for production and process control",
      "Perform cleaning validation studies for shared equipment",
      "Engage a qualified consultant for CGMP compliance evaluation",
      "Provide a detailed CAPA plan for documentation practices",
      "Conduct a risk assessment for potential contamination from shared equipment"
    ]
  },
  {
    "letter_name": "dental-technologies-inc-612599-11302021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP)",
      "Quality System (QS) regulations",
      "21 CFR 211.192",
      "21 CFR 211.160(b)",
      "21 CFR 211.100(a)",
      "21 CFR 820.90(a)",
      "21 CFR 820.70",
      "Section 501(a)(2)(B) of the FD&C Act",
      "Section 501(a)(2)(A) of the FD&C Act",
      "Section 201(h) of the FD&C Act"
    ],
    "recommendations": [
      "Provide procedures describing in-process and finished product sampling and testing.",
      "Conduct a comprehensive and independent assessment of manufacturing processes.",
      "Perform a comprehensive, independent assessment of the water system design, control, and maintenance.",
      "Conduct a retrospective, independent review of all batch failures, rejected batches, and complaints related to microbiological contamination.",
      "Establish adequate written procedures for production and process control.",
      "Implement a CAPA plan to improve cleaning processes and practices.",
      "Conduct a comprehensive, independent retrospective assessment of cleaning effectiveness.",
      "Provide a CAPA plan for operations management oversight of facilities and equipment.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "henan-kangdi-medical-devices-co-ltd-587699-12032019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to assure that the drug product bore an expiration date supported by appropriate stability testing"
    ],
    "recommendations": [
      "Conduct a comprehensive and independent review of laboratory practices and provide a detailed corrective action and preventive action (CAPA) plan.",
      "Provide a list of all analytical test methods and specifications used to analyze each batch of drug products.",
      "Summarize test results from retrospective testing of retain samples of all drug product batches currently in distribution.",
      "Provide a comprehensive, independent review of the material system to ensure adequate qualification of components.",
      "Establish a stability program to support expiration dates assigned to drug products.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "biolab-sciences-inc-621465-08232022",
    "violated_terms": [
      "FD&C Act",
      "PHS Act",
      "21 CFR 1271.10(a)(1)",
      "21 CFR 1271.10(a)(2)",
      "21 CFR 1271.10(a)(3)",
      "21 CFR 211.113(b)",
      "21 CFR 211.160(b)",
      "21 CFR 211.67(b)",
      "21 CFR 211.56(b)",
      "21 CFR 211.42(c)(10)(i)",
      "21 CFR 211.192",
      "21 CFR 211.84",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice.",
      "Provide specific plans for the disposition of all products.",
      "Explain intention to use inventory for potential research use.",
      "Inform FDA about the marketing status of Amnio Breathe™."
    ]
  },
  {
    "letter_name": "gasco-industrial-corporation-647393-02172023",
    "violated_terms": [
      "Failure to maintain adequate separate defined areas necessary to prevent contamination or mix-up (21 CFR 211.42(c))",
      "Failure to establish adequate written procedures for production and process control (21 CFR 211.100(a))",
      "Inadequate cleaning controls",
      "Inadequate water system design and controls",
      "Lack of a process validation program",
      "Quality control unit failed to ensure drug products are in compliance with CGMP (21 CFR 211.22)"
    ],
    "recommendations": [
      "Confirm whether you will discontinue manufacturing drugs on shared equipment",
      "Provide a plan to show how you will separate areas for pharmaceutical and industrial product manufacturing",
      "Provide a risk assessment for all drugs produced on shared equipment",
      "Improve cleaning validation program with emphasis on worst-case conditions",
      "Establish a comprehensive validation program for ensuring a state of control throughout the product lifecycle",
      "Provide a comprehensive assessment and remediation plan for the quality control unit"
    ]
  },
  {
    "letter_name": "cosmaceutical-research-lab-inc-600121-05292020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranding",
      "failure to ensure laboratory records included complete data",
      "failure to establish laboratory controls",
      "lack of stability-indicating methods",
      "inadequate investigation of out-of-specification results"
    ],
    "recommendations": [
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Provide an update on the unofficial injection assessment and data integrity assessments",
      "Conduct a complete assessment of documentation systems",
      "Provide a comprehensive, independent assessment of laboratory practices",
      "Establish and follow an adequate written testing program for stability characteristics",
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Provide a management strategy that includes a global CAPA plan"
    ]
  },
  {
    "letter_name": "advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "21 CFR 211.113(b)",
      "21 CFR 211.28(a)",
      "21 CFR 211.94(c)",
      "21 CFR 211.42(c)(10)(iv)",
      "21 CFR 211.42(a)",
      "21 CFR 211.100(a)",
      "21 CFR 211.188(b)",
      "21 CFR 211.87",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 505(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 351(a)(1) of the PHS Act"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug processing expertise to assist in the evaluation.",
      "Establish and follow appropriate written procedures to prevent microbiological contamination of drug products.",
      "Ensure manufacturing personnel wear appropriate clothing to protect drug products from contamination.",
      "Implement a system for monitoring environmental conditions in aseptic processing areas.",
      "Prepare batch production and control records for each batch of drug product.",
      "Notify the FDA fifteen (15) working days prior to resuming production of any sterile drugs."
    ]
  },
  {
    "letter_name": "dermameal-co-ltd-582118-09122019",
    "violated_terms": [
      "Failure to establish an adequate quality control unit.",
      "Releasing drug products before completing all required testing.",
      "Failure to establish and follow an adequate written testing program for stability.",
      "Failure to conduct identity testing for each component of a drug product.",
      "Failure to establish written procedures for production and process control.",
      "Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment."
    ],
    "recommendations": [
      "Provide a retrospective review of all batches released to ensure specifications have been met.",
      "Summarize test results obtained from testing retain samples of all drug products within expiry.",
      "Conduct a comprehensive assessment with corrective and preventive actions for the quality control unit.",
      "Revise the stability procedure and provide a timeline for execution.",
      "Describe how to test each component lot for conformity with specifications.",
      "Establish a detailed validation plan for the manufacturing process."
    ]
  },
  {
    "letter_name": "homeocare-laboratories-inc-603532-06222020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to test samples of each component for identity and conformity",
      "failure to clean, maintain, and sanitize equipment",
      "failure to establish adequate written procedures for production and process control"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications for drug products",
      "Conduct full chemical and microbiological testing of retain samples",
      "Provide a comprehensive independent assessment of laboratory practices",
      "Establish a comprehensive independent assessment and corrective action plan for stability program",
      "Conduct a comprehensive independent review of material system for supplier qualification",
      "Provide a summary of results obtained from testing all components",
      "Conduct a comprehensive independent retrospective assessment of cleaning effectiveness",
      "Provide a risk assessment for all distributed drug products manufactured with inadequate processes",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "cipla-limited-660904-11172023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "failure to submit a Field Alert Report (FAR)",
      "failure to thoroughly investigate discrepancies",
      "inadequate corrective actions and preventive actions (CAPAs)",
      "failure to establish and follow appropriate written procedures to prevent microbiological contamination",
      "failure to adequately investigate media fill contamination incidents",
      "failure to establish adequate written responsibilities and procedures applicable to the quality control unit",
      "failure to comply with Field Alert reporting requirements"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures.",
      "Conduct an independent assessment of the CAPA program.",
      "Perform an independent, retrospective review of all complaints and associated investigations for Albuterol Sulfate Inhalation Aerosol batches manufactured since April 2020.",
      "Conduct a comprehensive, independent third-party review of the media fill program.",
      "Provide a detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Assess the extent of data integrity deficiencies at the facility.",
      "Develop a management strategy that includes a global corrective action and preventive action plan."
    ]
  },
  {
    "letter_name": "inovaker-lab-sa-de-cv-609979-02252021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Consider initiating a recall of all hand sanitizer drug products currently in distribution in the U.S. market",
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status with FDA"
    ]
  },
  {
    "letter_name": "american-specialty-pharmacy-inc-dba-asp-cares-604003-04052021",
    "violated_terms": [
      "section 503B of the FDCA",
      "section 505 of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 582 of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "21 CFR 211.113(b)",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.165(a)",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "section 502(f)(1) of the FDCA"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Assess aseptic processing operations with the assistance of a third-party consultant with relevant sterile drug manufacturing expertise.",
      "Ensure that adverse event reporting procedures comply with section 503B(b)(5) of the FDCA and 21 CFR 211.198."
    ]
  },
  {
    "letter_name": "intas-pharmaceuticals-limited-662868-11212023",
    "violated_terms": [
      "Your firm’s quality control unit failed to ensure compliance with CGMP (21 CFR 211.22).",
      "Data integrity deficiencies due to manipulation of inspection records.",
      "Failure to investigate unexplained discrepancies or batch failures (21 CFR 211.192).",
      "Inadequate written procedures for production and process controls (21 CFR 211.100 (a)).",
      "Failure to prevent microbiological contamination of sterile drug products (21 CFR 211.113 (b))."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment and remediation plan for the QA department.",
      "Implement a detailed corrective action and preventive action (CAPA) plan for each violation.",
      "Establish a thorough investigation protocol for data integrity issues.",
      "Perform a complete risk assessment of contamination hazards in aseptic processes."
    ]
  },
  {
    "letter_name": "deb-usa-inc-570944-06112019",
    "violated_terms": [
      "Failure to establish adequate written responsibilities and procedures for the quality control unit (21 CFR 211.22(d))",
      "Failure to establish laboratory controls that include scientifically sound specifications and test procedures (21 CFR 211.160(b))",
      "Failure to follow required laboratory control mechanisms (21 CFR 211.160(a))",
      "Failure to ensure laboratory records included complete data from all tests (21 CFR 211.194(a))",
      "Failure to conduct appropriate laboratory testing for objectionable microorganisms (21 CFR 211.165(b))",
      "Inaccurate drug registration and listing information under Section 510(j) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and CAPA to ensure the quality control unit functions effectively",
      "Implement a written procedure for HPLC data management and conduct a retrospective review of chromatographic data",
      "Conduct an independent review of chemical and microbiological laboratory practices and provide a detailed CAPA plan",
      "Investigate the failure of laboratory personnel to follow written procedures and implement corrective actions",
      "Notify the eDRLS team of steps taken to correct drug registration and listing violations"
    ]
  },
  {
    "letter_name": "biotek-india-613295-05132021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drug",
      "misbranded drug",
      "failure to conduct adequate testing for identity and strength of active ingredients",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish and follow an adequate written testing program for stability characteristics"
    ],
    "recommendations": [
      "Engage a qualified CGMP consultant",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Provide a list of chemical and microbial specifications for drug products",
      "Conduct full chemical and microbiological testing of retain samples",
      "Provide a comprehensive, independent assessment of laboratory practices",
      "Establish a written testing program for stability characteristics",
      "Provide a summary of results from testing retain samples and components"
    ]
  },
  {
    "letter_name": "dongbang-cosmetics-co-ltd-610364-10222021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (c), (x) and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions"
    ]
  },
  {
    "letter_name": "bionateo-sp-zoo-614651-11042021",
    "violated_terms": [
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements",
      "perform a comprehensive audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of your corrective actions and preventive actions before pursuing resolution of your firm’s compliance status with FDA"
    ]
  },
  {
    "letter_name": "foothills-professional-pharmacy-ltd-598883-09092020",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "section 301(a) of the FDCA",
      "section 301(k) of the FDCA",
      "21 CFR 211.42(c)",
      "21 CFR 211.165(a)",
      "21 CFR 211.110(a)",
      "21 CFR 211.63",
      "21 CFR 211.166(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.192"
    ],
    "recommendations": [
      "Undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant drug manufacturing expertise to assist in conducting the comprehensive evaluation.",
      "Cease all office-use compounding.",
      "Notify the FDA in writing of the specific steps taken to correct violations within fifteen working days."
    ]
  },
  {
    "letter_name": "clientele-inc-607476-12032020",
    "violated_terms": [
      "Failure to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).",
      "Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).",
      "Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug product and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).",
      "Misbranding violations under section 502(c) and 502(a) of the FD&C Act."
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Conduct process performance qualification (PPQ) studies to support an ongoing program for monitoring process control.",
      "Implement routine monitoring of the water system to ensure it consistently produces water suitable for its intended use.",
      "Develop a comprehensive stability program that includes stability-indicating methods and ongoing stability studies for each drug product.",
      "Ensure that all labeling complies with the requirements of section 502 of the FD&C Act."
    ]
  },
  {
    "letter_name": "gulsah-uretim-kozmetik-sanayi-anonim-sirketi-611591-05132021",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product (21 CFR 211.165(a)).",
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1) and (2)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, for each lot of drug products.",
      "Provide an action plan and timelines for conducting full chemical and microbiological testing of reserve samples.",
      "Provide a comprehensive independent assessment of laboratory practices and a detailed plan to remediate and evaluate the effectiveness of the laboratory system.",
      "Conduct a comprehensive independent review of the material system to ensure supplier qualifications and adequate incoming material controls.",
      "Provide a comprehensive, independent assessment and corrective action plan for the stability program, including stability studies and ongoing programs."
    ]
  },
  {
    "letter_name": "accra-pac-inc-dba-voyant-beauty-643600-04202023",
    "violated_terms": [
      "Thorough investigation of discrepancies (21 CFR 211.192)",
      "Laboratory testing for objectionable microorganisms (21 CFR 211.165(b))",
      "Identity testing of components (21 CFR 211.84(d)(1))"
    ],
    "recommendations": [
      "Comprehensive assessment of investigation systems and action plan for improvements",
      "Testing results for all reserve samples of finished products",
      "Detailed method for testing benzene in finished products",
      "Periodic assessments of CAPA implementation",
      "Current sampling and testing procedures for incoming propellants",
      "List of microbiological specifications and summary of testing results",
      "Summary of test results for glycerin components and identity testing procedures"
    ]
  },
  {
    "letter_name": "guangzhou-zhongkebaishi-health-industry-co-ltd-613267-04192022",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), (c), (x), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status with FDA"
    ]
  },
  {
    "letter_name": "ficosota-ltd-594591-02282020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug product",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish the reliability of component supplier's test analyses",
      "quality control unit failed to ensure compliance with CGMP",
      "failure to establish an adequate written testing program for stability characteristics"
    ],
    "recommendations": [
      "Provide a comprehensive assessment of laboratory practices and a detailed remediation plan",
      "List chemical and microbial specifications for each batch of drug products",
      "Conduct full chemical and microbiological testing of retain samples",
      "Review material system for supplier qualification and testing",
      "Provide a comprehensive assessment and remediation plan for the quality control unit",
      "Establish a validation plan for process performance qualification",
      "Implement a comprehensive CAPA plan for OOS result investigations",
      "Establish a written testing program for stability characteristics",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo",
    "violated_terms": [
      "Failure to determine as ineligible a donor with risk factors for communicable disease agents",
      "Failure to establish written procedures for production and process controls",
      "Failure to have an adequate system to prevent contamination during aseptic processing",
      "Failure to establish laboratory controls that assure drug products conform to standards of identity, strength, quality, and purity",
      "Products are unapproved new drugs",
      "Products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Revise Donor Screening Guidance Document for sepsis",
      "Revise sepsis algorithm in SOP-0006 to comply with 1271.75(d)(1)",
      "Provide a list of all donors with risk factors for sepsis that were determined to be eligible",
      "Address CGMP violations in response to this letter",
      "Stop the manufacture and distribution of all viable bone matrix products until FDA standards are met"
    ]
  },
  {
    "letter_name": "eksa-mills-sa-de-cv-634706-10052022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Failure to clean, maintain, and sanitize equipment and utensils",
      "Adulterated drug products",
      "Quality control unit's failure to ensure compliance with CGMP",
      "Inadequate procedures for quality unit oversight",
      "Inadequate testing of incoming components",
      "Failure to adhere to a stability program",
      "Inadequate maintenance of batch records"
    ],
    "recommendations": [
      "Discontinue manufacturing drugs on shared equipment with non-pharmaceuticals",
      "Provide a plan to separate areas for dedicated manufacturing equipment",
      "Conduct a risk assessment for drugs previously manufactured on shared equipment",
      "Provide a comprehensive assessment and remediation plan for the quality unit",
      "Engage a qualified consultant to assist in meeting CGMP requirements",
      "Notify the FDA before resuming drug manufacturing operations"
    ]
  },
  {
    "letter_name": "honest-globe-inc-597177-03152021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "unapproved new drugs",
      "misbranded drugs",
      "failure to establish an adequate quality control unit",
      "failure to prepare batch production and control records",
      "failure to establish written procedures for production and process control",
      "failure to adequately qualify the equipment and validate the processes",
      "CBD not recognized as safe and effective",
      "CBD cannot be considered a safe and suitable inactive ingredient"
    ],
    "recommendations": [
      "Conduct an audit of all released batches for deviations and OOS results",
      "Provide an audit of all incoming component specifications",
      "Develop a comprehensive assessment and remediation plan for the quality control unit",
      "Perform a retrospective analysis and gap assessment of executed production records",
      "Revise master production records for all drug products",
      "Establish a data-driven and scientifically sound program for process control",
      "Engage a qualified third-party consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "cipla-limited-597511-02252020",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "jiangsu-meifan-biotechnology-co-ltd-676562-04032024",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Engage a qualified consultant as set forth in 21 CFR 211.34 to assist in meeting CGMP requirements before resuming drug manufacturing operations.",
      "Perform a comprehensive six-system audit of the entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs."
    ]
  },
  {
    "letter_name": "hangzhou-badi-daily-use-chemical-company-580819-08292019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug in violation of section 505(a) of the FD&C Act",
      "misbranded under sections 502(c) and (x) of the FD&C Act",
      "failed to have appropriate laboratory determination of satisfactory conformance",
      "failed to conduct at least one test to verify the identity of each component",
      "failed to establish adequate written procedures for production and process control",
      "failed to assure that the drug product bore an expiration date supported by appropriate stability testing",
      "adulterated within the meaning of section 601(c) of the FD&C Act",
      "misbranded under section 502(c) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a list of all analytical test methods and specifications used to analyze each batch of drug products",
      "Perform a comprehensive, independent review of laboratory practices and provide a detailed CAPA plan",
      "Provide a summary of formulations and test results from testing reserve samples of all drug products",
      "Perform a comprehensive, independent review of the material system to ensure adequate qualification of suppliers",
      "Describe how to test each component lot for conformity with specifications",
      "Provide chemical and microbiological quality control specifications for incoming components",
      "Test reserve samples of all glycerin lots for DEG and EG promptly",
      "Provide a detailed risk assessment for drug products containing glycerin",
      "Provide a data-driven and scientifically sound program for production processes",
      "Conduct PPQ studies for drug products",
      "Provide a comprehensive assessment and CAPA for the stability program",
      "Clarify intentions regarding resuming drug manufacturing",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "international-laboratories-corp-ltd-664352-08082023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide a commitment to provide test results for high-risk drug components used in the manufacture of drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for contamination.",
      "Describe how you will test each component lot for conformity with all appropriate specifications.",
      "Provide a comprehensive, independent review of your material system.",
      "Summarize your program for qualifying and overseeing contract facilities that test the drug products you manufacture.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "central-admixture-pharmacy-services-inc-687936-07102024",
    "violated_terms": [
      "failed to meet the conditions of section 503B of the FDCA",
      "drug products prepared, packed, or held under insanitary conditions",
      "adulterated under section 501(a)(2)(A) of the FDCA",
      "CGMP violations under section 501(a)(2)(B) of the FDCA",
      "unapproved new drug products under sections 505(a) and 301(d) of the FDCA",
      "misbranded drug products under section 502(f)(1) of the FDCA",
      "failure to report adverse events under section 503B(b)(5) of the FDCA"
    ],
    "recommendations": [
      "conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems",
      "engage a third party consultant with relevant sterile drug manufacturing expertise",
      "immediately and comprehensively assess your company’s global manufacturing operations",
      "notify the FDA of specific steps taken to address violations within fifteen (15) working days",
      "provide documentation of corrective actions and training related to violations"
    ]
  },
  {
    "letter_name": "aribio-hb-co-ltd-613107-10082021",
    "violated_terms": [
      "Adulteration Violations: The product labeled as containing 70% ethanol actually contained 58% ethanol, violating section 501(c) of the FD&C Act.",
      "Misbranding Violations: The product is misbranded under sections 502(a) and (x) of the FD&C Act due to misleading claims and lack of required information on the label."
    ],
    "recommendations": [
      "Conduct a detailed investigation into the discrepancy in ethanol content.",
      "Provide a list of all raw materials and suppliers used in manufacturing.",
      "Submit complete batch records for all distributed products.",
      "Include methanol content test methods for the hand sanitizer products."
    ]
  },
  {
    "letter_name": "bbc-group-limited-614659-08042021",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(ee) of the FD&C Act",
      "failure to exercise appropriate controls over computer or related systems (21 CFR 211.68(b))",
      "failure to establish laboratory controls (21 CFR 211.160(b))",
      "failure to clean, maintain, and sanitize equipment (21 CFR 211.67(a))"
    ],
    "recommendations": [
      "Retain a qualified consultant to assist in remediation",
      "Conduct a comprehensive investigation into data record inaccuracies",
      "Perform a current risk assessment of observed failures",
      "Develop a management strategy including a global corrective action and preventive action plan",
      "Conduct a comprehensive, independent assessment of laboratory practices and procedures",
      "Implement a CAPA plan for routine operations management oversight of facilities and equipment",
      "Provide a risk assessment for drug products manufactured in equipment with rust",
      "Engage a consultant for a comprehensive audit of CGMP compliance"
    ]
  },
  {
    "letter_name": "eugia-pharma-specialities-limited-681905-08152024",
    "violated_terms": [
      "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).",
      "Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).",
      "Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test."
    ],
    "recommendations": [
      "Provide a plan to ensure appropriate aseptic practices and cleanroom behavior during production, including supervisory oversight and quality assurance audits.",
      "Implement a comprehensive investigation into the extent of inaccuracies in data records and reporting, including interviews and assessments of data integrity deficiencies.",
      "Develop a management strategy that includes a global CAPA plan, corrective action plans, and interim measures to protect patients and ensure drug quality.",
      "Engage a qualified consultant to perform a comprehensive six-system audit of your operation for CGMP compliance and evaluate the efficacy of your CAPAs."
    ]
  },
  {
    "letter_name": "avaria-health-beauty-corp-663507-08032023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide DEG and EG test results for all lots of high-risk drug components used in the manufacture of drug products.",
      "Conduct a full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination.",
      "Establish a comprehensive assessment and remediation plan for the quality control unit to ensure effective functioning.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "centurion-laboratories-private-limited-571255-05042019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "laboratory records incomplete data",
      "failure to ensure compliance with established specifications",
      "inadequate controls over computer systems",
      "failure to follow written procedures for cleaning and maintenance of equipment",
      "inadequate cleaning and maintenance of equipment",
      "data integrity deficiencies"
    ],
    "recommendations": [
      "Provide corrective action and preventative action (CAPA) plan",
      "Assess all computer systems used for CGMP activities",
      "Evaluate the adequacy of cleaning procedures for manufacturing equipment",
      "Conduct a comprehensive investigation into data record inaccuracies",
      "Engage a qualified consultant for CGMP compliance",
      "Provide a management strategy including corrective action plan",
      "Perform a comprehensive audit of the entire operation for CGMP compliance"
    ]
  },
  {
    "letter_name": "grupo-yacana-mexico-sas-de-cv-609824-01262021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j) and (e) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "nonprescription drugs subject to section 505G of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements.",
      "Perform a comprehensive audit of the entire operation for CGMP compliance.",
      "Evaluate the completion and efficacy of corrective actions and preventive actions."
    ]
  },
  {
    "letter_name": "apollo-care-574756-03202019",
    "violated_terms": [
      "Drug products produced failed to meet the conditions of section 503B of the FDCA.",
      "Drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions.",
      "Failure to submit a report to FDA upon initial registration.",
      "Failure to submit complete reports identifying all drug products compounded during the previous six-month period.",
      "Drug products were misbranded under section 502(f)(1) of the FDCA.",
      "Failure to establish adequate written responsibilities and procedures applicable to the quality control unit.",
      "Failure to establish and follow appropriate written procedures to prevent microbiological contamination.",
      "Failure to thoroughly investigate any unexplained discrepancy or failure of a batch.",
      "Failure to maintain the buildings used in the manufacture in a clean and sanitary condition.",
      "Failure to prepare batch production and control records with complete information.",
      "Failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas.",
      "Failure to ensure that each person engaged in the manufacture has the necessary education, training, and experience.",
      "Failure to routinely calibrate, inspect, or check equipment used in the manufacture.",
      "Failure to establish and follow written procedures for the receipt, identification, storage, handling, sampling, testing, and approval of components."
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in the evaluation.",
      "Implement corrective actions to address each violation, including timelines for completion and supporting documentation.",
      "Ensure that all required information is included on product labels and that a Labeling Requirements SOP is established.",
      "Establish a system for monitoring environmental conditions and documenting excursions.",
      "Document staff competency and training related to aseptic processing and CGMP compliance."
    ]
  },
  {
    "letter_name": "inopak-ltd-569465-02212019",
    "violated_terms": [
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).",
      "Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (211.137(a)).",
      "Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).",
      "Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a))."
    ],
    "recommendations": [
      "Provide a comprehensive independent assessment of your overall system for investigating deviations, atypical events, complaints, OOS results, and failures.",
      "Your plan for conducting stability studies, including a procedure describing your stability program, stability-indicating methods, and stability studies to support each drug product in its container-closure system before distribution is permitted.",
      "List all the quality unit procedures that you have created and/or revised and provide your timeline to perform annual product reviews for drug products manufactured in 2016, 2017, and 2018.",
      "Provide the protocols for your process validation activities and describe how you will monitor sources of variability in your operation throughout the drug lifecycle."
    ]
  },
  {
    "letter_name": "hospira-healthcare-india-pvt-ltd-557890-03042019",
    "violated_terms": [
      "Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards (21 CFR 211.194(a)).",
      "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications (21 CFR 211.192).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product (21 CFR 211.165(a))."
    ],
    "recommendations": [
      "Include a final report on corrective actions and preventive actions (CAPA) that were implemented to assure that aseptic processing operations are maintained in a state of control.",
      "Provide a final report on changes implemented in the site’s quality control (QC) laboratories to enhance procedures, training, and CGMP documentation practices.",
      "Conduct a comprehensive, retrospective review of reliability of all microbiology laboratory data, including data relating to water system control and environmental monitoring."
    ]
  },
  {
    "letter_name": "auro-pharmacies-inc-dba-central-drugs-compounding-pharmacy-608369-06032020",
    "violated_terms": [
      "section 503A of the FDCA",
      "section 501(a)(2)(A) of the FDCA",
      "section 501(a)(2)(B) of the FDCA",
      "section 502(f)(1) of the FDCA",
      "section 505 of the FDCA",
      "21 CFR 211.84(d)(6)",
      "21 CFR 211.166(a)",
      "21 CFR 211.58",
      "section 301(a) of the FDCA",
      "section 301(d) of the FDCA",
      "section 301(k) of the FDCA"
    ],
    "recommendations": [
      "Conduct a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems.",
      "Engage a third-party consultant with relevant sterile drug manufacturing expertise to assist in the evaluation.",
      "Notify the FDA fifteen (15) days prior to resuming production of any sterile drugs in the future."
    ]
  },
  {
    "letter_name": "essnd-global-595850-02142020",
    "violated_terms": [
      "Failure to perform appropriate laboratory determination of satisfactory conformance to final specifications for drug products (21 CFR 211.165(a) and (b))",
      "Failure to test samples of each component for identity and conformity with specifications (21 CFR 211.84(d)(1) and (2))",
      "Failure to establish an adequate quality unit (21 CFR 211.22(a) and (d))"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications used to analyze each lot before disposition.",
      "Outline an action plan and timelines for conducting full chemical and microbiological testing of retain samples.",
      "Summarize results from testing retain samples and outline corrective actions if substandard quality is revealed.",
      "Detail the method for assay testing of active ingredients and timeline for implementation.",
      "Describe how each component lot will be tested for conformity with specifications and establish reliability of supplier's COA.",
      "Provide a comprehensive assessment and remediation plan for the quality unit."
    ]
  },
  {
    "letter_name": "kimera-labs-inc-649343-09012023",
    "violated_terms": [
      "FD&C Act",
      "Section 351(a) of the PHS Act",
      "current good manufacturing practice (CGMP) requirements",
      "section 501(a)(2)(B) of the FD&C Act",
      "21 CFR Parts 210 and 211",
      "21 CFR 211.113(b)",
      "21 CFR 211.192",
      "21 CFR 211.167(a)",
      "21 CFR 211.160(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.176",
      "21 CFR 211.42(c)(10)(v)",
      "21 CFR 211.165(e)",
      "21 CFR 211.84(a)",
      "21 CFR 211.166(a)"
    ],
    "recommendations": [
      "Cease manufacture and distribution of Amnio2X",
      "End use of stem cell master line to make XoGlo® and XoGlo®Pro products for commercial distribution",
      "Do not distribute products without a BLA or IND in effect",
      "Address CGMP violations and ensure compliance with the FD&C Act and PHS Act"
    ]
  },
  {
    "letter_name": "depq-internacional-s-de-rl-de-cv-608871-03182021",
    "violated_terms": [
      "adulterated under section 501(c) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "introduction or delivery for introduction of a misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Engage a consultant qualified to evaluate operations and assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Evaluate the completion and efficacy of corrective actions and preventive actions before pursuing resolution of compliance status with FDA",
      "Provide a detailed investigation into the discrepancies in ethanol and BZK concentrations",
      "Provide a list of all raw materials used to manufacture hand sanitizer drug products",
      "Provide a list of all batches of hand sanitizer drug products shipped to the United States",
      "Provide copies of the complete batch records for all batches distributed to the U.S."
    ]
  },
  {
    "letter_name": "abraxis-bioscience-llc-633713-10312022",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Effective implementation of CAPA for aseptic processing line",
      "Comprehensive evaluation and remediation of media fill failures",
      "Detailed investigation of contamination sources and root causes"
    ],
    "recommendations": [
      "Comprehensive risk assessment of contamination hazards",
      "Detailed remediation plan with timelines",
      "CAPA plan for routine operations and management oversight",
      "Evaluation of suitability of aseptic processing equipment",
      "Independent assessment of investigation systems and procedures",
      "Retrospective evaluation of media fill contamination events",
      "Review of sterilization cycles and their effectiveness",
      "List of complaints related to Abraxane drug products",
      "Updated risk assessment for product quality and patient safety"
    ]
  },
  {
    "letter_name": "inmar-supply-chain-solutions-llc-666158-01302024",
    "violated_terms": [
      "Adulterated Human Foods",
      "Adulterated Human Drugs",
      "Adulterated Devices",
      "Failure to exclude pests from the facility",
      "Failure to maintain the plant in a clean and sanitary condition",
      "Insanitary conditions observed",
      "Rodent infestation",
      "Failure to maintain drug products in a clean and sanitary condition",
      "Failure to prepare, pack, or hold products under sanitary conditions"
    ],
    "recommendations": [
      "Increase contracted pest control service visits",
      "Retrain personnel on inspection and rejection standards",
      "Increase external inspection and maintenance activities for the facility",
      "Destroy any OTC drug products with a compromised consumer package",
      "Implement specific activities and requirements for medical devices"
    ]
  },
  {
    "letter_name": "anumed-international-llc-674310-08202024",
    "violated_terms": [
      "unapproved new drugs",
      "misbranded drugs",
      "adulterated drugs",
      "failure to conduct identity testing",
      "failure to establish written procedures for production and process control",
      "failure to establish laboratory controls",
      "failure of quality control unit to ensure compliance with CGMP",
      "failure to provide adequate directions for use"
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Provide a description of how to test each component lot for conformity with specifications",
      "Establish a detailed summary of the validation program for ensuring a state of control",
      "Conduct a comprehensive, independent assessment of laboratory practices and procedures",
      "Implement a remediation plan to ensure the quality control unit functions effectively",
      "Perform a full risk assessment for drug products containing ingredients at risk for contamination"
    ]
  },
  {
    "letter_name": "bingbing-pharmaceutical-co-ltd-584327-10032019",
    "violated_terms": [
      "Your firm failed to maintain written production, control, or distribution records specifically associated with a batch of a drug product for at least one year after the expiration date of the batch (21 CFR 211.180(a)).",
      "Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).",
      "Your firm failed to maintain an adequate written record of each complaint (21 CFR 211.198(b))."
    ],
    "recommendations": [
      "Provide a complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient.",
      "Provide a detailed risk assessment of drug products on the market without any manufacturing documentation and without retains or stability samples to support investigations and expiration dating.",
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.",
      "Provide a comprehensive assessment and remediation plan to ensure your quality control unit is given the authority and resources to effectively function.",
      "Provide a comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States."
    ]
  },
  {
    "letter_name": "grupo-plast-y-kosas-sa-de-cv-609493-01252021",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "adulterated under section 501(c) of the FD&C Act",
      "unapproved new drugs under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a) and (ee) of the FD&C Act",
      "misbranded under sections 502(j) and (e) of the FD&C Act",
      "nonprescription drugs subject to section 505G of the FD&C Act",
      "misbranded under section 502(j) of the FD&C Act",
      "misbranded under section 502(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "not conforming to the 1994 TFM",
      "not meeting the conditions under section 505G(a)(3) of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate operations",
      "perform a comprehensive audit of the entire operation for CGMP compliance",
      "evaluate the completion and efficacy of corrective actions and preventive actions",
      "request a Regulatory Meeting to discuss corrective actions"
    ]
  },
  {
    "letter_name": "global-sanitizers-llc-614124-11082021",
    "violated_terms": [
      "Refusal to permit access to any record as required by section 704(a)",
      "Adulterated within the meaning of section 501(d)(2)",
      "Adulterated within the meaning of section 501(a)(2)(B)",
      "Unapproved new drug in violation of section 505(a)",
      "Misbranded under section 502(ee)",
      "Misbranded under section 502(c)",
      "Misbranded under section 502(i)",
      "Misbranded under section 502(i)(1)",
      "Failure to establish an adequate Quality Unit",
      "Failure of the Quality Unit to approve production procedures",
      "Failure of the Quality Unit to establish adequate controls for released materials",
      "Failure of the Quality Unit to establish adequate control for incoming components",
      "Misbranding under section 502(o)",
      "Failure to properly list drug products"
    ],
    "recommendations": [
      "Consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market and within expiry.",
      "Provide a detailed investigation into how the drug products were substituted with methanol.",
      "Provide a list of all raw materials used to manufacture all hand sanitizer drug products.",
      "Provide a list of all batches of hand sanitizer drug products distributed in the United States.",
      "Provide copies of the complete batch records for all batches distributed to the U.S.",
      "Conduct a comprehensive, independent review of your material system.",
      "Develop a comprehensive assessment and remediation plan for the Quality Unit.",
      "Conduct a complete assessment of documentation systems used throughout manufacturing and laboratory operations.",
      "Clarify whether you intend to resume manufacturing any drugs at this facility or another in the future."
    ]
  },
  {
    "letter_name": "brenntag-great-lakes-llc-660268-10262023",
    "violated_terms": [
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)."
    ],
    "recommendations": [
      "Confirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.",
      "A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "advanced-cosmetic-research-laboratories-inc-635176-09262022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.58",
      "21 CFR 211.22(a)",
      "21 CFR 211.22(d)",
      "section 505(a) of the FD&C Act",
      "section 502(ee) of the FD&C Act",
      "sections 301(d) and (a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a corrective action and preventative action (CAPA) plan for facilities and equipment management.",
      "Provide photographic evidence of repairs made to facilities and equipment.",
      "Provide a comprehensive assessment and remediation plan for the quality control unit.",
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide a complete assessment of documentation systems used throughout manufacturing and laboratory operations.",
      "Provide an assessment of data integrity deficiencies at the facility."
    ]
  },
  {
    "letter_name": "jubilant-generics-limited-569799-03062019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "failure to thoroughly investigate discrepancies",
      "inadequate investigations into deviations and consumer complaints",
      "failure to test and reject non-conforming in-process materials",
      "inadequate management of product quality issues",
      "repeat violations of CGMP"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent assessment of the overall system for investigations",
      "Provide a summary of all atypical or failing dissolution test results",
      "Submit the final investigation for PR 8065",
      "Conduct an independent, retrospective review of all complaints and associated investigations",
      "Conduct an independent, retrospective review of all investigations into batch rejects and critical defects",
      "Engage a qualified CGMP consultant",
      "Conduct a comprehensive, independent evaluation of the change management system"
    ]
  },
  {
    "letter_name": "enprani-co-ltd-580548-08152019",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "failed to maintain a current registration for the establishment",
      "failed to list the drugs manufactured at this facility",
      "failed to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failed to establish an adequate quality control unit",
      "failed to establish written procedures for production and process control",
      "failed to establish an adequate written testing program",
      "failed to exercise appropriate controls over computer or related systems",
      "failed to maintain establishment registration and drug listing obligations"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial test methods and specifications used to analyze each lot of drug product",
      "Provide completed chemical and microbial analytical method validation, equipment validation, and updated test methods",
      "Provide a summary of test results obtained from testing reserve samples of all drug products within expiry",
      "Provide an independent comprehensive assessment with corrective and preventive actions (CAPA) for the quality unit",
      "Provide protocols for validation and qualification activities",
      "Provide a comprehensive assessment and CAPA plan to ensure the adequacy of the stability program",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting",
      "Provide a current risk assessment of the potential effects of observed failures on drug quality",
      "Provide a management strategy that includes a global corrective action and preventive action plan",
      "Ensure the consultant is qualified to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "froggys-fog-llc-623283-04142022",
    "violated_terms": [
      "Failure to establish written procedures for production and process control (21 CFR 211.100(a))",
      "Inadequate process validation and water system validation protocols",
      "Failure to perform appropriate laboratory determination of satisfactory conformance to final specifications (21 CFR 211.165(a) and (b))",
      "Failure to establish laboratory controls (21 CFR 211.160(b))",
      "Failure to conduct identity testing for each component of a drug product (21 CFR 211.84(d)(1) and (2))",
      "Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))",
      "Misbranding of SIMPLY 70 HAND SANITIZER GEL under section 502(a) of the FD&C Act"
    ],
    "recommendations": [
      "Provide a detailed summary of the validation program for ensuring a state of control throughout the product lifecycle",
      "Submit a timeline for performing process performance qualification for each marketed drug product",
      "Establish a detailed program for designing, validating, maintaining, controlling, and monitoring manufacturing processes",
      "Implement a procedure for routine microbial testing of the water system",
      "Conduct full chemical and microbiological testing of retain samples for all batches of drug products",
      "Provide a comprehensive review of the material system for incoming raw materials",
      "Develop a risk assessment for all drugs produced on shared equipment",
      "Establish a cleaning validation program with detailed timelines and assessments"
    ]
  },
  {
    "letter_name": "calvin-scott-company-inc-606987-08252020",
    "violated_terms": [
      "Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a))."
    ],
    "recommendations": [
      "Provide a comprehensive assessment of your stability program and CAPA plan to ensure that the expiration dates assigned to your repackaged products are scientifically justified.",
      "Provide a comprehensive assessment and Corrective and Preventive Action (CAPA) plan of your cleaning program that includes appropriate remediations to your cleaning processes and practices.",
      "Provide a comprehensive independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function."
    ]
  },
  {
    "letter_name": "broncolin-sa-de-cv-609329-12212020",
    "violated_terms": [
      "adulterated under section 501(d)(2) of the FD&C Act",
      "adulterated under section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(j), (a), (e), (f)(2), and (ee) of the FD&C Act",
      "introduction or delivery for introduction of misbranded drug into interstate commerce prohibited under section 301(a) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a detailed investigation into the substitution of ethanol with methanol",
      "Provide a list of all raw materials used to manufacture hand sanitizer products",
      "List all batches of hand sanitizer drug products shipped to the U.S.",
      "Commit to testing hand sanitizer products for methanol and ethanol per USP monograph",
      "Submit copies of complete batch records for all batches of hand sanitizer distributed to the U.S.",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "cosmo-bio-co-ltd-611552-01062022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug introduced or delivered for introduction into interstate commerce",
      "misbranded under section 502(ee) of the FD&C Act",
      "failed to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failed to establish and follow an adequate written testing program for stability characteristics",
      "failed to establish and follow adequate written procedures for cleaning and maintenance of equipment"
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications for drug products",
      "Provide an action plan and timelines for conducting full chemical and microbiological testing",
      "Provide a summary of all results obtained from testing retain samples",
      "Provide a comprehensive assessment and corrective and preventive action plan for stability program",
      "Implement an adequate cleaning validation program",
      "Describe steps for change management before introducing new manufacturing equipment or products",
      "Provide a summary of updated SOPs for verification and validation of cleaning procedures"
    ]
  },
  {
    "letter_name": "kobayashi-healthcare-international-inc-637313-01272023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "failure to conduct appropriate laboratory testing for objectionable microorganisms",
      "failure to ensure drug products comply with CGMP",
      "lack of adequate quality control unit",
      "failure to establish adequate procedures for maintaining and investigating customer complaints",
      "failure to provide adequate scientific basis for product safety",
      "failure to conduct full microbiological testing",
      "failure to validate microbiological test methods",
      "failure to comply with the final administrative order for external analgesic drug products"
    ],
    "recommendations": [
      "Provide a list of microbiological specifications used to analyze each lot of drug products",
      "Submit an action plan and timelines for conducting full microbiological testing",
      "Provide a summary of results from testing retain samples from each batch",
      "Conduct an independent assessment of microbiological test methods",
      "Perform appropriate scientific studies to evaluate antimicrobial effectiveness testing",
      "Develop a comprehensive assessment and remediation plan for the quality control unit",
      "Conduct a retrospective review of each batch currently on the market",
      "Engage a consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "baja-fur-sa-de-cv-590791-12132019",
    "violated_terms": [
      "Thorough investigation of unexplained discrepancies (21 CFR 211.192)",
      "Documentation of batch production and control records (21 CFR 211.188(b))",
      "Establishment of adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b))"
    ],
    "recommendations": [
      "Comprehensive assessment of the system for investigating deviations and discrepancies, including a detailed action plan for remediation.",
      "Complete investigations into all batches with out-of-specification results, including root cause analysis and corrective actions.",
      "Detailed CAPA plan to prevent distribution of failing drug products.",
      "Appropriate microbiological batch release specifications and testing methods conforming to USP standards.",
      "Summary of updated SOPs for cleaning validation and change management processes."
    ]
  },
  {
    "letter_name": "biolyte-laboratories-llc-603584-03182021",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated products",
      "unapproved new drugs",
      "misbranding regulations",
      "failure to have appropriate laboratory determination of satisfactory conformance",
      "failure to conduct at least one test to verify the identity of each component",
      "failure to establish a written testing program for stability characteristics",
      "failure to comply with labeling requirements for dietary supplements"
    ],
    "recommendations": [
      "Engage a consultant qualified to assist in meeting CGMP requirements",
      "Perform a comprehensive audit of the entire operation for CGMP compliance",
      "Provide a list of chemical and microbiological specifications for each batch",
      "Conduct microbiological testing methods capable of recovering bioburden",
      "Commit to testing each batch using qualified methods",
      "Establish a written testing program for stability characteristics",
      "Conduct a comprehensive review of the material system for supplier qualification",
      "Provide a summary of results obtained from testing all components"
    ]
  },
  {
    "letter_name": "eco-lips-inc-631629-09202022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "failure to establish an adequate written testing program",
      "failure to establish an adequate stability program",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to establish written procedures for production and process control",
      "failure to follow adequate written procedures for cleaning and maintenance of equipment",
      "failure to maintain written records for annual product reviews"
    ],
    "recommendations": [
      "Provide a comprehensive independent assessment and CAPA plan for stability program",
      "Conduct a retrospective independent review of all invalidated OOS results",
      "Provide a detailed summary of validation program for manufacturing processes",
      "Implement a CAPA plan for cleaning and disinfection processes",
      "Conduct annual product reviews for all drug products"
    ]
  },
  {
    "letter_name": "avlon-industries-inc-652903-07182023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to establish adequate written procedures for production and process control.",
      "Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Provide results of tests for DEG and EG in retain samples of all glycerin lots or any other high-risk components.",
      "Establish a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "green-pharmaceutical-co-ltd-663544-08232023",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products."
    ],
    "recommendations": [
      "Provide (b)(4) test results from testing retains for all lots of high-risk drug components used in the manufacture of drug products.",
      "Provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function.",
      "Engage a qualified consultant to evaluate your operations and assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "aqualex-co-ltd-672292-06122024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug product",
      "Unapproved new drug",
      "Misbranded drug",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to validate manufacturing processes",
      "Inadequate design of water system",
      "Quality control unit failures",
      "Inadequate laboratory testing for objectionable microorganisms",
      "Failure to establish an adequate written testing program for stability characteristics"
    ],
    "recommendations": [
      "Provide a detailed summary of your validation program for ensuring a state of control throughout the product lifecycle",
      "Implement a comprehensive remediation plan for the design, control, and maintenance of the water system",
      "Provide a comprehensive assessment and remediation plan to ensure your quality control unit is effective",
      "Conduct appropriate laboratory testing for each batch of drug product",
      "Establish and follow an adequate written testing program for stability characteristics",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "colorful-products-corporation-624415-05102022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.22",
      "21 CFR 211.165(a)",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)",
      "21 CFR 211.180(e)",
      "21 CFR 211.67(a)",
      "21 CFR 211.68(b)"
    ],
    "recommendations": [
      "Provide a comprehensive assessment and remediation plan for the quality unit.",
      "Conduct a comprehensive, independent assessment of the overall system for investigating deviations.",
      "Perform a comprehensive, independent assessment of the change management system.",
      "Implement a comprehensive, independent assessment and CAPA plan for the stability program.",
      "Conduct an assessment of each drug product process for data-driven and scientifically sound programs.",
      "Provide a comprehensive, independent retrospective assessment of cleaning effectiveness.",
      "Develop a CAPA plan based on the retrospective assessment of the cleaning program.",
      "Engage a qualified consultant to assist in meeting CGMP requirements.",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records."
    ]
  },
  {
    "letter_name": "apothecus-pharmaceutical-corp-585666-11082019",
    "violated_terms": [
      "21 CFR 211.192",
      "21 CFR 211.22 (a)",
      "21 CFR 211.68(b)",
      "section 501(a)(2)(B) of the FD&C Act"
    ],
    "recommendations": [
      "Conduct a retrospective independent review of all invalidated OOS results.",
      "Review and remediate the overall system for investigating OOS results.",
      "Provide a comprehensive assessment with a CAPA plan to ensure the quality unit has the needed authority and resources.",
      "Ensure appropriate stability data for each drug product before distribution.",
      "Implement strict controls over CGMP electronic data.",
      "Provide a detailed CAPA plan to remediate documentation practices.",
      "Summarize interim controls to prevent deletion and modification of data.",
      "Conduct a comprehensive investigation into the extent of inaccuracies in data records and reporting."
    ]
  },
  {
    "letter_name": "gpt-pharmaceuticals-private-ltd-590938-12172019",
    "violated_terms": [
      "Quality control unit responsibilities (21 CFR 211.22)",
      "Cleaning and maintenance of equipment (21 CFR 211.67(a))",
      "Control over computer systems (21 CFR 211.68(b))"
    ],
    "recommendations": [
      "Comprehensive assessment and remediation plan for quality unit oversight",
      "CAPA plan for routine maintenance and cleaning processes",
      "Investigation into data integrity issues with detailed corrective action plans"
    ]
  },
  {
    "letter_name": "amman-pharmaceutical-industries-668867-02142024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated drug products",
      "failure to perform operations within specifically defined areas",
      "inadequate design of facility and equipment",
      "failure to ensure adequate environmental monitoring",
      "failure to establish and follow appropriate written procedures",
      "failure to ensure that laboratory records included complete data",
      "failure to establish an adequate quality control unit"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent risk assessment of all contamination hazards",
      "Provide a detailed remediation plan with timelines",
      "Implement routine operations management oversight of facilities and equipment",
      "Establish appropriate written procedures to prevent microbiological contamination",
      "Ensure laboratory records include complete data",
      "Provide the quality control unit with appropriate authority and resources",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Notify FDA before resuming drug manufacturing operations"
    ]
  },
  {
    "letter_name": "generitech-corporation-618333-03012022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Adulterated drug products",
      "Unapproved new drugs",
      "Misbranding",
      "Failure to investigate unexplained discrepancies",
      "Failure to test samples of each component",
      "Failure to establish adequate written procedures for production and process control",
      "Failure to clean and maintain equipment",
      "Quality Unit (QU) authority not exercised",
      "Repeated violations"
    ],
    "recommendations": [
      "Conduct a retrospective, independent review of all invalidated OOS results",
      "Develop a comprehensive review and remediation plan for OOS result investigation systems",
      "Provide a detailed action plan to remediate the system for investigating deviations",
      "Conduct a comprehensive, independent review of your material system",
      "Establish a detailed summary of your validation program for ensuring a state of control",
      "Perform appropriate process performance qualification (PPQ) for each marketed drug product",
      "Conduct a comprehensive, independent retrospective assessment of cleaning effectiveness",
      "Engage a qualified CGMP consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "clean-solutions-llc-686995-09062024",
    "violated_terms": [
      "Your firm failed to conduct at least one test to verify the identity of each component of a drug product.",
      "Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals.",
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for each batch of drug product.",
      "Your firm failed to establish written procedures for production and process control.",
      "Your firm’s quality control unit failed to ensure drug products manufactured are in compliance with CGMP."
    ],
    "recommendations": [
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements.",
      "Establish adequate procedures for complaint handling, change control, and employee training.",
      "Implement an ongoing stability program and perform periodic product reviews.",
      "Ensure adequate equipment cleaning procedures and appropriate batch production and control records."
    ]
  },
  {
    "letter_name": "ag-hair-limited-638646-11282022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Failure to thoroughly investigate discrepancies or failures of a batch",
      "Inadequate investigation of customer complaints",
      "Failure to establish laboratory controls",
      "Inadequate microbiological testing and specifications",
      "Failure to test samples of each component for identity and conformity"
    ],
    "recommendations": [
      "Provide a comprehensive, independent assessment of the overall system for investigating deviations, discrepancies, complaints, OOS results, and failures.",
      "Provide appropriate microbiological lot release specifications for each drug product.",
      "Provide a description of how to test each component lot for conformity with specifications.",
      "Clarify intent to cease manufacturing and distribution of hand sanitizer drug products.",
      "Engage a qualified consultant to assist in meeting CGMP requirements."
    ]
  },
  {
    "letter_name": "hnc-products-inc-607359-09102020",
    "violated_terms": [
      "current good manufacturing practice (CGMP) regulations",
      "adulterated drug products",
      "misbranded drug products",
      "failure to thoroughly investigate unexplained discrepancies",
      "failure to establish adequate written procedures for production and process control",
      "failure to establish an adequate quality control unit",
      "failure to fulfill registration and listing obligations",
      "failure to ensure accuracy and integrity of data"
    ],
    "recommendations": [
      "Conduct a retrospective review of all invalidated OOS results",
      "Provide a comprehensive review and remediation plan for OOS result investigation systems",
      "Establish a detailed summary of the validation program for ensuring a state of control",
      "Provide a timeline for performing appropriate process performance qualification (PPQ)",
      "Establish an adequate quality control unit with the authority to approve or reject components and products",
      "Engage a qualified consultant to assist in remediation",
      "Provide a comprehensive investigation into the extent of inaccuracies in data records",
      "Submit drug listing information to the FDA for all drugs manufactured"
    ]
  },
  {
    "letter_name": "central-admixture-pharmacy-services-inc-675065-03252024",
    "violated_terms": [
      "Adulterated Drug Products: Specific examples of insanitary conditions and CGMP violations",
      "Failure to ensure compliance with CGMP and established specifications",
      "Inadequate investigation of discrepancies and failures",
      "Lack of supporting documentation for corrective actions"
    ],
    "recommendations": [
      "Comprehensive assessment of operations, including facility design and processes",
      "Engagement of a third-party consultant for evaluation of aseptic processing operations",
      "Immediate corrective actions to address identified violations and prevent recurrence"
    ]
  },
  {
    "letter_name": "american-cleaning-solutions-632881-09062022",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "21 CFR 211.67(b)",
      "21 CFR 211.100(a)",
      "21 CFR 211.100(b)",
      "21 CFR 211.84(d)(1)",
      "21 CFR 211.84(d)(2)",
      "21 CFR 211.22",
      "21 CFR 211.165(a)",
      "21 CFR 211.192",
      "21 CFR 211.100(a)",
      "21 CFR 211.166(a)",
      "21 CFR 211.180(e)",
      "section 501(a)(2)(B) of the FD&C Act",
      "section 501(d)(2) of the FD&C Act"
    ],
    "recommendations": [
      "Establish and follow written procedures for cleaning and maintenance of equipment.",
      "Establish adequate written procedures for production and process control.",
      "Conduct tests to verify the identity of each component of a drug product.",
      "Validate and establish the reliability of component supplier’s test analyses.",
      "Ensure appropriate testing for the identity and strength of active ingredients.",
      "Conduct thorough investigations for out-of-specifications results.",
      "Document and assess production and process control changes.",
      "Establish an adequate, ongoing stability program.",
      "Perform annual product reviews.",
      "Investigate and determine the causes of any violations and prevent their recurrence."
    ]
  },
  {
    "letter_name": "foshan-biours-biosciences-co-ltd-611319-03102021",
    "violated_terms": [
      "Your firm failed to have appropriate laboratory determination of satisfactory conformance to final specifications for the drug product (21 CFR 211.165(a)).",
      "Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).",
      "Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a))."
    ],
    "recommendations": [
      "Provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of drug products before a lot disposition decision.",
      "Develop an adequate cleaning validation program with emphasis on worst-case conditions in drug manufacturing operations.",
      "Provide a comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of the stability program."
    ]
  },
  {
    "letter_name": "handock-cosmetics-co-ltd-658737-10042023",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under section 502(ee) of the FD&C Act",
      "misbranded under section 502(x) of the FD&C Act",
      "failure to conduct identity testing on components",
      "failure to validate supplier test analyses",
      "quality control unit failed to ensure compliance with CGMP",
      "failure to use appropriately designed equipment",
      "failure to provide evidence of equipment qualification and maintenance",
      "failure to include a complete domestic address on product labels",
      "failure to comply with establishment registration and drug listing requirements"
    ],
    "recommendations": [
      "Conduct a comprehensive, independent review of the material system",
      "Provide a summary of results from testing retain samples of all drug product batches",
      "Provide a comprehensive assessment and remediation plan for the quality control unit",
      "Implement a CAPA plan for routine equipment and facilities management oversight",
      "Engage a qualified consultant to evaluate operations and assist in meeting CGMP requirements",
      "Clarify intentions regarding future drug manufacturing for the U.S. market",
      "Review and update drug listing information with FDA"
    ]
  },
  {
    "letter_name": "health-solutions-pharmacy-center-inc-dba-professional-compounding-pharmacy-606489-03312020",
    "violated_terms": [],
    "recommendations": []
  },
  {
    "letter_name": "kingston-pharma-llc-572904-05142019",
    "violated_terms": [
      "Failure to establish adequate written responsibilities and procedures for the quality control unit (21 CFR 211.22(d)).",
      "Failure to establish written procedures for production and process control (21 CFR 211.100(a)).",
      "Failure to maintain a written testing program for stability characteristics (21 CFR 211.166(a)).",
      "Failure to maintain buildings in a good state of repair (21 CFR 211.58).",
      "Misbranding of RESFRIOL-ITO Children’s Cold Cough & Sore Throat and Brosolvan under various sections of the FD&C Act."
    ],
    "recommendations": [
      "Provide a retrospective evaluation of all distributed batches of finished drug products to ensure specifications were met.",
      "Submit a risk assessment for distributed drug products manufactured using unvalidated processes.",
      "Conduct a retrospective review of all missing or delayed stability testing and provide an updated summary of stability data.",
      "Provide evidence of repairs made to the facility and a plan for periodic checks.",
      "Implement a comprehensive audit of manufacturing operations for CGMP compliance."
    ]
  },
  {
    "letter_name": "intercos-europe-spa-682273-08152024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "Failure to test samples of each component for identity and conformity",
      "Failure to validate and establish the reliability of component supplier’s test analyses",
      "Failure to thoroughly investigate any unexplained discrepancy or failure of a batch",
      "Failure to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance"
    ],
    "recommendations": [
      "Provide DEG and EG test results from testing reserve samples for all lots of high-risk drug components",
      "Conduct a full risk assessment for drug products that contain any ingredient at risk for DEG or EG contamination",
      "Perform complete investigations into all microbial test results that were above the microbial action limit",
      "Provide a comprehensive, independent assessment of laboratory practices and documentation systems",
      "Engage a qualified consultant to assist in meeting CGMP requirements"
    ]
  },
  {
    "letter_name": "enviroserve-chemicals-cleaners-ltd-674090-09092024",
    "violated_terms": [
      "Current Good Manufacturing Practice (CGMP) regulations",
      "adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act",
      "unapproved new drug under section 505(a) of the FD&C Act",
      "misbranded under sections 502(a), 502(c), and 502(ee) of the FD&C Act",
      "failed to conduct at least one test to verify the identity of each component of a drug product",
      "failed to validate and establish the reliability of your component supplier’s test analyses",
      "failed to have appropriate laboratory determination of satisfactory conformance to final specifications",
      "failed to establish and follow an adequate written testing program for stability characteristics",
      "failed to establish an adequate quality control unit",
      "misbranding due to misleading representation of FDA approval",
      "misbranding due to extraneous information in the Drug Facts panel",
      "noncompliance with section 505G of the FD&C Act"
    ],
    "recommendations": [
      "engage a consultant qualified as set forth in 21 CFR 211.34",
      "perform a comprehensive six-system audit of your entire operation for CGMP compliance",
      "evaluate the completion and efficacy of all CAPAs before pursuing resolution of compliance status"
    ]
  }
]